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Abstract
Schizophrenia is a severe neuropsychiatric disorder that presents with diverse symptoms, some of which
remain resistant to treatment. Increased risk of neurodevelopmental disorders such as schizophrenia
has been observed following gestational infection in humans, leading to development of maternal
immune activation (MIA) animal models. Increased density of the serotonin 5-HT2AR receptor (5-HT2AR),
the primary target of hallucinogenic drugs and a key target of atypical antipsychotics, has been observed
in postmortem antipsychotic-free prefrontal cortex samples from schizophrenia subjects, a change
reflected in frontal cortex of adult MIA offspring. To model MIA, we administered 20 mg/kg i.p. of the
viral mimetic poly-(I:C) on E12.5 of murine pregnancy and observed increased 5-HT2AR mRNA in adult
MIA offspring frontal cortex. Prepulse inhibition of startle deficits, a phenotype seen within disorders
such as schizophrenia, were also seen in MIA offspring. Dendritic spines are essential for appropriate
synaptic communication and synaptic plasticity. MIA decreases mature mushroom spine density in
mouse frontal cortex in a 5-HT2AR-dependent manner, implicating the receptor in MIA-induced synaptic
deficits. Due to evidence that glucocorticoid receptor (GR) signaling and stress affect 5-HT2AR expression
in other experimental systems, we investigated GR dysregulation as a potential underlying factor for
increased 5-HT2AR expression following MIA. We observed decreased GR immunoreactivity in the
nuclear, but not cytoplasmic, compartment of MIA offspring frontal cortex as well as decreased GR
enrichment at a binding site on the 5-HT2AR promoter. Postmortem human samples demonstrate
dysregulation of GR immunoreactivity in prefrontal cortex of schizophrenia subjects relative to controls
as well. Directly manipulating GR signaling by administering the endogenous agonist corticosterone
increased 5-HT2AR mRNA expression in mouse frontal cortex without affecting 5-HT2CR or dopamine D2
expression. This increase in expression is associated with decreased enrichment of the GR at the 5-HT2AR
promoter binding site. Stereotaxic administration of an AAV vector to overexpress a constitutively
translocating GR construct, ΔGR, decreased 5-HT2AR, but not 5-HT2CR or D2, expression in mouse frontal
cortex. Additionally, ΔGR expression in frontal cortex improved PPI in a 5-HT2AR-dependent manner.
These findings support a negative regulatory relationship between GR signaling and 5-HT2AR expression
in mouse frontal cortex and may carry implications for the pathophysiology underlying 5-HT2AR
dysregulation in neuropsychiatric disorders such as schizophrenia.

xiii

Introduction
IA. Maternal immune activation models reflect important elements of schizophrenia pathophysiology.
IA.1. Schizophrenia is a complex neuropsychiatric disorder produced by both genetic and
environmental factors.
Schizophrenia continues to be one of the most severe neuropsychiatric disorders, generally presenting
after adolescence and lasting for the remainder of life.1 For formal diagnosis, a patient must exhibit
evidence of the disorder for at least 6 months, distinguishing it from more transient psychotic illnesses.1
Schizophrenia is relatively common for its degree of severity, affecting 0.3-1% of the population,1, 2 and
is characterized by the wide variety of ways in which it can present. Conventionally, schizophrenia
symptoms have been categorized into clusters: positive, elements that are not present in healthy
individuals; negative, elements that are present in healthy individuals and absent in schizophrenia
patients; and cognitive, decreases in elements such as working memory and executive function, based
on how they affect the patient.3
Current diagnostic criteria for schizophrenia include the presence of features such as hallucinations,
sensory perceptions in the absence of concurrent stimuli; negative symptoms such as avolition, a
decrease in will to perform actions; abnormal behaviors such as catatonia, a state of diminished
responsiveness; delusions, beliefs that are strongly held despite inconsistence with available
information; and significant alterations in patterns of speech.1 Schizophrenia therefore affects a wide
variety of domains, many of which are important for functioning within society.4 Given that there is
currently no cure for the disorder,1 improved understanding of the condition and more effective
treatments are necessary to decrease the burden of this disorder.

1

The current understanding of schizophrenia pathophysiology involves a complex process in which
genetically susceptible individuals are exposed to insult stressors at key periods during the lifespan.5 In
line with this, both genetic and environmental components to schizophrenia development have been
identified.6 On the genetic side, large genome-wide association studies have identified key loci that
contribute to increased risk of schizophrenia development,7 though no gene by itself is capable of
producing schizophrenia.2 However, some disorders, such as the 22q11.2 deletion, carry significant
schizophrenia risk.8 In addition, there is a high degree of concordance between monozygotic twins,
further emphasizing the genetic nature of the disorder.9
Schizophrenia development also involves a significant environmental component. A variety of factors,
such as exposure to war, living in an urban environment, and adolescent cannabis use10 have been
found to be associated with increased schizophrenia risk. Maternal infection during human pregnancy is
a particularly salient insult that has been found to be associated with schizophrenia risk, with increased
risk being reported during both the first and second trimesters.10-12 Interestingly, this risk has been
found with a variety of agents. Bacterial infections, such as gonococcal and upper respiratory infections
have been found to increase risk during the first trimester.12 Increased risk of schizophrenia spectrum
disorders has also been reported with viral infections such as influenza, in which anti-influenza
antibodies in maternal serum trended towards association with increased risk of schizophrenia spectrum
disorders in adult offspring 11 and multiple studies have found increased schizophrenia incidence in
people born following influenza epidemics.10 Higher rates of schizophrenia spectrum disorders were
observed in a cohort of subjects with gestational exposure to rubella as compared to the general
population.13 A trend has also been reported with the parasite toxoplasmosis in a study evaluating the
relationship between anti-toxoplasmosis antibodies in maternal serum collected during pregnancy and
development of schizophrenia spectrum disorders in a birth cohort.14 Interestingly, maternal infection
has also been found to be associated with increased risk of other neurodevelopmental conditions, such
2

as autism.15 In a large Danish study of about 1.6 million children, maternal hospitalization with first
trimester viral infection or second trimester bacterial infection during pregnancy was associated with
increased risk of autism spectrum disorder.16

IA.2. Maternal immune activation models have been developed in animals.
Following findings of similar effects resulting from diverse infectious agents, it has been proposed that
this increased risk is due to the convergence of the agents on the maternal immune system.17 These
infections are believed to elicit a maternal immune response, which results in cytokines that exert
effects on the fetus.17 This has led to the concept of maternal immune activation, in which a maternal
immune response to infection produces long lasting neurodevelopmental effects on the offspring.18 The
effects of this immune response, interacting with additional stressors later in life, are thought to
produce disorders such as schizophrenia in genetically susceptible hosts.5, 18
Following these associations in humans, maternal immune activation (MIA) animal models have been
developed to explore this environmental aspect of neurodevelopmental disorder pathophysiology.5
Similar to the variety of infections linked to increased risk of schizophrenia, a diverse set of agents have
been used to induce MIA.19-22 Among the approaches that have been used, one of the most intuitive is
the direct use of infectious agents. A mouse-adapted influenza virus in pregnant mice, for example, was
used in early MIA experiments to induce phenotypes in the offspring.20, 23 A direct approach such as this
contains both advantages and disadvantages. An important advantage is that induction of complete
agents has the potential to elicit both innate and adaptive immune responses, which might allow for a
more complex series of induced effects.24 In terms of downsides, an infectious agent requires an
incubation period, which can make it more difficult to determine the critical period for the maternal
immune response-induced effects that are observed.25 For example, a paper that uses both mouse-
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adapted influenza as well as a viral mimetic agent administers influenza at embryonic day 9.5 (E9.5) of
gestation while administering the agent at E12.5, citing previous studies showing that the peak immune
response elicited by the two would occur on the same day.23 Thus, using infectious agents for MIA
produces a wider ranging, but less precise, response than other approaches.
In addition to these intact infectious agents, agents that mimic their presence have also been used for
MIA.5 They produce a more precise, controlled immune response that can be observed within hours26, 27
and do not require the same biosafety containment associated with infectious agents.24 These mimetic
agents tend to bind a particular molecular target that recognizes specific elements of infectious agents,
resulting in downstream signaling cascades as if the infectious agent had been present.
Lipopolysaccharide (LPS), for example, a component of the outer membrane of gram negative bacteria,
is recognized by toll-like receptor 4 (TLR4).28 When administered to a pregnant rodent, it binds the TLR4
and elicits a downstream signaling cascade, resulting in sickness behaviors (such as lethargy, ptosis, and
decreased feeding in the dam29) and producing MIA-induced phenotypes in the adult offspring.30-32
Other approaches to MIA induction have involved viral mimetics26 and, in some cases, variable stress
without administration of any agent.22

IA.3. Poly-(I:C) is a well-validated approach for MIA induction.
The MIA-inducing agent used in these studies is polyinosinic:polycytidylic acid (poly-(I:C)), a doublestranded RNA analog which consists of a string of inosines and cytidines.33 It exerts its effect primary
through binding to TLR3, which acts to recognize the double-stranded RNA of viruses, resulting in a
downstream immune cascade,33 including production of proinflammatory cytokines such as interleukin 6
(IL-6), TNF-α, and IL-1β.27 In one study, cytokine induction was observed to peak around 3 hours after
administration.27 Among acute sickness behaviors produced by poly-(I:C) are decreased activity,
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diminished body weight, and increased body temperature.27 Poly-(I:C) has been extensively used to
produce MIA-induced phenotypes by a variety of laboratories, with variable dosage, timing, and
administration schedules.19, 22, 23, 34, 35 These approaches reveal the complex interplay of factors needed
to properly execute a MIA model.
One of these factors is related to poly-(I:C) itself. There can be significant variability between poly-(I:C)
lots, with an order of magnitude in plasma IL-6 induction being possible between batches.36 In addition,
factors such as the vendor and molecular weight of the poly-(I:C) can influence the degree of immune
response seen in injected mice.37 In addition to the variability in poly-(I:C), factors inherent to the
animals used in the studies are also important for observing MIA effects in offspring. Mice from different
vendors have been reported to exhibit varying degrees of susceptibility to MIA-induced phenotypes.35 At
least part of this has been reported to be due to gut microbiome components, with segmented
filamentous bacteria (Candidatus Savagella) in the gut being necessary for development of maternal gut
Th17 helper T cells.38 These cells have been shown to be essential for IL-17a production and MIA-induced
phenotypes within a particular poly-(I:C)-induced model.38 Downstream signaling mediators after TLR3
also include IL-6,26, 33 which has been shown to be both necessary within the mother to elicit MIA
phenotypes as well as sufficient, when administered to pregnant mice on E12.5, to induce MIA-like
phenotypes in offspring.39 MIA models therefore require the successful triggering of complex signaling
cascades in mice possessing factors that make them susceptible to immune activating agents.

IA.4. MIA induces neurodevelopmental disorder-related phenotypes in offspring.
In line with the disorders it intends to model, MIA has proven to be a pleiotropic insult, producing
phenotypes reminiscent of multiple neurodevelopmental disorders such as schizophrenia and autism.5,
15, 19, 35

This variegated presentation remains a key limitation of the model. Offspring within MIA models
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have disruptions in a variety of body systems, highlighting the impact of disrupting development during
critical periods of gestation. Some of these changes are anatomic. Clear alterations of cortical layering,
detected by decreased special AT-rich sequence binding protein 2 (SATB2) staining35 and involving
cortical patches centered around the dysgranular zone of primary somatosensory cortex,40 have been
reported in MIA offspring. Alterations in the integrity of the gut barrier, accompanied by alterations in
gut expression of tight junction genes, gut microbiota changes, and increased gut permeability, have
also been reported.19
In addition to these more overt alterations, MIA models also exhibit a diverse range of functional
impairments. Similar to the difficulties that schizophrenia symptoms pose for patients attempting to
function in society,4 MIA offspring exhibit deficits in a variety of domains necessary for survival and
reproduction. At the molecular level, key signaling molecules needed for appropriate neuronal function,
such as brain-derived neurotropic factor;34 phosphorylation of its receptor, TrkB;34 and the extracellular
signaling molecule reelin;41 are dysregulated in frontal cortex of MIA offspring. At the behavioral level,
MIA offspring have been shown to exhibit deficits in patterns of locomotor behavior.20 Altered memory
function34, 42, 43 and social deficits19, 35, 38, 40 have also been reported in MIA offspring. As pups, MIA
offspring mice exhibit altered patterns of ultrasonic vocalizations in response to maternal separation.35,
38, 40

Adult male MIA offspring mice have also been shown to produce fewer ultrasonic vocalizations in

response to a novel female. Decreased social contacts, increased latency to contact, and decreased
social interaction time have also been reported.19, 20 Increased stereotyped behavior has been observed
in the marble burying assay19, 38 and increased anxiety-like behavior has been seen in the open field in
MIA offspring.19, 38, 40 In a more complex executive task, MIA offspring have decreased performance in
the delayed spatial alternation task at 40 s, but not 10 s of delay.22 MIA therefore produces a variety of
behavioral effects in adult offspring, resulting in numerous possibilities for impaired survival.
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MIA offspring have also been shown to exhibit deficits in sensorimotor gating,5 a phenotype observed to
be dysregulated in schizophrenia as well as other conditions such as obsessive-compulsive disorder,
Tourette syndrome, and Huntington’s disease.44 Sensorimotor gating is an evolutionarily conserved
phenomenon in which organisms are able to manage incoming sensory information, excluding
information that is not needed for survival.45 Sensorimotor gating is observed across a variety of
modalities, with gating to acoustic and tactile stimuli being possibilities for evaluation in organisms.44
The most common mechanism of evaluating sensorimotor gating is prepulse inhibition of startle (PPI), in
which a stimulus of sufficient magnitude to elicit a startle response (pulse) is presented to an organism
with or without a lower magnitude, but detectable, stimulus (prepulse). In an organism with a properly
functioning nervous system, the presence of the prepulse will decrease the magnitude of the startle to
the pulse. The prepulse thus, in essence, telegraphs the pulse, allowing an organism to reduce the
resources devoted to responding to it.44 Prepulse inhibition involves both cortical and subcortical
structures, with both prepulse processing and top-down modulatory circuits being involved.46 A variety
of MIA approaches have revealed PPI deficits in adult offspring, supporting the validity of the model.19, 20,
47

In addition, it has been shown that the antipsychotics clozapine and chlorpromazine, which have been

used in schizophrenia treatment, promote improvement in PPI specifically in MIA offspring.20
In addition to the gross anatomic, molecular, and behavioral changes, MIA models have also been
shown to exhibit synaptic dysfunction.48 This, similar to other changes in MIA models, reflects
alterations observed in neurodevelopmental disorders such as schizophrenia. Postmortem samples from
schizophrenia subjects have shown a decrease in basal spine density in prefrontal cortex pyramidal
neurons.49 In the tufts of apical dendrites of cortical pyramidal neurons, a decrease in total dendritic
spines is observed in juvenile mice, an alteration that lasts until adulthood.48 Layer 5 neurons in the
medial prefrontal cortex of rats, in contrast, exhibited a decrease in total basal spine density in adult,
but not juvenile, MIA offspring.50 Increased total and filopodia spines in basal dendrites of layer 5
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intrinsically bursting neurons have also been reported following MIA.51 Dendritic spine dysregulation,
accompanying behavioral alterations, is therefore a well-established phenotype in MIA offspring.

IB. Multiple lines of evidence implicate the 5-HT2AR in schizophrenia pathophysiology.
IB.1. 5-HT2AR pharmacology is relevant for schizophrenia and associated phenotypes.
Alterations in neurotransmitter signaling systems have long been proposed to be a crucial component of
schizophrenia pathophysiology.2 Drugs targeting monoaminergic receptor systems have been a mainstay
of schizophrenia treatment for decades, with both typical and atypical antipsychotics targeting them,
particularly the dopamine D2 receptor.52 Among the monoaminergic receptors implicated in
schizophrenia pathophysiology is the serotonin 5-HT2A receptor (5-HT2AR).52, 53 The 5-HT2AR is a Gqcoupled seven-transmembrane receptor within the serotonergic receptor system.54 It, alongside the
closely related 5-HT2B and 5-HT2C receptors, belongs to one of the seven serotonin receptor subfamilies,
all of which, excluding 5-HT3R, are G protein-coupled receptors.55, 56 The 5-HT2AR is found in brain regions
such as the cortex, thalamus, and hippocampus,57 as well as on vascular and immune cells.58, 59 Within
mouse cortex, 5-HT2AR expression is observed primarily on layer 5 pyramidal cells, a subset of
interneurons, and cells in layer 6b adjacent to the corpus callosum.60
5-HT2AR pharmacology implicates the receptor in schizophrenia-related phenotypes. Hallucinogenic
drugs, also called psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), and 2,5-dimethoxy4-iodoamphetamine (DOI), represent a substantial subset of 5-HT2AR agonists.61, 62 In humans, these
drugs produce thought and perceptual alterations that are reminiscent of features observed in
schizophrenia.63 Other 5-HT2AR agonists, such as lisuride, do not produce these perceptual alterations in
humans.64 Explorations into mechanisms to explain this difference are ongoing, but these pharmacologic
effects are thought to in part involve elements such as differential receptor phosphorylation,65 biased
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agonism,66 and divergent activation of downstream signaling genes.62 In rodents, 5-HT2AR agonists that
produce hallucinations in humans elicit a specific behavior called the head twitch response. In 5-HT2AR
knockout mice, psychedelics fail to increase rates of head twitch response62, 67 and 5-HT2AR antagonists
are similarly able to block the effect of psychedelics, both in rodents68, 69 and in humans.70 This evidence
therefore converges on the fact that psychedelic drugs elicit their hallucinogenic effect in a 5-HT2ARdependent manner. 5-HT2AR signaling is therefore able to prominently impact thought and perception,
phenomena whose disruption are hallmarks of schizophrenia.
In addition to the psychedelic effect of some 5-HT2AR agonists, many atypical antipsychotic drugs, such
as clozapine and risperidone, possess a relatively high affinity for the 5-HT2AR and serve as antagonists
for the receptor.52 Some of these drugs, clozapine in particular, have been found to be more effective in
the context of treatment-resistant schizophrenia than first generation, or typical, antipsychotics, such as
haloperidol.4 Inhibition of 5-HT2AR signaling is thought to play a role in the effectiveness of this class of
antipsychotics.52 In addition, the highly selective 5-HT2AR inverse agonist pimavanserin is effective in
Parkinson’s disease psychosis, for which it has exhibited improvement relative to placebo.52, 71, 72
Therefore, through drugs that promote and inhibit its signaling, the 5-HT2AR is implicated in
schizophrenia-relevant phenotypes.

IB.2. 5-HT2AR dysregulation has been demonstrated in both schizophrenia and MIA models.
In addition to the pharmacologic evidence suggesting 5-HT2AR relevance for schizophrenia, more direct
evidence is available from postmortem samples. Within the prefrontal cortex (Brodmann area 9),
postmortem samples from human schizophrenia subjects exhibit increased 5-HT2AR density relative to
age-matched controls.53 Interestingly, this finding was only present in samples from subjects that were
antipsychotic-free at death,53 suggesting that a component of antipsychotic response may involve
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decreasing 5-HT2AR density. In another study in postmortem prefrontal cortex samples from
schizophrenia subjects and controls, using a radiolabeled 5-HT2AR agonist, neutral antagonist, and
inverse agonists, it was found that increased density of the 5-HT2AR was observed with the agonist,
[3H]LSD in samples from antipsychotic-free schizophrenia subjects, while decreased density was
observed with the inverse agonist, [18F]altanserin, suggesting that there is increased presence of a pool
of 5-HT2AR in a state able to be activated,73 further supporting increased 5-HT2AR signaling as a
component of schizophrenia pathophysiology.
MIA models reflect the increase in 5-HT2AR density observed in human samples. Increased 5-HT2AR
expression in mouse frontal cortex has been observed in MIA offspring at both the receptor density and
mRNA level, with increases being observed in models induced with mouse-adapted influenza,21, 43 poly(I:C), and variable stress.22, 74 Increased 5-HT2AR immunoreactivity has also been shown in prefrontal
cortex in male, but not female, MIA offspring rats following induction with LPS.32 In addition to the
dysregulation of the receptor itself, increased expression of key downstream signaling molecules, PLCβ1
and RGS4, has been shown.74 The pharmacologic effects of 5-HT2AR agonists have also been shown to be
altered in MIA offspring. Induction of mRNA for genes such as c-fos, Egr-1, Egr-2, BDNF, and COX-2 by
the hallucinogen DOI are potentiated in frontal cortex of MIA offspring mice.21, 74 In MIA offspring rats,
increased c-Fos protein is observed following DOI administration in the ventromedial prefrontal cortex
in males while MIA offspring females exhibit decreased c-Fos induction in both dorsomedial and
ventromedial prefrontal cortex.32 At the behavioral level, increased rates of the head twitch response
following DOI administration are observed in MIA mouse offspring.21, 22, 74 Interestingly, both this
increase in head twitch as well as the increase in 5-HT2AR density itself are not observed in prepubertal
mice.21, 22 Thus, similar to schizophrenia being an adult onset disorder, 5-HT2AR changes that occur in
MIA models are an adult-onset phenomenon.
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IB.3. The 5-HT2AR and its signaling have been implicated in key MIA-related phenotypes.
In addition to the dysregulation of 5-HT2AR and its signaling pathways in MIA models, there are specific
MIA-associated phenotypes in which the 5-HT2AR has been implicated, through both MIA models and
independent paradigms. The degree to which MIA-induced alterations in these phenotypes are 5-HT2ARdependent, however, remains unknown. One of these paradigms is PPI. Multiple lines of evidence
suggest that the 5-HT2AR and its signaling are important modulators of PPI. In healthy humans,
administration of the 5-HT2AR agonist prodrug psilocybin produces PPI deficits at a short interstimulus
interval while increasing it with longer interstimulus intervals.75 In rats, psychedelics such as DOI and LSD
have been shown to produce PPI deficits,76 with the effect of LSD being blocked by the 5-HT2AR
antagonist MDL 11,939.64 In addition, psychedelics such as DOI have in some studies been shown to
induce PPI deficits in mice, though this effect appears to be less consistent than in other species.77 In
addition, homozygosity for the TT/AA allele of the T102C/A1438G allele of the 5-HT2AR promoter is
associated with increased baseline PPI in healthy humans.78 There is therefore a large body of evidence
implicating 5-HT2AR signaling in PPI, suggesting a need for further investigation into the significance of
the receptor for this behavioral paradigm within the context of MIA.
Frontal cortex dendritic spine density also has evidence for potential 5-HT2AR involvement. Dendritic
spines are a receptive component of excitatory synapses that exhibit a variety of morphologies
depending on synaptic strength and activity, rendering them an essential component of synaptic
plasticity. Spine morphologies on mature neurons include stubby, thin, and mushroom, with mushroom
spines being understood to represent the most robust synapses.79 5-HT2AR knockout mice on a C57BL/6J
background have been shown by our group to exhibit decreased frontal cortex total spine density as
well as decreases in stubby and thin spines relative to wild types,80 suggesting that the receptor plays a
role in determining spine density in this brain region. The ability of 5-HT2AR agonists to affect spine
density and plasticity has been a recent topic of interest, particularly in the context of novel approaches
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to depression treatment.80-82 In rat cortical neuronal cultures, administration of the psychedelics LSD,
DOI, and N,N-dimethyltryptamine increase dendritic spine density. Similar increases in spine density in
rat cortex are observed with systemic N,N-dimethyltryptamine administration.83 Chronic treatment with
the atypical antipsychotic clozapine in mice results in a decrease in 5-HT2AR density in mouse frontal
cortex as well as a decrease in the density of mushroom spines in a manner dependent on a
downstream 5-HT2AR signaling target.84 Additionally, the 5-HT2AR agonist DOI has been shown by our
group to produce increased stubby and thin spine density in a 5-HT2AR-dependent manner in mouse
frontal cortex.80 Thus agents that promote or inhibit 5-HT2AR signaling have impact on cortical dendritic
spine density, prompting further inquiry into the degree to which 5-HT2AR alterations underlie the
dendritic spine alterations observed in MIA offspring.

IC. Glucocorticoid receptor alterations may underlie 5-HT2AR dysregulation in MIA models.
IC.1. Stress and glucocorticoid receptor signaling have been implicated in 5-HT2AR regulation.
Although there is strong evidence to demonstrate 5-HT2AR dysregulation in MIA models, the underlying
cause of this dysregulation remains unknown. In light of the numerous lines of evidence implicating the
receptor in schizophrenia-related phenotypes, the underlying cause of altered 5-HT2AR expression in the
model is important to address. Among the potential causes of 5-HT2AR dysregulation within the context
of MIA, alterations in glucocorticoid receptor (GR) signaling are an appealing target for exploration.
Schizophrenia is conceptualized as a disorder produced in part by stressors experienced by susceptible
individuals5, 18 and GR signaling, as a component of the hypothalamic-pituitary-adrenal axis, is an integral
part of the mammalian stress response system.85 Alterations in glucocorticoid signaling have been
proposed to play a role in schizophrenia pathophysiology.86 Some, but not all studies of cortisol
secretion in schizophrenia patients relative to controls reveal alterations in the disorder.87 Within an
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Australian cohort, postmortem prefrontal cortex samples reveal dysregulation of key signaling
molecules in the GR signaling system, with increased mRNA expressions of the negative regulator FKBP5
and the chaperone PTGES3 as well as decreased mRNA expression of the negative regulator BAG1.88
Dysregulation of GR signaling has also been observed in MIA models, with increased plasma
corticosterone being observed in female, but not male, MIA offspring rats under standard housing
conditions.31 GR mRNA was decreased in the amygdala of both male and female MIA offspring rats, with
FKBP5 mRNA also decreased in the female amygdala.31 Although the finding was observed in juvenile
(P42) rats, MIA offspring males, but not females, exhibit both increased corticosterone and decreased
GR immunoreactivity in the hippocampus.30
The relationship of both receptors to stress serves as additional evidence that GR dysregulation may
play a role in 5-HT2AR dysregulation in MIA models. The 5-HT2AR and its signaling have been found to be
susceptible to a wide variety of stressors. Maternal separation of pups, an early life stressor, increases
rates of head twitch in response to the 5-HT2AR agonist DOI in rats.89 LPS administration to adult mice
has been shown to increase frontal cortex 5-HT2AR immunoreactivity90 while sleep deprivation in mice
increases cortical expression of 5-HT2AR mRNA.91 The pharmacologic stressor, acute methamphetamine
binge, produces increased murine frontal cortex 5-HT2AR immunoreactivity and rates of DOI-induced
head twitch response as well.92 Thus stress, a key component of the response to which is mediated by
the hypothalamic-pituitary-adrenal axis, has been extensively found to regulate 5-HT2AR.
Direct regulation of the 5-HT2AR by the GR has also been observed. Use of transgenic mice containing a
yeast artificial chromosome to increase GR expression results in increased 5-HT2AR immunoreactivity in
the hippocampus and increased 5-HT2AR density in the frontal cortex, while GR heterozygote mice
exhibit decreased 5-HT2AR density in frontal cortex.93 Exposure to corticosterone, the endogenous GR
ligand in rodents, in organotypic hippocampal slice cultures from mice also increases 5-HT2AR
immunoreactivity.93 In intact rats, a short course of high dose corticosterone is sufficient to increase
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rates of the head shake behavior (essentially the same behavior as head twitch response in mice)
following DOI administration, though this study did not investigate the molecular alterations that might
be responsible for this phenotype.94 Another study, using an intraventricular siRNA approach to knock
down GR expression in the rat brain produces increased rates of DOI-induced head shakes as well as
increased 5-HT2AR density and mRNA expression in the frontal cortex.95 There is therefore significant
evidence establishing that GR signaling plays a role in modulating 5-HT2AR expression. Apparent
discrepancies between the various studies, however, prevent the directionality of the regulatory
relationship from being clearly established.

IC.2. Potential mechanisms have been identified for GR regulation of 5-HT2AR expression in MIA
models.
To discuss potential mechanisms by which the GR might exert its regulatory effect on 5-HT2AR
expression, a discussion of basic GR signaling mechanisms is needed. The GR, alongside receptors such
as those for progesterone and estrogen, is within the nuclear receptor family.96 As a nuclear receptor, its
endogenous ligand, cortisol in humans and corticosterone in rodents, is able to cross the cell membrane
and bind the GR in the cytoplasm.88, 96-98 Hormone binding induces conformational and protein
interaction changes in the receptor, promoting nuclear translocation.98 Once in the nucleus, the GR acts
as a transcription factor, promoting or inhibiting gene expression depending on both the particular
glucocorticoid response element (GRE) at a particular locus and the protein interaction partners of the
GR within a particular context.88, 98 The GR possesses a wide variety of protein binding partners, such as
the immunophilin positive and negative regulators, FKBP4 and FKBP5, respectively, which modulate
behavior of the receptor.98 Given that the GR is at the center of a complex signaling pathway, potential
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mechanisms by which it could regulate the 5-HT2AR include both direct action as a transcription factor 96
as well as downstream signaling mechanisms within a more complex signaling cascade.99
In support of direct GR regulation of the 5-HT2AR, a putative response element in the GR subfamily has
been identified. This progesterone response element on the human 5-HT2AR promoter was
demonstrated to be bound by the GR in vitro by electrophoretic mobility shift assay.100 The site is
conserved across species, with a similar sequence being found on the murine 5-HT2AR promoter.100 Thus,
a mechanism capable of linking GR signaling and 5-HT2AR dysregulation within the context of MIA has
been proposed.
In this dissertation, the contribution of GR signaling alterations to 5-HT2AR dysregulation in a poly-(I:C)induced MIA mouse model is investigated. In MIA offspring and controls, GR immunoreactivity in the
nuclear and cytoplasmic compartments of mouse frontal cortex are investigated; to determine potential
MIA-induced alterations in GR occupancy of the putative binding site, enrichment of the GR at the 5HT2AR promoter is also evaluated in these mice. 5-HT2AR knockout mice were used to determine if key
MIA-relevant phenotypes are 5-HT2AR dependent. To evaluate the translational significance of these
studies, GR immunoreactivity was investigated in postmortem prefrontal cortex samples from
schizophrenia subjects and controls. To further explore the regulatory relationship between GR signaling
and 5-HT2AR expression, additional models of corticosterone administration and intracortical viral vector
gene delivery were also used. The data generated from these models support a negative regulatory
relationship between GR signaling and 5-HT2AR expression, with implications for the phenotypes
observed in a MIA mouse model.
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Methods

M1. Materials and Drugs
Poly-(I:C) potassium salt was obtained from Millipore Sigma (P9582). After weighing, poly-(I:C) was
dissolved in normal saline to a concentration of 4 mg/ml poly-(I:C) (the total salt concentration was 40
mg/ml) in a 50 ml Falcon tube by rotating the tube and then spun down briefly at 800 ✕ g. The resulting
solution was then aliquoted and stored at -20°C until the day that mice were injected.
Corticosterone was obtained from Millipore Sigma (46148) and was diluted in DMSO to a concentration
of 100 mg/ml. Aliquots were stored at -20°C until a working solution was needed. This solution was
diluted 1:3 DMSO : ethanol to generate a final injection solution.
Diethylpyrocarbonate-treated water was generated by stirring 0.1% by volume DEPC (Sigma-Aldrich)
into ddH2O at room temperature overnight in a fume hood. The DEPC was then inactivated by
autoclaving and the water was stored at room temperature until use.

M2. ΔGR Vector Generation
Neuro-2a Cell Culture
Neuro-2a cells (original stock obtained from ATCC, product CCL-131™) were maintained in a growth
medium of DMEM with glucose, L-glutamine and sodium pyruvate (Corning) supplemented with 5%
qualified FBS (Gibco) and 1% 10,000 U/ml penicillin/ 10,000 µg/ml streptomycin solution (Gibco). Cells
were split as needed by removal of growth medium, washing with DPBS (Corning), incubation in 0.25%
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trypsin-EDTA solution (Sigma Aldrich) to release the cells, and addition of growth medium to quench the
trypsin. Cells were then transferred to new flasks with fresh growth medium.
Cloning, Restriction, and Ligation
The initial cDNA used to generate the ΔGR vector was obtained from a frontal cortex sample from an
adult male 129S6/SvEv mouse (see Table M1 for primers). 100 ng of cDNA were amplified using 2.5 units
of PfuUltra high fidelity DNA polymerase (Agilent) in a reaction buffer consisting of 1✕ PfuUltra HF
reaction buffer supplemented to a final concentration of 3 mM Mg2+ with MgSO4, 0.5 µM forward
primer, 0.5 µM reverse primer, and 25 mM dNTPs (each). Primers were designed to amplify the coding
sequence for residues 1-524 of the mouse glucocorticoid receptor as well as introduce a BamHI
restriction site upstream and a AscI site downstream of the construct. Amplification was carried out in a
thermal cycler according to the following program: 95°C for 2 min, 30✕ (95°C for 30 s, 60°C for 95°C,
72°C for 1 min), 72°C for 10 min.
The resulting PCR products were resolved on an 0.5% agarose gel containing 0.006% ethidium bromide
in SB buffer (10 mM NaOH, 38 mM H3BO3 in diH2O). The ΔGR amplification product band was visualized
using a gel documentation system (Thermo Scientific) and excised. DNA from the band was then
extracted using a PCR clean-up/gel extraction kit (Macherey-Nagel). The excised DNA in agarose was
incubated in 200 µL Buffer NT1 at 50°C for 5-10 min with intermittent vortexing until the gel was
dissolved. DNA was then bound to a NucleoSpin column and centrifuged at 11,000 ✕ g for 30 s. The
column was then washed twice by two rounds of adding 700 µL Buffer NT3 and centrifuging at 11,000 ✕
g for 30 s. The column was then dried by an additional spin at 11,000 ✕ g for 1 min. DNA was eluted in
three rounds by addition of 20 µL of Buffer NE heated to 70°C, incubation at room temperature (5 min
for the first round and 1 min for the subsequent two), and centrifugation at 11,000 ✕ g for 1 min (final
elution volume of 60 µL).
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0.3 µL of the purified DNA was then amplified once again with the ΔGR primers, run on a 0.5% agarose
gel, and purified a subsequent time as before, with the exception that the first incubation before elution
was for 1 min. As a source for the destination vector for the ΔGR construct, we used an adenoassociated virus plasmid containing a CaMKIIα-BamHI-5-HT2AR-AscI-P2A-eYFP construct (which was
generated and is available within the Maeso lab). 1 µg of the vector plasmid and 0.5 µg of the ΔGR
construct were cut with 10 units each of BamHI and AscI in CutSmart™ Buffer (New England Biolabs) for
1 hour at 37°C. For the vector reaction, 1 µL of calf intestine alkaline phosphatase (New England Biolabs)
was added for the last 10 min. The vector reaction product was run on a 0.5% gel and the band of the
appropriate size for the cut backbone vector was excised. Both this band and the ΔGR construct
restriction product were purified using the same kit as before. These purified products were then ligated
with T4 DNA ligase (New England Biolabs) with T4 DNA Ligase Buffer in ddH2O and a 1:10 vector: insert
ratio (25 ng vector, 62.5 ng insert).
Plasmid Purification and Vector Packaging
1 µL of this ligation product was added to 50 µL of XL1-Blue competent cells (Agilent) for transformation.
The cells and ligation product were incubated on ice for 30 min, heat shocked at 42°C for 45 s, and then
returned to ice for 2 min. 500 µL of room temperature S.O.C. medium (Invitrogen) were added and the
cells were incubated at 37°C for 1 hour with shaking. Cells were then plated on ampicillin selective
plates (0.05 mg ampicillin/ml LB agar) made with LB agar and incubated overnight at 37°C. Colonies
were picked the next day and further incubated in 5ml LB broth containing 0.05 mg/ml ampicillin.
Plasmids from these colonies were then purified using a QIAPrep Miniprep kit (Qiagen). The colonies
were pelleted by centrifugation at 5400 ✕ g for 10 min at 4°C. The pellet was resuspended in 250 µL of
Buffer P1 supplemented with RNase A and LyseBlue reagent. 250 µL of Buffer P2 were added and
samples were mixed by inversion, then incubated at room temperature for 5 min. 350 µL of Buffer N3
were added and samples were mixed by inversion, then centrifuged at 17,900 ✕ g for 10 min. 800 µL of
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the supernatant was transferred to a QIAprep 2.0 Spin Column and centrifuged at 17,900 ✕ g for 30 s.
The column was washed with 500 µL Buffer PB and centrifuged at 17,900 ✕ g for 30 s, then washed with
750 µL buffer PE. The column was then dried by centrifugation at 21,130 ✕ g for 1 min. DNA was eluted
in 50 µL Buffer EB by adding buffer to the column, incubating for 1 min, and centrifuging at 17,900 ✕ g
for 1 min. The resulting purified plasmids were sequenced (Eurofins) to confirm the correct insert.
A colony containing the correct insert confirmed by sequencing was grown in 250 ml LB with 0.05 mg/ml
ampicillin overnight at 37°C. Plasmids from the colonies were then purified using a Plasmid Maxi kit
(Qiagen). The colonies were centrifuged at 6,000 ✕ g for 15 min at 4°C and the pellet was resuspended in
10 ml of Buffer P1 supplemented with RNase A solution and LyseBlue reagent. 10 ml of Buffer P2 were
added and samples were inverted and incubated at room temperature for 5 min. 10 ml of chilled Buffer
P3 were added and mixed by inversion, then incubated on ice for 20 min. The samples were then
centrifuged at 20,000 ✕ g for 30 min at 4°C. A Qiagen 500 tip column was equilibrated with 10 ml of
Buffer QBT and the supernatant from sample centrifugation was added to the column. The column was
then washed twice with 30 ml of Buffer QC. DNA was eluted with 15 ml Buffer QF and DNA was
precipitated with 10.5 ml of isopropanol. Samples were then centrifuged at 15,000 ✕ g for 30 min at 4°C.
The supernatant was removed and the DNA pellet was washed with 5 ml of 70% ethanol. Following
centrifugation at 15,000 ✕ g for 10 min, the supernatant was removed, the pellet was dried, and DNA
was dissolved in 800 µL of DEPC-treated water (Quality Biological). Following validation of the construct
in N2a cells (see below), the final CaMKIIα-ΔGR-P2A-eYFP plasmid was packaged into AAV8 viral
particles by the UNC Vector Core.
Transfection of N2a Cells
To prepare a surface for adherence of N2a cells, #1 coverslips (Fisherbrand) were incubated in 10 M
NaOH at room temperature overnight with gentle shaking, washed, and autoclaved. The coverslips were
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coated in poly-D-lysine (Sigma-Aldrich) in borate buffer (50.1 mM BH3O3, 12.5 mM Na2B4O7·10H2O)
overnight. The next day, coverslips were washed three times in sterile water, then allowed to dry. For
transfection experiments where immunofluorescence was the endpoint, N2a cells were then plated on
these poly-D-lysine-coated coverslips and allowed to grow. N2a cells on coverslips in 6 well plates were
transfected with 4 µg of plasmid DNA with 5 µL of polyethyleneimine made up to a final volume of 300
µL with Opti-MEM™ reduced serum medium (Gibco) that were added to growth medium. Prior to
transfection, DNA, polyethyleneimine, and Opti-MEM™ were combined, shaken, and incubated for 10
min at room temperature. For mock transfection, only polyethyleneimine and Opti-MEM™ were added
to cells. The medium was replaced with regular growth medium the day after transfection. Cells were
processed for immunofluorescence 48 hours after transfection.
For western blotting, N2a cells in 10 cm plates were transfected with 6 µg of plasmid DNA with 10 µL of
polyethyleneimine made up to a final volume of 300 µL with Opti-MEM™ as described above. To
harvest, transfected N2a cells were washed with DPBS three times before being dislodged with a cell
scraper in cold DPBS. Cells were then pooled and spun down for 5 min at 188 ✕ g at room temperature.
The supernatant was removed and pelleted cells were frozen at -80°C until they were subjected to
subcellular fractionation as described below.
Immunofluorescence in N2a Cells
Transfected cells grown on coverslips were fixed by incubation in 4% PFA in PBS (137 mM NaCl, 2.68 mM
KCl, 10.1 mM Na2HPO4, 1.76 mM KH2PO4, pH 7.4) at room temperature for 15 min with shaking. Cells
were washed for 5 min in PBS three times with shaking before permeabilization in 0.2% Triton X-100 in
PBS for 10 min. Cells were then washed again before incubation in blocking buffer (5% FBS, 1% BSA,
0.05% NaN3 in PBS) for 30 min at room temperature with shaking. Coverslips containing the cells were
then placed facedown in 50 µL of primary antibody (see below) in blocking buffer on a slide that had
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been covered with Parafilm (Bemis) and incubated for 1.5 hours at room temperature. Cells were then
washed in PBS and incubated in 50 µL of a fluorescent secondary antibody for 1 hour in the dark on a
Parafilm-covered slide. After washing 6 times in PBS, nuclei were stained by incubation in a 1:1000
dilution of 20 mM Hoechst solution (final concentration 0.02 mM; Thermo Scientific) in DPBS for 5 min.
Slides were washed twice in PBS, dried, and mounted in Prolong Diamond antifade mountant. After
curing overnight, slides were sealed and stored at 4°C until use. The plasmids used were the CaMKIIαΔGR-P2A-eYFP plasmid described above as well as a plasmid to express the full-length human GR under
the control of the CMV promoter (Addgene construct pCMV-GR11; plasmid #89105 deposited by the
laboratory of Dr. Elizabeth Wilson). The primary antibody used was 1:50 mouse-anti-GR (Santa Cruz, sc393232) and the secondary antibody used was 1:1000 Alexa Fluor 568-conjugated goat-anti-mouse
(Invitrogen, A-11004).
Images were acquired using the 405, 488, and 561 nm laser lines of an LSM 710 confocal laser scanning
microscope (Zeiss). A 63x objective was used, resulting in 1912 ✕ 1912 pixel images with a 0.07 µm ✕
0.07 µm pixel size.

M3. Animal Techniques
Animals Used
Experiments were conducted in adult mice (10.5-22.5 weeks). Mice were obtained from either Charles
River (C57BL6/N), Taconic (C57BL6/N and 129S6/SvEv), Jackson Laboratories (C57BL6/J) or, for wild type
and 5-HT2AR knockout mice, from the ongoing mouse colonies in the González-Maeso laboratory (on a
background strain of Taconic 129S6/SvEv). The 5-HT2AR KO mice used were complete knockouts that
contain a stop cassette to interfere with transcription and translation (Weisstaub et al, 2006).
Experiments requiring 5-HT2AR KO mice and the corticosterone time course (see below) were conducted
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in mice on a Taconic 129S6/SvEv background from the Maeso colony. All other experiments were
conducted in C57BL6/N mice from Charles River. C57BL6/N mice from Taconic and C57BL6/J mice from
Jackson Laboratories were used exclusively in the microbiome evaluation experiment (see below).
Male mice were used for experimental animals, except for dendritic spine experiments and for RT-qPCR
validation of the ΔGR vector, where both sexes were used. Female mice were used for poly-(I:C)
validation experiments, evaluation of cecal 16S rRNA gene presence, immunofluorescence validation of
the ΔGR vector, and as mothers in maternal immune activation experiments. Older mice (39 weeks)
were used for immunofluorescence validation of the ΔGR vector. Within experiments, mice were age
matched between groups. All procedures involving animals were approved by VCU’s Institutional Animal
Care and Use Committee. Every effort was made to minimize animal use and distress.
Genotyping
Mouse ear samples were collected and proteinase K digested in GNT-K buffer (0.01% by weight gelatin,
0.45% by volume IGEPAL CA-630, 0.45% by volume Tween 20, 0.01% by weight proteinase K, 50 mM KCl,
1.5 mM MgCl2, 10 mM Tris base, pH 8.5) for 2 hours at 55°C, followed by heat inactivation at 95°C for 15
min. 3 µL of the resulting DNA-containing solution were combined with 22 µL of working Taq
polymerase and primer solution (12.5 µL 2✕ DreamTaq Green PCR Master Mix [Thermo Scientific], 0.455
µM WT forward primer, 0.909 µM 5-HT2AR KO forward primer, 0.455 µM common reverse primer (see
Table M1 for sequences), remainder of the volume made up with ddH2O) and amplified according to the
following program: 95°C for 1 min, 2✕ (95°C for 15 s, 64°C for 15 s, 72°C for 45 s), 6✕ (95°C for 15 s, 61°C
for 15 s, 72°C for 45 s), 20✕ (95°C for 15 s, 58°C for 15 s, 72°C for 45 s), 20✕ (95°C for 15 s, 55°C for 15 s,
72°C for 45 s), 72°C for 10 min, hold at 4°C. Amplified samples were then resolved on a 0.5% agarose gel
and visualized using a gel documentation system as described above. A 500 bp amplification product
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indicated a WT allele and a 410 bp product indicated a 5-HT2AR KO allele. Earlier in the experiments, an
approach using PuReTaq™ Ready-To-Go™ PCR beads (Cytiva) was used for genotyping.
Poly-(I:C) Validation
Adult female C57BL6/N WT or 129S6/SvEv 5-HT2AR heterozygote mice were injected i.p. with 20 mg/kg
poly-(I:C) and observed for sickness behavior, such as lethargy, ptosis, and hunched posture. After 2.5
hours, the mice were sacrificed by either decapitation and exsanguination for analysis of IL-6 in serum or
by cervical dislocation for analysis of IL-6 mRNA in frontal cortex. Following decapitation, trunk blood
was collected and allowed to clot at room temperature for at least 30 minutes. The blood was then
centrifuged at 1000 ✕ g at 4°C for 10 minutes; the serum supernatant was collected and stored at -80°C
until the day of the ELISA assay. For RT-qPCR, mice were sacrificed by cervical dislocation, the head was
dissected, and the brain was removed and washed in normal saline at 4°C. Frontal cortex (+1.4 to +1.9
from bregma) was dissected and stored in an Eppendorf tube at -80°C until use.
Maternal Immune Activation
Female mice used as mothers for MIA experiments were WT C57BL6/N mice from Charles River that had
been either ordered timed pregnant or ordered and bred with C57BL6/N males from Charles River. For
experiments where WT and 5-HT2AR KO offspring were needed, 129S6/SvEv female 5-HT2AR
heterozygote mice on a Taconic background were bred within the González-Maeso lab colony. For inhouse bred mice, females were monitored for a mating plug and pregnancy was evaluated using both
weight gain and visual appearance of the flanks. Mouse weights were tracked with a small laboratory
scale (Ohaus). On day E12.5 of pregnancy, mice were weighed and injected i.p. with either 20 mg/kg
poly-(I:C) or vehicle, then monitored for sickness behavior. MIA at E12.5 was chosen because the first
and second trimesters have been shown to be a critical period for increased risk of schizophrenia
development following infection in humans2, 12 and induction at E12.5 has been demonstrated to
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produce MIA-induced phenotypes in offspring.26 To reduce litter loss, injected mice were pair housed
with another female of the same strain and provided with enrichment Bio-Huts™ for mice (Bio-Serv) as
shelter in the cage. Offspring were weaned between 3-4 weeks of age and were evaluated in molecular
and behavioral experiments as adults.
Corticosterone Administration
Corticosterone was prepared as described in the Materials and Drugs section above. Adult mice were
injected s.c. with 50 mg/kg corticosterone dissolved in a final solution of 1 DMSO: 3 ethanol. To
minimize the amount of DMSO injected into animals, an injection volume of 2 µL/g was used. For the
corticosterone time course, all mice (excluding the No Injection group, which received no injections
during the time course) received a total of 16 injections over eight days, with the number of vehicle
injections and corticosterone injections being determined by the treatment group. Injections were given
twice a day, spaced roughly 12 hours apart. Mice were sacrificed 8.5-13 hours after the last injection for
molecular analyses to allow washout from the acute effects of corticosterone.
For the short term, high dose corticosterone experiments, mice received 50 mg/kg corticosterone or
vehicle s.c. twice a day for four days. Mice were then either sacrificed or tested for PPI 8.5-13.5 hours
after the last injection.
Prepulse Inhibition of Startle
PPI experiments were conducted following a previously described paradigm.101 Mice were placed in SRLab™ Startle Response system (San Diego Instruments) chambers and allowed to habituate to
background noise for 5 minutes. Following habituation, mice were exposed to 5 startle only trials. They
were then subjected to 65 pseudorandomized trials consisting of interspersed no stimulus trials; startle
only trials; or 73 dB, 77 dB, or 85 dB prepulse trials. The session concluded with 5 additional startle only
trials. %PPI was calculated based on the averages for each trial type during those 65 trials by the
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equation: %PPI = (1 -

VMax of prepulse trials
)
VMax of stimulus only trials

x 100%. Startle magnitude was calculated as the average

of the VMax values for the 5 initial startle only trials. Background noise was maintained at 69 dB for the
duration of the experiment. The startle-inducing stimulus was a 120 dB pulse lasting for 20 ms. For
prepulse trials, a 20 ms prepulse of 73 dB, 77 dB, or 85 dB was administered prior to the startle stimulus.
The interstimulus interval was 100 ms from the start of the prepulse to the start of the startle stimulus.
The intertrial interval was an average of 15 s, with a range of 12-18 s. Each PPI session lasted a total of
about 30 minutes.

M4. Molecular Techniques
ELISA
ELISAs were performed using the Mouse IL-6 ELISA MAX™ kit (BioLegend). The day before assay
conduction, 100 µL of a 1:200 dilution of Capture Antibody (ELISA antibodies were included as part of
the kit) in coating buffer (100 mM NaHCO3, 33.6 mM Na2CO3 in ddH2O, pH 9.5) was added to wells of a
96 well Nunc MaxiSorp™ plate (Invitrogen) and incubated at 4°C overnight. The next day, the wells were
washed (solution added and then plate inverted and tapped on surface to remove liquid) in 300 µL Wash
Buffer (137 mM NaCl, 2.68 mM KCl, 10.1 mM Na2HPO4, 1.76 mM KH2PO4, 0.05% Tween 20, pH 7.4) three
times. The wells were then blocked in 200 µL Assay Diluent (137 mM NaCl, 2.68 mM KCl, 10.1 mM
Na2HPO4, 1.76 mM KH2PO4, 1% BSA in ddH2O, pH 7.4) by sealing and incubating at room temperature for
1 hour with shaking. The wells were then washed 4 times in Wash Buffer. 100 µL of 1:100 dilutions of
serum samples in Assay Diluent were added to wells in triplicate, as were mouse IL-6 standards (7.8 –
500 pg/ml) diluted in Assay Diluent, before sealing and incubation with shaking at room temperature for
2 hours. The wells were then washed 4 times in Wash Buffer. 100 µL of a 1:200 dilution of Detection
Antibody in Assay Diluent was added to each well and the plate was sealed and incubated at room
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temperature for 1 hour with shaking. The wells were then washed 4 times in Wash Buffer before
addition of 100 µL of a 1:1000 dilution of Avidin-HRP in Assay Diluent, sealing, and incubation at room
temperature for 30 min with shaking. The plate was then washed 5 times in Wash Buffer, with soaking
of wells for 30 sec to 1 min during each wash. 100 µL of TMB Substrate Solution (BioLegend, a 1:1
mixture of TMB Substrate A and TMB Substrate B) was added to each well and incubated in the dark for
5-10 min. The reaction was stopped by addition of 100 µL Stop Solution (BioLegend) and absorbance
was read at 450 nm with subtraction of the absorbance at 570 nm using a VICTOR Nivo™ multimode
plate reader (PerkinElmer). Sample concentrations were determined using the curve obtained using the
IL-6 standards.
Total mRNA Extraction
Mouse frontal cortex samples that had been stored at -80°C (as described in Poly-(I:C) Validation above)
were thawed on ice. Once thawed, samples were minced with a razor blade before transferring to an
Eppendorf tube. The minced tissue was then homogenized in 1 ml of QIAzol lysis reagent (Qiagen) by
passing it up and down using a 20G needle and syringe. The homogenized tissue was then transferred to
a clean Eppendorf tube and 200 µL of chloroform were added before vortexing for 15 s. The samples
were then incubated at room temperature for 3 minutes before centrifugation at 12,000 ✕ g for 4
minutes at 4°C. The resulting aqueous phase was then transferred to a clean Eppendorf tube and mixed
with an equivalent volume of 70% ethanol by vortexing. The remainder of the extraction process was
completed using a Qiagen RNeasy kit. After vortexing with ethanol, samples were loaded onto RNeasy
MinElute spin columns and centrifuged at 8000 ✕ g at room temperature in rounds of 30 s until all of the
sample had been loaded onto the columns (two rounds of loading and centrifugation). The columns
were then washed with 350 µL of Buffer RW1 and centrifuged at 8000 ✕ g at room temperature for 30 s.
On-column DNase I digestion was performed by adding 80 µL of a 1:7 dilution of DNase I stock solution
in Buffer RDD from an RNase-Free DNase Set (Qiagen) to the columns and incubating for 15 min at room
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temperature. The columns were then washed with 350 µL of Buffer RW1 and centrifuged for 30 s at
room temperature. The columns were washed in 500 µL of Buffer RPE and centrifuged for 30 s. For a
final wash, 500 µL of Buffer RPE were added to the columns, which were then centrifuged at 21,130 ✕ g
for 3 min to remove all liquid. 50 µL of RNase-free water were then incubated on the columns for 2 min
before elution of RNA by centrifugation at 8000 ✕ g for 1 min. Sample concentrations were evaluated
using a NanoDrop 2000 spectrophotometer measuring at wavelengths of 260 and 280 nm (Thermo
Scientific) in anticipation of reverse transcription. Non-sterile tools used to manipulate frontal cortex
samples during extraction were sprayed with RNaseZap™ solution (Invitrogen) and rinsed with diH2O
before use.
Reverse Transcription
1000 ng of RNA from each sample were brought to 10 µL volume with ddH2O. 5 µL of Master Mix 1 (1 µL
of 50 µM Oligo(dT), 1 µL 10 mM dNTP mix, 1 µL 100 mM dithiothreitol [all from Invitrogen], 2 µL ddH2O
per sample) were added to each sample before heating at 65°C for 5 minutes. 5 µL of Master Mix 2 (4 µL
5x First-Strand Buffer [250 mM Tris-HCl at pH 8.3, 375 mM KCl, 15 mM MgCl2], 0.5 µL RNaseOUT™
Ribonuclease Inhibitor, 0.5 µL SuperScript™ III Reverse Transcriptase [all from Invitrogen]) were added
to each sample, which was then incubated at 50°C for 1 hour followed by heat inactivation of Reverse
Transcriptase at 70°C for 15 min. The resulting cDNA was then diluted 1:30 in ddH2O and stored at -80°C
until use.
qPCR
qPCR reactions were performed in quadruplicate for each combination of sample and primer. Each 5 µL
reaction contained 2 µL of the 1:30 dilution of cDNA generated by reverse transcription (or 20 ng of DNA
for the microbiome evaluation experiment, 2 µL of precipitated gDNA for ChIP experiments; see below)
as well as 0.5 µL of 2 µM primer stock solution and 2.5 µL of PowerUp™ SYBR™ Green Master Mix.
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Samples and primers were loaded onto MicroAmp™ optical 384 well plates (Applied Biosystems), which
were sealed and briefly pulse centrifuged to collect samples at the bottom of the wells. qPCR was
performed using a QuantStudio™ 6 Flex Real-Time PCR System (Applied Biosystems). Amplification was
for 40 cycles (45 cycles were used for the GR ChIP-qPCR experiment in untreated mice). The median
values from amplification quadruplicates were used for analysis. Primers used for qPCR are listed in
Table M1.
Microbiome Evaluation
Adult female mice were sacrificed and the cecum and appendix was dissected out and cut based on
previously described protocols.102 Cecum and appendix contents were transferred to pre-weighed
Eppendorf tubes using sterile inoculation loops (BD Difco). The tube filled with cecum contents was then
weighed again to obtain wet weights and samples were frozen at –80°C until use. DNA was isolated
using a PowerFecal DNA Isolation kit (MO BIO Laboratories). Samples were placed in a Dry Bead tube
and vortexed with 750 µL of Bead Solution. 60 µL of Solution C1 were added and the tubes were
vortexed, then heated at 65°C for 10 min. Cells in the sample were then lysed by vortexing at maximum
speed for 10 min. Tubes were centrifuged at 13,000 ✕ g for 1 min and the supernatant was transferred
to a clean tube. 250 µL of Solution C2 were added to precipitate other compounds in the sample and
tubes were vortexed before incubation at 4°C for 5 min. Tubes were again centrifuged at 13,000 ✕ g for
1 min and the supernatant was transferred to a clean tube. 200 µL of Solution C3 were added and
samples were vortexed, then incubated at 4°C for 5 min before an additional centrifugation at 13,000 ✕
g for 1 min. The supernatant was transferred to a clean tube and 1,200 µL of Solution C4 were added
and vortexed to facilitate binding of DNA to spin columns. Samples were transferred to a Spin Filter
column and centrifuged at 13,000 ✕ g for 1 min in three rounds to load samples onto columns. The
columns were then washed with Solution C5 and centrifuged for 1 min at 13,000 ✕ g. The column was
then dried by an additional centrifugation at 13,000 ✕ g. After placing the columns into a clean
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Collection Tube, samples were eluted into 50 µL of Solution C6 by centrifugation at 13,000 ✕ g for 1 min.
The eluted DNA was then stored at -80°C until use. 20 ng of sample were loaded into each reaction for
qPCR and values were reported based on copies of the 16S rRNA gene per wet weight of cecum
contents.
Subcellular Fractionation
Neuro 2a cells or mouse frontal cortex samples were homogenized in 1 ml of Tris-HCl (50 mM, pH 7.4)
supplemented with 0.25 M sucrose using a Teflon-glass homogenizer. The samples were then
centrifuged at 1000 ✕ g for 5 min at 4°C. The supernatant (S1 fraction) was transferred to a new tube.
The pellet (P1 fraction) was resuspended in Tris-HCl and transferred to a new tube for use as the nuclear
fraction, which was resuspended in Tris-HCl. The S1 fraction was centrifuged at 40,000 ✕ g for 20 min at
4°C. The resulting supernatant (S2 fraction) was retained as the cytoplasmic fraction. The pellet (P2
fraction) was resuspended in 10 ml of Tris-HCl to wash the pellet. The P2 fraction was then resuspended
in 1 ml of Tris-HCl. Protein was quantified using the Bradford protein assay (Bio-Rad Protein Assay Dye
Reagent Concentrate) with 10-40 µg of BSA as the standard, measuring absorbance at 595 nm with a
Genesys 20 spectrophotometer (Thermo Scientific). Following quantification, the nuclear fraction was
centrifuged at 1000 ✕ g for 5 min at 4°C and the supernatant was removed. The P2 fraction was
centrifuged at 17,000 ✕ g for 15 min at 4°C and the supernatant was removed. The nuclear, cytoplasmic,
and P2 fractions were stored at -80°C until the day of western blotting.
Western Blotting
Samples for western blotting were prepared as follows: 20 µg of protein diluted in Tris-HCl were mixed
with 5✕ Laemmli buffer (7.5% by volume β-mercaptoethanol, 313 mM tris, 10% SDS by weight, 67.5%
glycerol by volume, scant volume of bromophenol blue to add color to buffer, in diH2O). The samples
were then heat denatured for 5-10 min at roughly 97°C. Samples were then kept on ice until loading.
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Samples were loaded onto an SDS-PAGE gel (12%) and run at room temperature using an Mini-PROTEAN
Tetra cell system (Invitrogen; running buffer: 192 mM glycine, 25.0 mM tris, 0.347 mM SDS). Samples
were transferred onto a nitrocellulose membrane (Amersham™, 0.45 µm pore size) in a Mini Trans-Blot
system overnight at 4°C (Invitrogen; transfer buffer: 192 mM glycine, 25 mM tris base, 10% methanol).
Blots were then washed in TBST (65 mM tris base, 150 mM NaCl, 0.05% Tween 20, pH 7.6) and blocked
for 1 hour at room temperature (blocking buffer: 2.5% by weight nonfat dry milk, 0.5% by weight BSA in
TBST). Blots were then incubated in primary antibody (see below) in blocking buffer for 1 hour at room
temperature or overnight at 4°C. The blots were washed in TBST, blocked for 30 min at room
temperature, and incubated in a 1:5000 dilution of HRP-conjugated secondary antibody for 1-1.5 hours
at room temperature. Following a final round of washing, the blots were incubated in a working solution
of SuperSignal™ West Pico PLUS Chemiluminescent Substrate (Thermo Fisher, 1:1 mixture of
Luminol/Enhancer and Stable Peroxide Solutions) for 5 min at room temperature. The blots were then
dried and imaged using a ChemiDoc MP Imaging System (Bio-Rad). Blots were stripped between use of
different antibodies by incubation in mild stripping buffer (200 mM glycine, 3.47 mM SDS, 1% Tween 20,
pH 2.2) for 15 min at room temperature as necessary. Primary antibodies used were 1:100 mouse-antiGR (Santa Cruz, sc-393232), 1:3000 mouse-anti-α-tubulin (Abcam, ab7291), and 1:3000 rabbit-anti-βactin (Abcam, ab8227). Secondary antibodies used were 1:5000 ECL HRP-linked mouse IgG (Amersham,
NA931) and 1:5000 ECL HRP-linked rabbit IgG (Amersham, NA934). Densitometry was evaluated using
ImageJ (NIH).
Chromatin Immunoprecipitation
Crosslinked chromatin immunoprecipitation (as opposed to native chromatin immunoprecipitation for
histones) was performed using a MAGnify™ Chromatin Immunoprecipitation System (Applied
Biosystems). One hemisphere of mouse frontal cortex tissue was minced with a razor blade in 250 µL of
cold DPBS (Corning), then transferred to an Eppendorf tube. The tissue was then homogenized by
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passing it up and down through an 18G needle 10 times, then through a 21G needle 20 times. An
additional 200 µL of room temperature DPBS were added, then formaldehyde was added to a final
concentration of 1% for crosslinking. Chromatin was crosslinked for 10 min, with swirling of the tubes
every 2 min. The reaction was then quenched with a final concentration of 125 mM glycine. The samples
were then transferred to fresh tubes and centrifuged at 200 ✕ g at 4°C for 10 min. The supernatant was
discarded and, to wash the chromatin, 500 µL of cold DPBS were used to resuspend the pellet before
centrifuging again at 200 ✕ g at 4°C for 10 min. This process of washing was then repeated a second
time.
150 µL of Lysis Buffer containing 1✕ Protease Inhibitors were added to each pellet and the samples were
gently vortexed before incubation on ice for 5 min. Samples were then either snap frozen and stored at
-80°C until further processing or taken directly for sonication. The chromatin was then sheared using a
Covaris S2 ultrasonicator (done for 20 cycles at Intensity 2 with 200 bursts per cycle, a duty cycle of 5%,
and a cycle time of 60 s at 4°C), then transferred to a fresh tube. Debris was pelleted by spinning at
17,000 ✕ g for 5 min at 4°C. The chromatin supernatant was then transferred to a fresh tube.
10 µL Protein A/G Dynabeads (Invitrogen) were added to 100 µL cold Dilution Buffer in PCR tubes, then
captured using a magnet. The buffer was removed, then 100 µL of cold Dilution Buffer were added to
each tube. 2 µL of 1 mg/ml rabbit-anti-GR (Abcam ab3579) or 1 mg/ml rabbit negative control IgG
(Millipore PP64B) were added to the tubes and antibodies were conjugated to beads for at least 1 hour
at 4°C.
The sheared chromatin was diluted 1:9 in cold Dilution Buffer with 1✕ Protease Inhibitors. A 10 µL
aliquot of this dilution was kept for the input control. The antibody-conjugated beads were collected on
a magnet and the liquid was removed from the tubes. 100 µL of diluted chromatin were added to the
beads and the tubes were rotated at 4°C overnight to immunoprecipitate the chromatin. The next day,
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beads were captured on a magnet and the liquid was removed. 100 µL of cold IP Buffer 1 were added
and used to resuspend the beads, the tubes were rotated at 4°C for 5 min, the beads were captured on
a magnet, and the liquid was removed. This washing process was then repeated two more times. 100 µL
of IP Buffer 2 were added to the beads, the beads were resuspended, the tubes were rotated at 4°C for
5 min, the beads were captured on a magnet, and the liquid was removed. This washing process was
repeated one additional time.
The input samples were thawed and 43 µL of Reverse Crosslinking Buffer and 1 µL of Proteinase K were
added. After the second wash with IP Buffer 2, 53 µL of Reverse Crosslinking Buffer and 1 µL of
Proteinase K were added to the beads, which were then gently vortexed for resuspension. Crosslinking
for the input and immunoprecipitation samples was then reversed by heating at 55°C for 15 min. The
beads were then captured and the liquid, which contained the immunoprecipitated DNA, was
transferred to a fresh tube. The tubes were incubated at 65°C for 15 min to inactivate Proteinase K, then
cooled on ice for at least 5 min.
For each sample, 50 µL of DNA Purification Buffer were combined with 20 µL of DNA Purification Beads
and added to the immunoprecipitated DNA and input samples. The samples were pipetted up and down
to mix and incubated at room temperature for 5 min. The beads were captured on a magnet and the
liquid was removed. 150 µL of DNA Wash Buffer was added to each sample and pipetted up and down
to mix. The beads were captured on a magnet and the liquid was removed, then 150 µL of DNA Elution
Buffer was added and samples were mixed by pipetting. Samples were incubated at 55°C for 20 min to
elute the DNA and beads were captured on a magnet. The liquid, which contained the DNA, was
transferred to a new tube and stored at -80°C until the day of analysis. Samples were evaluated by qPCR,
with each anti-GR ChIP, IgG ChIP, and input sample being run in quadruplicate. Primers targeting sites on
the 5-HT2AR promoter and gene were used for amplification (see Table M1).

32

M5. Murine Surgeries and Imaging Techniques
Stereotaxic Surgeries
Adult mice were anesthetized with 2% isoflurane (Covetrus) and their heads were shaved around the
surgical site using an electric razor. After securing the head in the bite and ear bars of a stereotaxis (Kopf
Instruments), lubricant ophthalmic ointment (Major) was applied to protect the eyes and the head was
cleaned and sterilized with povidone iodine swabsticks (Dynarex) interspersed with 70% ethanol.
Anesthesia was maintained using 1-2% isoflurane via nose cone throughout the procedure. A midline
incision was made on the dorsal surface of the head and the skin flaps were secured with bulldog clamps
(Fine Science Tools). Subcutaneous tissue above the skull was removed using hydrogen peroxide.
Bregma was identified and marked and the skull was established to be flat by adjusting the head until
lambda and bregma were at the same dorsoventral coordinate. The injection coordinates were +1.6mm
rostrocaudal, -2.4mm dorsoventral, +2.6mm mediolateral relative to bregma. Following calculation of
final coordinate values, bilateral holes were drilled in the skull at the rostrocaudal and mediolateral
coordinates using an Ideal brand Micro-Drill™. Bilateral Hamilton syringes were advanced through the
drilled holes at a 10° angle and positioned at the injection coordinates in mouse brain. 0.5 µL (ΔGR
experiments) or 1.5 µL (dendritic spine experiments) of adeno-associated viral vector solution were
delivered at a rate of 0.1 µL/min. Following injection, the Hamilton syringes were left in mouse cortex
for an additional 5 min before removal. The incision site was then closed using Vetbond™ tissue
adhesive (3M) and the mouse was returned to a cage with a heat source for recovery. Mice were
monitored for appropriate wound healing as well as signs of distress or hypothermia. Experiments were
conducted in injected mice after 3 weeks, when transgene expression is maximal.103 Vectors used for
injection included AAV8-CaMKIIα-eYFP and AAV8-CaMKIIα-ΔGR-P2A-eYFP, both of which had been
packaged by the UNC Vector Core.
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Perfusion and Sectioning
Mice that had been injected with the AAV8-CaMKIIα-eYFP vector 3 weeks prior were anesthetized with
9 mg/ml ketamine (Henry Schein) / 5 mg/ml xylazine (AnaSed) i.p. in normal saline. Anesthetized mice
were suspended using needles through their paws, the abdomen was opened, and the diaphragm was
displaced by blunt dissection. The anterior portion of the rib cage was removed, exposing the heart. The
left ventricle was pierced by a 22G needle (SURFLO winged infusion set, Terumo) and PBS was pumped
into the circulatory system (Mini Pump Variable Flow, Thomas Scientific) to clear it of blood. The inferior
vena cava was cut to allow for outflow. After about 10 ml of PBS had been pumped through the
circulatory system, mice were perfused with 30 ml of 4% PFA in PBS. Following perfusion, the brain was
dissected and stored in 30% sucrose in PBS at 4°C until sectioning. Perfused frontal cortex was cut into
50 µm sections on a VT1000S vibratome (Leica) using a speed of about 5 and a frequency of about 5 and
sections were stored at 4°C in PBS until immunofluorescence.
Dendritic Spine Quantification
For immunofluorescence, sections were incubated in 4% PFA in PBS for 20 min. All washes during the IF
protocol were conducted with shaking. Sections were washed in PBS for 10 min, then permeabilized in
0.1% Triton X-100 in PBS for 15 min. After an additional two washes in PBS, sections were blocked in
blocking buffer (5% BSA in 0.1% Triton X-100 in PBS). Sections were then incubated in a 1:1000 dilution
of rabbit-anti-GFP primary antibody (Invitrogen, A-11122) in blocking buffer overnight at 4°C. Sections
were then washed in PBS and incubated in a 1:2000 dilution of Alexa Fluor 488-conjugated anti-rabbit
secondary antibody (Invitrogen, A-11008) in blocking buffer at room temperature for 1 hour. The
sections were then washed three times in PBS and mounted on #1.5 coverslips (Fisher) in ProLong
Diamond antifade mountant (Invitrogen). After placement on slides, the sections were allowed to cure
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overnight before sealing with nail polish top coat (Seche Vite). Slides were stored at 4°C in the dark until
imaging.
Slides were imaged by confocal laser scanning microscopy using the 488 nm laser line of an LSM 710
microscope. Z-stacks were acquired for layer 5 dendrites in mouse frontal cortex using a 63✕ objective
with 2.5✕ zoom, yielding stacks of 632 ✕ 632 pixel images with a pixel size of 0.09 µm ✕ 0.09 µm ✕ 0.2
µm. Files were converted to TIFF files for analysis. Dendrite image stacks were then analyzed using
NeuronStudio software104 by a blinded experimenter. Dendritic lengths were determined by tracing the
dendrite images within the software. With its Rayburst sampling algorithm, NeuronStudio was used to
classify dendritic spines as stubby, thin, or mushroom in morphology.
Immunofluorescence in mouse cortex
Brains of mice that had been stereotaxically injected with AAV8-CaMKIIα-eYFP or AAV8-CaMKIIα-ΔGRP2A-eYFP and perfused as described above were cut into 50 µm sections as described. The resulting
slices were then subjected to the same immunofluorescence staining protocol as described in the
Dendritic Spine Quantification section, with the following exceptions: The primary antibody used was a
1:50 mouse-anti-GR (Santa Cruz, sc-393232) and the secondary antibody was 1:2000 Alexa Fluor 568conjugated goat-anti-mouse (Invitrogen, A-11004).
Images were acquired using the 488 and 561 nm laser lines of an LSM 710 confocal laser scanning
microscope. A 63✕ objective was used, resulting in 1912 ✕ 1912 pixel images with a 0.07 µm ✕ 0.07 µm
pixel size.
Fluorescein-labeled Probe Design
The National Center for Biotechnology Information Basic Local Alignment Search Tool and Primer-BLAST
(NIH) were used to identify a unique 162 bp sequence in mouse 5-HT2AR cDNA spanning exons 1 and 2.
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The primer sequences are included in Table M1. The target sequence was amplified from mouse cDNA
by PCR with 4 units of Platinum™ Taq in 1✕ PCR Buffer containing 1.5 mM MgCl2, 0.2 mM dNTPs (all
from Invitrogen), 0.4 µM forward primer, and 0.4 µM reverse primer using the following program: 95°C
for 1 min, 2✕ (95°C for 15 s, 64°C for 15 s, 72°C for 45 s), 6✕ (95°C for 15 s, 61°C for 15 s, 72°C for 45 s),
20✕ (95°C for 15 s, 58°C for 15 s, 72°C for 45 s), 20✕ (95°C for 15 s, 55°C for 15 s, 72°C for 45 s), 72°C for
10 min, hold at 4°C. The PCR product was then run on a 0.7% gel made with low-melting agarose (Gold
Biotechnology) containing 0.006% ethidium bromide in SB buffer. The sample was excised and placed in
an Eppendorf tube that had been pre-weighed to allow calculation of gel weight. The DNA was then
purified using the same Macherey-Nagel PCR clean-up/gel extraction kit as described above, with the
following exceptions: buffer NT1 was used at a volume of 200 µL/100 ng gel and the final elution was
into 15 µL of Buffer NE.
The purified DNA was then introduced into a plasmid vector using a Zero Blunt™ TOPO™ PCR Cloning kit
(Invitrogen). To accomplish this, 4 µL of purified DNA were combined with 1 µL of Salt Solution and 1 µL
pCR™-Blunt II-TOPO™ vector (both Invitrogen) and incubated for 30 min at room temperature. 2 µL of
the resulting plasmid solution were used to transform One Shot™ TOP10 Chemically Competent E. coli
(Invitrogen). Cells were left on ice for 30 min, then heat shocked at 40°C for 30 s. 250 µL of S.O.C.
medium were added and the cells were shaken in tubes at 37°C for 1 hour. 50 or 150 µL of this solution
were spread on kanamycin selective plates made with LB agar and cultured at 37°C overnight. The next
day, colonies were selected and grown in 5 ml of LB broth with 0.03 mg/ml kanamycin at 37°C overnight.
The plasmid was then purified using a QIAprep Spin Miniprep kit (Qiagen) as described above, with the
following exception: the initial spin was at 6,800 ✕ g for 3 min at 15-25°C and DNA was eluted into 30 µL
of Buffer EB. A NanoDrop 2000 spectrophotometer was used to evaluate plasmid concentration. 3 µg of
plasmid were linearized using 60 units of high fidelity HindIII in CutSmart™ Buffer (New England Biolabs)
for at least 1 hour at 37°C. The fluorescein-labeled RNA probe was then transcribed using 1 µg of
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linearized probe with 40 units of SP6 or T7 polymerase (Thermo Scientific) and 1✕ Fluorescein RNA
Labeling Mix (Roche) in 0.5✕ Transcription Buffer (Thermo Scientific) at 37°C for 2 hours. The kit enables
labeling via incorporation of fluorescein-12-uridine triphosphate into RNA. DNA was removed from the
probe by incubation with 2.73 Kunitz units (in 1 µL) of DNase I (Qiagen) at 37°C for 30 min; protein was
subsequently removed by incubation with 0.3 milliAnson units (in 0.5 µL) of Proteinase K (Millipore) for
15 min at 55°C, followed by incubation at 90°C for 5 min in order to inactivate the enzyme. To this
solution, RNA was precipitated by addition of 20 µL 1✕ TE buffer made with DEPC-treated water (DEPCTE buffer; 10 mM tris, 1 mM EDTA, pH 8.0), 32 µL 5M ammonium acetate, and 200 µL ethanol, vortexing
and incubating at -20°C for 1 hour. The sample was then centrifuged at 17,000 ✕ g for 30 min at 4°C and
the supernatant was removed. The pellet was resuspended in 250 µL of 70% ethanol made with DEPCH2O. The tube was then agitated to remove the pellet from the wall of the tube and the probe was then
stored at -80°C. The probe was then centrifuged at 17,000 ✕ g for 30 min at 4°C, the supernatant was
removed, and the pellet was resuspended in 30 µL of RNase-free water (Invitrogen) for use. A sense
strand probe for the same 5-HT2AR site was generated in the same manner and used as a negative
control.
Fluorescence in situ Hybridization
Adult mice were perfused and brains sectioned as described above, with the following exceptions:
RNaseZap™ solution was used to treat all non-sterile tools that contacted the brain and resulting
sections. 10 ml DEPC-PBS was used to clear the circulation and perfusion was done with 10 ml of 4% PFA
in DEPC-PBS made with electron microscopy grade PFA (Electron Microscopy Sciences). Following
perfusion, brains were stored in cryoprotectant (2% by volume DMSO, 20% by volume glycerol in DEPCPBS) until sectioning. Frontal cortices were cut into 20 µm sections in cryoprotectant and stored at 4°C
until hybridization.
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20 µm sections of mouse frontal cortex were washed for 5 min in DEPC-PBS twice with shaking. Sections
were then mounted and dried on Superfrost™ Plus microscope slides (Fisherbrand). Slides were placed
in Coplin jars and incubated for 10 min in SSC 5x buffer (748 mM NaCl, 74.8 mM Na3C6H5O7·H2O in DEPCH2O, pH 7) with shaking. A border was drawn around the sections with a Liquid Blocker hydrophobic pen
(Daido Sangyo Co.) and slides were placed in a pre-heated, humidified StainTray™ Slide Staining System
(Simport). The slides were covered with blocking solution (50% by volume formamide, 25% by volume
SSC 20✕ buffer [2.99 M NaCl, 299 mM Na3C6H5O7·H2O in DEPC-H2O, pH 7], 25% by volume DEPC-H2O,
0.8% by volume salmon sperm DNA [Invitrogen]) and incubated at 37°C for 2 hours. The fluoresceinlabeled RNA probe was diluted (1:40 for experimental; 1:20, 1:40, and 1:100 to evaluate probe dilution;
1:20 for sense strand negative control) in hybridization buffer (50% by volume formamide, 40% by
volume 50% dextran sulfate solution [Millipore], 10% SSC 20✕) and the resulting solution was heated at
77°C for 5 min. The blocking solution was removed from the sections and the probe in hybridization
buffer was added; the slides were then covered with HybriSlip™ hybridization covers (Grace Bio-Labs),
sealed with Fixogum rubber cement (Marabu), and incubated overnight at 37°C. The next day, the slide
covers were removed and slides were washed at room temperature in SSC 2✕ buffer (299 mM NaCl, 29.9
mM Na3C6H5O7·H2O in ddH2O, pH 7) for 5 min three times in Coplin jars with shaking. The slides were
then washed for 30 min with shaking in SSC 2✕ buffer that had been heated to 43°C. The slides were
washed for 30 min with shaking in SSC 0.1✕ buffer (15 mM NaCl, 1.5 mM Na3C6H5O7·H2O in ddH2O, pH 7)
that had been heated to 43°C. Autofluorescence was then reduced by incubating slides with shaking in
Coplin jars containing 0.1% Sudan Black B that had been dissolved in 70% ethanol in the dark overnight
and syringe filtered using a 0.45 µm filter (Corning). Slides were then washed three times in PBS with
shaking. Sections were dried, mounted in Duolink In Situ Mounting Medium with DAPI (Sigma-Aldrich),
covered with #1.5 coverslips, and sealed.
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The 488 nm laser line of an LSM 710 confocal laser scanning microscope was used to acquire images
from mouse frontal cortex (delineated by +1.4 to +1.9 mm relative to bregma). Images were acquired
with a 63✕ objective, yielding 1912 ✕ 1912 pixel images with a pixel size of 0.07 µm ✕ 0.07 µm. Files were
converted to TIFF format for analysis. Fluorescence intensity was evaluated by a blinded experimenter
using ImageJ.

M6. Experiments Involving Postmortem Human Samples
Postmortem Human Brain Tissue Samples
The collection of postmortem tissue samples in the laboratory of Dr. J Javier Meana was described by Dr.
Carolina Muguruza Millan: Human brains were obtained at autopsies performed in the Basque Institute
of Legal Medicine, Bilbao, Spain. The study was developed in compliance with policies of research and
ethical review boards for postmortem brain studies (Basque Institute of Legal Medicine, Spain).
Retrospective searches were conducted for previous medical diagnosis and treatment using examiners’
information and records of hospitals and mental health centers. After searching antemortem
information, 32 subjects who had met criteria of schizophrenia according to the Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV105 and DSM-IV TR106) were selected. Toxicological
screening for antipsychotics, other drugs and ethanol was performed in blood, urine, liver and gastric
contents samples. The toxicological assays were performed at the National Institute of Toxicology,
Madrid, Spain, using a variety of standard procedures including radioimmunoassay, enzymatic
immunoassay, high-performance liquid chromatography and gas chromatography–mass spectrometry.
The schizophrenia subjects were divided into 16 antipsychotic-free (AP-free) and 16 antipsychotictreated (AP-treated) subjects according with the presence or absence of antipsychotics in blood at the
time of death.
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Controls for the present study were chosen among the collected brains on the basis, whenever possible,
of the following cumulative criteria: (i) negative medical information on the presence of
neuropsychiatric disorders or drug abuse and (ii) appropriate sex, age, postmortem delay (time between
death and autopsy, PMD) and freezing storage time to match each subject in the schizophrenia group.
Causes of death among the schizophrenia patients included suicide (n=19), accidents (n=2) and natural
deaths (n=11). Controls’ causes of death included accidents (n=20) and natural deaths (n=12).
Specimens of prefrontal cortex (Brodmann’s area 9) were dissected at autopsy (0.5–1.0 g tissue) on an
ice-cooled surface and immediately stored at −80°C until use. Tissue pH values were within a relatively
narrow range (control subjects: 6.48 ± 0.08; schizophrenia subjects: 6.28 ± 0.05). The definitive pairs of
AP-free schizophrenia subjects and respective matched controls are shown in Table M2, and the
definitive pairs of AP-treated schizophrenia subjects and respective matched controls are shown in Table
M3. All the parameters taken into account for the pairs matching (age, PMD and storage time) were not
statistically different between groups, as shown in Tables M2 and M3 (p > 0.05, two tailed t-test). Pairs
of schizophrenia patients and matched controls were processed simultaneously and under the same
experimental conditions.
Western Blotting in Postmortem Human Brain
300 mg of postmortem human prefrontal cortex samples were homogenized using a chilled Teflon-glass
grinder containing 6 ml homogenization buffer (0.32 M sucrose in 5 mM Tris-HCl, pH 7.4). Samples were
then centrifuged at 1,100 ✕ g at 4°C for 15 min. The supernatant (S1 fraction) was transferred to a new
tube and kept on ice. The pellet (P1 fraction) was resuspended in 6 ml homogenization buffer and
centrifuged under the same conditions as before. The P1 fraction was retained as the nuclear fraction
and resuspended in 700 µL incubation buffer (5 mM Tris-HCl, pH 7.4) to store at -80°C until use. The S1
fraction was centrifuged at 40,000 ✕ g at 4°C for 10 min and the resulting supernatant (S2) was retained
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as the cytoplasmic fraction. The cytoplasmic fraction was stored at -80°C. Protein concentration was
determined using the Bradford protein assay with BSA as the standard.
Samples for western blotting were prepared by heating nuclear and cytoplasmic samples combined with
denaturing and reducing agents (to final concentrations of 2.5% β-mercaptoethanol, 2% SDS, 8%
glycerol, 0.01% bromophenol blue) at 95°C for 5 min. Appropriate amounts of sample to load on a blot
were determined using a sample pool for each fraction. 25 µg of nuclear samples and 15 µg of
cytoplasmic fraction were run on 12% SDS-PAGE gels and transferred onto nitrocellulose membranes
(Amersham™, 0.45 µm pore size). Blots were then incubated for 1 hour in blocking buffer (2.5% by
weight nonfat dry milk, 0.5% by weight BSA in 5 mM Tris-HCl, pH 7.4) and then incubated in primary
antibodies overnight at 4°C in TBST incubation buffer (blocking buffer supplemented with 0.01% Tween
20). The next day, blots were washed and incubated in fluorescent secondary antibodies, then imaged
using an Odyssey infrared imaging system (LI-COR Biosciences). Signal was quantified as integrated
intensity using Image Studio™ Lite version 5.2 (LI-COR Biosciences). Primary antibodies used were 1:100
mouse-anti-GR (Santa Cruz, sc-393232) and 1:20,000 rabbit-anti-β-actin (Abcam, ab8227). Secondary
antibodies used were 1:6000 Alexa Fluor 680-conjugated goat-anti-mouse (Invitrogen, A21057) and
1:10,000 DyLight™ 800-conjugated donkey-anti-rabbit (Rockland, 611-745-127).

M7. Statistical Analysis
For RT-qPCR experiments, amplification was normalized to a correction factor calculated from
amplification of housekeeping genes. For each housekeeping gene, the difference between Ct values
from individual samples and the overall median Ct value from all samples was calculated. For each
sample, the median was then taken from all housekeeping genes for each sample to calculate the
correction factor.
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For western blotting in mouse samples, densitometry was analyzed with normalization to the
housekeeping gene and by blot. For chromatin immunoprecipitation, data were analyzed by calculating
anti-GR fold change over IgG. For dendritic spine analysis, densities for each spine types, as well as the
total density, were calculated from spine number and dendritic segment length. Dendritic spine
densities were then reported as spines per µm. For FISH, a region of interest was drawn around the
border for each cell and mean fluorescence intensity in the region of interest was used for analysis. Cells
were selected from among two fields for each animal. For western blotting in postmortem human
samples, target protein immunoreactivity was corrected using both β-actin immunoreactivity and a
standard pool sample that was loaded onto every gel. Each sample was analyzed on at least two gels,
with at least four measurements taken per sample.
Statistical analysis was performed using GraphPad Prism software versions 8 and 9. For experiments
with one factor with two levels, a two-tailed Student’s t-test was used. For experiments with one factor
with more than two levels, a one-way ANOVA was used with Bonferroni’s post-hoc test as appropriate.
Experiments with two factors were analyzed by two-way ANOVA with Bonferroni’s post-hoc test as
appropriate. For GR immunoreactivity in postmortem samples, a paired two-tailed Student’s t-test was
used and Grubb’s test was used to identify outliers. For the corticosterone time course, a one-way
ANOVA was used with Dunnett’s post-hoc test to allow for direct comparison of every group with
Vehicle. For corticosterone and ΔGR PPI experiments, a three-way ANOVA was also included. For
analysis of the relationship between VMax and average %PPI, Pearson’s correlation was used. Sample
sizes were not formally calculated, but were determined based on previous experiments. Following
analysis of results, power analysis was conducted using G*Power107 to determine sample sizes necessary
to determine if trends detected in experiments reflect genuine effects on relevant phenotypes. All
figures depict the mean with SEM for error bars.
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Primer Set

Sequence

Source

Wild Type Fwd

GTGTGATGGCTCTTGATTATGC

Ibi et al, 2017

5-HT2AR KO Fwd
Common Rev

TCTCTTGATTCCCACTTTGTGGTT
CTGTGGGATTTTCTTTCTGCTT

SFB

SFB736
SFB884

GACGCTGAGGCATGAGAGCAT
GACGGCACGGATTGTTATTCA

Kim et al, 2017

Universal Bacteria

UniF340
UniR514

ACTCCTACGGGAGGCAGCAGT
ATTACCGCGGCTGCTGGC

Kim et al, 2017

IL-6

Fwd
Rev

TAGTCCTTCCTACCCCAATTTCC
TTGGTCCTTAGCCACTCCTTC

Chow, Yan, and Wu, 2016

5-HT 2A R

Fwd
Rev

GCAGTCCATCAGCAATGAGC
GCAGTGGCTTTCTGTTCTCC

Kurita et al, 2012

5-HT 2C R

Fwd
Rev

GTATTCCCTCCCTTCCTTGC
CGTGTGTGAATGAGCAGAGC

Kurita et al, 2012

D2

Fwd
Rev

CTCTACCCTCCAATCCACTC
CATCCACAGCCTCCTCTAAG

Kurita et al, 2012

GR

Fwd
Rev

TTCGCAGGCCGCTCAGTGTT
TTGGGAGGTGGTCCCGTTGCT

Nguyen et al, 2016

FKBP4

Fwd
Rev

GAGGAAATGCAAAAGGTCCA

Lebsack et al, 2010

FKBP5

Fwd
Rev

GTACAACAAAGCCGTGGAGTG
GCCCTGTTCTGAGGATTGACT

Zheng et al, 2016

DUSP1

Fwd
Rev

CTGCCTTGATCAACGTCTCA
GTCTGCCTTGTGGTTGTCCT

*

GILZ

Fwd
Rev

TGGTGGCCATAGACAACAAG
CTTCAGGGCTCAGACAGGAC

*

PER1

Fwd
Rev

TACCAGCCATTCCGCCTAAC
TCCGGGGAGCTTCATAACCA

*

Actin

Fwd
Rev

AGAGGGAAATCGTGCGTGAC
CAATAGTGATGACCTGGCCGT

Chow, Yan, and Wu, 2016

GAPDH

Fwd
Rev

TGCGACTTCAACAGCAACTC
CTTGCTCAGTGTCCTTGCTG

Kurita et al, 2012

MAPK5

Fwd
Rev

CATTGCCCAGTGTATCCTCC
ACCTGCTTTACCACCTCTGC

Kurita et al, 2012

rpS3

Fwd
Rev

AGGTTGTGGTGTCTGGGAAG
GAGGCTTCTTGGGACCAATC

Kurita et al, 2012

-361 to -204

Fwd
Rev

CCATCCCTCCTGGACACATCA
GTCATATTTTTAGGCTGAGGGGTG

+92 to +201

Fwd
Rev

GATTCCTCTCTGTGCGCTCG
TTCCAGCACGGTTGAAGTCT

+698 to +886

Fwd
Rev

AGCAGCATATCCAACCCGAGAA
TGGCTCTTGATTATGCCTCGC

+1003 to +1137

Fwd
Rev

GACTCGCTAGTCTCTCCACA
GCCTCGAGTCGTCACCTAAT

+1170 to +1340

Fwd
Rev

TCCGAAGCCTCGAACTGGA
CCAGTATGTTTCCCGCAATGG

+1692 to +1880

Fwd
Rev

CCTGTATTCCAATACTCTGTGAGC
AGCACTAATGCTCTCTCTGCAA

ΔGR Cloning

Fwd
Rev

TTTTGGATCCATGGACTCCAAAGAATCCTT
TTTTGGCGCGCCTGAGACTCCTGCAGTGGCTT

5-HT 2A R Antisense Probe

Fwd
Rev

GCAGAATGCCACCAACTATTTC
TTTACCTGGATGTGCTCTTCTC

Genotyping Primers
5-HT2AR Genotyping

Microbiome Primers

qPCR Primers

CTTCTCGTTGTTGCTGTCCA

ChIP Primers

Cloning Primers

FISH Probe Primers

Negative Control Sense Probe Fwd
Rev

GAGAAGAGCACATCCAGGTAAA
GAAATAGTTGGTGGCATTCTGC
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Table M1 | Primers used in these studies are listed. All primers were synthesized by Integrated DNA
Technologies. For ChIP primers, numbering is relative to the transcriptional start site. Fwd: Forward,
Rev: Reverse. Papers Listed in Table: Chow, Yan, and Wu, 2016;26 Ibi et al, 2017;84 Kim et al, 2017;38
Kurita et al, 2012;108 Nguyen et al, 2016;109 Lebsack et al, 2010;110 Zheng et al, 2016.111 *Primer
sequences for DUSP1, GILZ, and PER1 were generously provided by Dr. Gretchen Neigh.
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Sex
(F/M)

Age at death
(years)

Postmortem
delay (h)

Storage time
(months)

Antipsychotic
treatment

Additional
drugs

Schizophrenia 1
Control 1

M
M

30
29

51
18

203
68

(-)

(-)
(-)

Schizophrenia 2
Control 2

M
M

48
47

20
18

122
142

(-)

(-)
BDZ

Schizophrenia 3
Control 3

M
M

31
31

11
13

113
99

(-)

(-)
ETH (0.96 g/l)

Schizophrenia 4
Control 4

M
M

45
44

3
21

106
92

(-)

BDZ
(-)

Schizophrenia 5
Control 5

M
M

27
28

24
30

104
178

(-)

(-)
(-)

Schizophrenia 6
Control 6

M
M

46
46

22
24

69
67

(-)

(-)
(-)

Schizophrenia 7
Control 7

M
M

48
49

11
8

50
43

(-)

(-)
(-)

Schizophrenia 8
Control 8

M
M

45
47

18
15

59
44

(-)

(-)
(-)

Schizophrenia 9
Control 9

M
M

34
36

15
48

62
117

(-)

(-)
(-)

Schizophrenia 10
Control 10

M
M

52
51

7
13

66
46

(-)

BDZ
(-)

Schizophrenia 11
Control 11

M
M

49
46

12
6

33
28

(-)

BDZ
ETH (1.91 g/l)

Schizophrenia 12
Control 12

M
M

60
62

12
9

43
66

(-)

BDZ
(-)

Schizophrenia 13
Control 13

F
F

67
66

22
16

52
24

(-)

(-)
(-)

Schizophrenia 14
Control 14

M
M

34
33

23
28

116
28

(-)

(-)
ETH (0.97 g/l)

Schizophrenia 15
Control 15

M
M

32
32

52
4

121
44

(-)

BDZ
ETH (2.98 g/l)

Schizophrenia 16
Control 16
Schizophrenia

M
M
1F/15
M
1F/15
M

(-)

(-)
(-)

Control

32
32
42.5±2.9

21
16
20.3 ±3.4

122
33
90.1±10.9

42.4±2.9

17.9±2.7

69.9±11.2

Table M2 | Demographic characteristics of antipsychotic-free schizophrenia subjects and their
respective control subjects. Antipsychotics were not detected in blood samples of schizophrenia
subjects. Abbreviations: benzodiazepines (BDZ), ethanol (ETH).
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Sex

Postmortem
delay (h)

Storage
time
(months)

Antipsychotic
treatment

Additional drugs

(F/M)

Age at
death
(years)

Schizophrenia 17
Control 17

M
M

30
29

18
36

130
185

OLZ

(-)
ETH (1.71 g/l)

Schizophrenia 18
Control 18

M
M

32
32

8
4

125
24

QTP

BDZ
(-)

Schizophrenia 19
Control 19

M
M

23
23

16
17

120
93

SUL

(-)
(-)

Schizophrenia 20
Control 20

M
M

35
36

3
23

120
63

QTP

BDZ
(-)

Schizophrenia 21
Control 21

M
M

33
33

23
4

107
99

CLZ

(-)
(-)

Schizophrenia 22
Control 22

M
M

35
36

11
18

70
140

CLZ

BDZ
ETH (1.69 g/l)

Schizophrenia 23
Control 23

F
F

42
38

38
22

129
46

CLZ, QTP, SUL

BDZ
(-)

Schizophrenia 24
Control 24

M
M

37
41

8
24

75
180

OLZ

BDZ, ETH (0.90 g/l)
(-)

Schizophrenia 25
Control 25

F
F

60
60

23
48

54
60

CLZ, SUL

BDZ
BDZ

Schizophrenia 26
Control 26

F
F

56
58

13
20

119
176

CLZ

(-)
(-)

Schizophrenia 27
Control 27

M
M

43
44

5
29

21
24

OLZ

BDZ
(-)

Schizophrenia 28
Control 28

M
M

58
57

6
3

21
39

CLP

(-)
(-)

Schizophrenia 29
Control 29

M
M

51
50

18
2

22
33

PAL

BDZ
(-)

Schizophrenia 30
Control 30

M
M

51
50

28
24

25
20

OLZ,CLP

BDZ
(-)

Schizophrenia 31
Control 31

M
M

34
33

21
17

28
33

HAL

BDZ
(-)

APZ

(-)
(-)

Schizophrenia 32
Control 32
Schizophrenia
Control

M
M
3F/13M
3F/13M

58
56
42.4±2.9
42.3±2.9

16
15
15.9 ±2.3
19.1±3.1

33
18
74.9±11.4
77.1±15.3

Table M3 | Demographic characteristics of antipsychotic-treated schizophrenia subjects and their
respective control subjects. Therapeutic levels of aripriprazole (APZ), clotiapine (CLP), clozapine (CLZ),
haloperidol (HAL), olanzapine (OLZ), paliperidone (PAL), quetiapine (QTP) and sulpiride (SUL) were
detected in blood samples of schizophrenia subjects. Abbreviations: benzodiazepines (BDZ), ethanol
(ETH).
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Results

RA. Poly-(I:C)-elicited immune responses and gut microbiota evaluation support use of 129S6/SvEv
and C57BL6/N mice as mothers for maternal immune activation experiments
RA.1. Poly-(I:C) elicits an immune response in both 129S6/SvEv and C57BL6/N female mice
Maternal immune activation paradigms have been developed in rodents to model environmental risk
factors for neurodevelopmental disorders such as schizophrenia and recapitulate alterations observed in
those disorders.5 Although poly-(I:C) has been extensively used to induce MIA models,26 the immune
response to poly-(I:C) has been demonstrated to be variable based on both source and lot.36 To confirm
effects of poly-(I:C) in adult mice within our experimental system, we administered 20 mg/kg poly-(I:C)
i.p. to adult female mice of either the 129S6/SvEv or C57BL6/N strain and sacrificed the mice 2.5 hours
later. Most, but not all, poly-(I:C)-treated mice exhibited sickness behavior (such as ruffled fur, hunched
posture, decreased activity, and ptosis) following treatment (data not shown). Given that IL-6 is a key
proinflammatory mediator elicited by poly-(I:C) administration,39 we evaluated IL-6 induction in injected
mice. Poly-(I:C) elicited immune responses in 129S6/SvEv mice, with both increased IL-6 mRNA by RTqPCR in mouse frontal cortex (Fig. 1a; t4 = 5.21, p < 0.01) as well as increased serum IL-6 by ELISA (Fig.
1c; t4 = 10.65, p < 0.001). Similarly, poly-(I:C) increased IL-6 mRNA in mouse frontal cortex in C57BL6/N
mice (Fig. 1b; t4 = 3.25, p < 0.05), as well as serum IL-6 (Fig. 1d; t6 = 3.07, p < 0.05). In addition, at 24
hours after poly-(I:C) administration, treated female C57BL6/N mice exhibited decreased percent weight
change relative to controls (Fig. 1e; t14 = 5.17, p = 0.0001). Therefore, the poly-(I:C) used in our
experiments elicits a prominent immune response in both 129S6/SvEv and C57BL6/N female mice,
allowing its use for subsequent MIA experiments.
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Fig. 1 | Poly-(I:C) elicits an immune response in injected mice. a-d. Adult female mice were injected i.p.
with 20 mg/kg poly-(I:C) or vehicle 2.5 hours before sacrifice and IL-6 induction was assessed by either
RT-qPCR in samples from mouse frontal cortex (a,b) or ELISA in mouse serum (c,d). a,c. In 129S6/SvEv
mice, poly-(I:C) elicits an increase in IL-6 mRNA (n = 3 mice/group; t4 = 5.21, p < 0.01) as well as IL-6
protein (n = 3 mice/group; t4 = 10.65, p < 0.001). b,d. In C57BL/6N mice, poly-(I:C) produces an increase
in IL-6 mRNA (n = 3 mice/group; t4 = 3.25, p < 0.05) as well as IL-6 protein (n = 4 mice/group; t6 = 3.07, p
< 0.05). e. WT C57BL/6N mice were injected i.p. with poly-(I:C) or vehicle and percent change in baseline
weight was evaluated 24 hours later. Poly-(I:C) produces a decrease in percent body weight change at 24
hours relative to vehicle (n = 8 mice/group; t14 = 5.17, p = 0.0001). Statistical analysis was performed by
two-tailed Student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001.

RA.2. Mice used as mothers in our MIA experiments are positive for segmented filamentous bacteria
Segmented filamentous bacteria (Candidatus Savagella, SFB) within the maternal gut microbiome have
been demonstrated to be necessary for MIA-induced phenotypes in offspring.38 In those studies, mice
from Taconic have been demonstrated to be SFB positive, while mice from Jackson Laboratories have
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been demonstrated to be negative. To evaluate the gut microbiota of mice to be used as mothers in our
studies, we extracted DNA from cecum contents from mice from our 129S6/SvEv colony, C57BL6/N mice
from Charles River, C57BL6/J mice from Jackson Laboratories, and C57BL6/N from Taconic and
performed qPCR for the 16S rRNA gene. Since the 16S rRNA gene is detectably variable by taxon, we
used primers specific to the 16S rRNA gene of SFB.38 To profile the total abundance of bacterial 16S
rRNA in the cecum, we also used universal bacterial 16S rRNA gene primers, which detect the gene
across the vast majority of bacterial taxa.38 qPCR for the SFB 16S rRNA gene revealed that the gut
microbiome from mice purchased from Charles River exhibit significantly greater enrichment of the gut
microbiome for SFB compared to mice from the other three sources (Fig. 2a; F[3,8] = 8.40, p < 0.01;
Bonferroni’s post-hoc: p < 0.05 for CRL vs.129S6/SvEv, p < 0.05 for CRL vs JAX, p < 0.05 for TAC).
Excluding mice from Charles River, both 129S6/SvEv mice from our colony as well as mice from Taconic
exhibit significantly greater microbiome enrichment for SFB compared to mice from Jackson (Fig. 2b;
F[2,6] = 30.95, p < 0.001; Bonferroni’s post-hoc test: p < 0.01 for 129S6/SvEv vs. JAX, p < 0.001 for TAC
vs. JAX, p = 0.059 for TAC vs. 129S6/SvEv), consistent with previous findings. Evaluating universal
bacterial 16S rRNA, mice from Jackson exhibit significantly greater abundance of 16S rRNA gene copies
in the cecum compared to mice from any of the other three sources (Fig. 2c; F[3,8] = 11.09, p < 0.01;
Bonferroni’s post-hoc test: p < 0.01 for JAX vs. 129S6/SvEv, p < 0.05 for JAX vs. CRL, p < 0.01 for JAX vs.
TAC). Mice to be used as mothers in our MIA studies are therefore positive for SFB.
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Fig. 2 | Female mice from Charles River (C57BL6/N), Taconic (C57BL6/N), and the in-house Maeso lab
129S6/SvEv colony, but not from Jackson Laboratories (C57BL6/J), have gut microbiota enriched for
segmented filamentous bacteria. DNA was extracted from mouse cecum contents and qPCR was
performed for the 16S ribosomal RNA gene using primers for either segmented filamentous bacteria
(a,b) or universal bacterial primers that detect the gene across bacterial taxa (c). a. Mice from different
sources exhibit differing levels of SFB DNA within cecum contents (n = 3 mice/group; F[3,8] = 8.40, p <
0.01). Mice from Charles River exhibit higher levels of SFB DNA compared to mice from any of the other
three sources (p < 0.05 for CRL vs. 129S6/SvEv, p < 0.05 for CRL vs. JAX, p < 0.05 for CRL vs. TAC). b. The
same data as in a are depicted, but the mice from Charles River are excluded. Similarly, mice from
different sources exhibit differing levels of SFB DNA within cecum contents (F[2,6] = 30.95, p < 0.001).
Mice from the Maeso lab 129S6/SvEv colony and from Taconic exhibit higher levels of SFB compared to
mice from Jackson (p < 0.01 for 129S6/SvEv vs. JAX, p < 0.001 for TAC vs. JAX) and mice from Taconic
exhibit a trend towards higher SFB DNA compared to the 129S6/SvEv colony (p = 0.059). c. Mice from
different sources exhibit differing levels of total 16S rRNA gene DNA in cecum contents (n = 3
mice/group; F[3,8] = 11.09, p < 0.01). Mice from Jackson exhibit higher total 16S rRNA gene DNA
compared to mice from the other three groups (p < 0.01 for JAX vs. 129S6/SvEv, p < 0.05 for JAX vs. CRL,
p < 0.01 for JAX vs. TAC). Statistical analysis was performed by one-way ANOVA followed by Bonferroni’s
post-hoc test. *p < 0.05, **p < 0.01, ***p < 0.001.
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RB. MIA induces 5-HT2AR dysregulation as well as alters 5-HT2AR-related phenotypes in adult offspring
RB.1. Maternal poly-(I:C) induces MIA phenotypes in adult offspring
Following evaluation of our model components, we administered 20 mg/kg poly-(I:C) or vehicle control
to pregnant C57BL6/N female mice on day E12.5 of pregnancy and evaluated MIA-associated
phenotypes in adult offspring. MIA-induced dysregulation of the 5-HT2AR in adult offspring frontal cortex
has been shown by us and others, including at the receptor density level by radioligand binding and at
the mRNA level by RT-qPCR.21, 74 In order to both verify increased 5-HT2AR mRNA expression in mouse
frontal cortex in our model as well as explore this dysregulation within the context of intact (as opposed
to homogenized) tissue, we decided to take a fluorescence in situ hybridization (FISH) approach. Frontal
cortex slices from brains of perfused adult MIA and control offspring were hybridized with a fluorescein
labeled 5-HT2AR mRNA antisense probe. As validation of the specificity of the FISH signal, we observe
decreasing signal with increasing dilution of the probe (Fig. 3a). Signal is absent with use of a sense
strand 5-HT2AR mRNA probe (Fig. 3b). The location in frontal cortex used for quantification is depicted in
Fig. 3c. FISH in MIA and control offspring frontal cortex demonstrates that cells from MIA offspring
exhibit increased 5-HT2AR mRNA relative to cells from control offspring (Fig. 3d,e; t120 = 2.12, p < 0.05).
Therefore 5-HT2AR mRNA is increased in MIA offspring frontal cortex.
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Fig. 3 | Maternal immune activation increases 5-HT2AR mRNA expression in frontal cortex of adult
offspring. a,b. Control experiments demonstrate signal specificity. a. Signal in mouse frontal cortex
decreases with increasing dilution factors of the antisense probe. b. Signal is absent when a sense probe
is used. c. 20 µm sections from frontal cortex (1.4-1.9 mm relative to bregma; see rectangle) of adult
mice born to poly-(I:C)-treated mothers or controls were hybridized with fluorescein-labeled antisense
probes against 5-HT2AR mRNA. d. Representative images of probe-labeled cells in mouse frontal cortex
(1:40 dilution) are shown. Mean fluorescence intensity within the boundaries of cells was used for
quantification. e. MIA increases 5-HT2AR mRNA expression in mouse frontal cortex (n = 61 cells from 4
mice/group; 2-3 litters/group were used; t120 = 2.12, p < 0.05). Statistical analysis was performed by
two-tailed Student’s t-test. *p < 0.05.
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Prepulse inhibition of startle (PPI) is a sensorimotor gating behavioral paradigm that has been shown to
be altered in both schizophrenia as well as MIA animal models.20, 44 The 5-HT2AR has been implicated in
PPI through pharmacology as well as human 5-HT2AR gene polymorphisms.64, 77, 78 We conducted PPI
assays according to a standard paradigm101 (Fig. 4a) in both MIA and control C57BL6/N offspring mice.
Similar to previous findings, we observed PPI deficits in MIA adult offspring relative to controls (Fig. 4b;
Prepulse Intensity: F[2,153] = 46.90, p < 0.0001; Maternal Treatment: F[1,153] = 12.52, p < 0.005;
Interaction: F[2,153] = 0.044, p < 0.05), both as a main effect as well as a trend towards a decrease in
%PPI specifically at the 85 dB prepulse level (Bonferroni’s post-hoc test: p = 0.074). In addition, adult
MIA mice exhibit a decrease in startle magnitude during the initial 5 trials of our PPI paradigm (Fig. 4c;
t51 = 2.25, p < 0.05). Our MIA offspring are therefore confirmed to have both molecular and behavioral
alterations with relevance to 5-HT2AR-related phenotypes.

Fig. 4 | Maternal immune activation produces PPI deficits in adult offspring. a. Schematic of
experimental paradigm for PPI. Adult mice born to poly-(I:C)-treated mothers or controls were placed in
acoustic startle chambers and allowed to habituate to 69 dB of background noise for 5 minutes.
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Following 5 stimulus only trials (120 dB), mice were subjected to 65 interspersed trials of startle stimulus
alone, no stimulus, or prepulse followed by startle stimulus. Average values from these trials were used
to calculate %PPI. b. MIA produces a main effect of decreased %PPI in adult offspring as well as a trend
towards a decrease in %PPI at the 85 dB prepulse level (n = 21-32 mice/group; 3-4 litters/group were
used; Prepulse Intensity: F[2,153] = 46.90, p < 0.0001; Maternal Treatment: F[1,153] = 12.52, p < 0.005;
Interaction: F[2,153] = 0.044, p > 0.05; p = 0.074 at 85 dB prepulse level). c. MIA produces a decrease in
startle magnitude in adult offspring (n = 21-32 mice/group; 3-4 litters/group were used; t51 = 2.25, p <
0.05). Statistical analysis was performed by two-way ANOVA followed by Bonferroni’s post-hoc test (b)
or two-tailed Student’s t-test (c). *p < 0.05, ***p < 0.001.

RB.2. MIA decreases mushroom spine density in offspring frontal cortex in a 5-HT2AR-dependent
manner
Alterations in dendritic spine density in prefrontal cortex have been reported in samples from
schizophrenia subjects relative to healthy controls.49 5-HT2AR signaling has been reported to have
relevance for dendritic spine density.80, 83 To determine if MIA offspring exhibit alterations in dendritic
spine density as well as if these alterations might be 5-HT2AR dependent, we induced MIA in 129S6/SvEv
5-HT2AR heterozygote female mice with 20 mg/kg poly-(I:C) or provided control treatment (Fig. 5a). We
then sterotaxically injected the resulting WT and 5-HT2AR KO adult offspring with an AAV8-CaMKIIα-eYFP
viral vector to allow visualization of dendrites on cortical pyramidal neurons (Fig. 5b). For stubby spines,
MIA induces a trend towards decreased spine density (Fig. 6a, Table 1; Maternal Treatment: F[1,363] =
3.64, p = 0.057; Genotype: F[1,363] = 1.96, p > 0.05; Interaction: F[1,363] = 4.91e-005, p > 0.05). Neither
MIA nor genotype affects density of thin spines (Fig. 6b; Maternal Treatment: F[1,363] = 0.48, p > 0.05;
Genotype: F[1,363] = 1.97, p > 0.05; Interaction: F[1,363] = 0.11, p > 0.05). MIA produces a decrease in
mushroom spine density (Fig. 6c; Maternal Treatment: F[1,363] = 6.58, p < 0.05) and a Maternal
Treatment x Genotype Interaction (F[1,363] = 8.46, p < 0.01). There was also a trend towards decreased
mushroom spine density in 5-HT2AR KO mice (Genotype: F[1,363] = 3.01, p = 0.084) relative to WTs. MIA
reduces mushroom spine density in WT (Bonferroni’s post-hoc test: p < 0.001), but not 5-HT2AR KO (p >
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0.05) offspring. 5-HT2AR KO offspring exhibit decreased mushroom spine density compared to WT
controls, regardless of treatment (p < 0.01 for WT Control vs. 5-HT2AR KO Control, p < 0.05 for WT
Control vs. MIA 5-HT2AR KO). For total spine density, there are trends towards a decrease in MIA
offspring as well as 5-HT2AR KO mice (Fig. 6d; Maternal Treatment: F[1,363] = 3.72, p = 0.054; Genotype:
F[1,363] = 3.58, p = 0.059; Interaction: F[1,363] = 0.55, p > 0.05). Immunofluorescence confirms viral
vector expression in layers 2/3 and 5 (Fig. 6e) and representative images of dendrites and spines are
shown (Fig. 6f). Therefore, MIA induces a decrease in mature mushroom spines on cortical pyramidal
neurons in mouse frontal cortex in a 5-HT2AR-dependent manner.
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Fig. 5 | Maternal immune activation was induced in 5-HT2AR heterozygote mothers to generate wild
type and 5-HT2AR KO offspring. The breeding scheme for generating MIA offspring for dendritic spine
experiments is depicted. a. 5-HT2AR heterozygote female mice were bred and used as mothers for these
experiments. On E12.5 of pregnancy, the mice were injected with 20 mg/kg poly-(I:C) or vehicle. b. Adult
WT and 5-HT2AR KO offspring born to these mothers were used in dendritic spine experiments.
Heterozygote offspring were sacrificed.

Fig. 6 | Maternal immune activation produces decreased mushroom spine density in frontal cortex of
WT, but not 5-HT2AR KO, adult offspring. An AAV8-CaMKIIα-eYFP viral vector was stereotaxically
injected into mouse frontal cortex to allow visualization of dendrites (see methods for coordinates) (e,f).
Dendritic spines were classified and quantified using NeuronStudio software (a-d). a. MIA produces a
trend towards a main effect of decreased stubby spine density (n = 5-8 mice/group; 3-5 litters/group;
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73-109 dendrites/group for all spine types; Maternal Treatment: F[1,363] = 3.64, p = 0.057; Genotype:
F[1,363] = 1.96, p > 0.05; Interaction: F[1,363] = 4.91e-005, p > 0.05). b. Neither MIA nor genotype affects
thin spine density (Maternal Treatment: F[1,363] = 0.48, p > 0.05; Genotype: F[1,363] = 1.97, p > 0.05;
Interaction: F[1,363] = 0.11, p > 0.05). c. MIA produces a main effect of decreased mushroom spine
density (Maternal Treatment: F[1,363] = 6.58, p < 0.05) as well as a Maternal Treatment x Genotype
Interaction (F[1,363] = 8.46, p < 0.01). In addition, there is a trend towards a main effect of Genotype
(F[1,363] = 3.01, p = 0.084). Post-hoc tests reveal decreased mushroom spine density in MIA WT
offspring relative to Control WT offspring (p < 0.001), but no difference between MIA and Control 5HT2AR KO offspring (p > 0.05). In addition, 5-HT2AR KO offspring exhibit decreased mushroom spine
density relative to Control WT offspring regardless of maternal treatment (p < 0.01 for WT Control vs. 5HT2AR KO Control, p < 0.05 for WT Control vs. 5-HT2AR KO MIA). d. Both Maternal Treatment and
Genotype produce trends towards a main effect on total spine density (Maternal Treatment: F[1,363] =
3.72, p = 0.054; Genotype: F[1,363] = 3.58, p = 0.059; Interaction: F[1,363] = 0.55, p > 0.05). e. eYFP from
viral infection can be observed in layers 2/3 as well as layer 5. f. Representative images of dendritic
segments are depicted. Statistical analysis was performed by two-way ANOVA followed by Bonferroni’s
post-hoc test. *p < 0.05, ***p < 0.001. To simplify the graphs, only group main effect comparisons and
within genotype post-hoc comparisons are depicted in this figure. All comparison results are shown in
Table 1.

Spine Type
Stubby

Comparison

Significance

Control vs. MIA
WT vs. 2A KO
Interaction

p = 0.057
n.s.
n.s.

Spine Type
Mushroom

Main Effects

Comparison

Significance

Control vs. MIA
WT vs. 2A KO
Interaction

*
p = 0.084
**

WT Con vs. WT MIA
WT Con vs. 2A KO Con
WT Con vs. 2A KO MIA
WT MIA vs. 2A KO Con
WT MIA vs. 2A KO MIA
2A KO Con vs. 2A KO MIA

***
**
*
n.s.
n.s.
n.s.

Control vs. MIA
WT vs. 2A KO
Interaction

p = 0.054
p = 0.059
n.s.

Main Effects

Post-hoc Tests

Thin

Total
Main Effects

Main Effects
Control vs. MIA
WT vs. 2A KO
Interaction

n.s.
n.s.
n.s.

Table 1 | Samples were generated and analyzed as in Fig. 6. All comparisons from a two-way ANOVA are
reported in the table for each spine type. For spine types with significant main effects, the results of
Bonferroni’s post-hoc test are also reported. WT: wild type, 2A KO: 5-HT2AR KO.
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RC. MIA alters GR expression and 5-HT2AR promoter occupancy in mouse frontal cortex
RC.1. The GR binds the 5-HT2AR promoter in adult mouse frontal cortex
Following from these findings regarding alterations in 5-HT2AR expression and related phenotypes in MIA
offspring, we sought to determine which mechanisms might underlie this dysregulation. Because 5HT2AR expression has been shown to be regulated by a wide variety of stressors and glucocorticoid
signaling has been shown to regulate 5-HT2AR expression in other experimental systems,89, 91, 93, 95 we
investigated alterations in GR signaling as a potential underlying mechanism for 5-HT2AR alterations in
MIA mice. A putative conserved 5-HT2AR promoter binding site has been proposed by Falkenberg and
Rajeevan and demonstrated for the human 5-HT2AR promoter in vitro.100 To determine whether the GR
binds this predicted site in mouse frontal cortex, we first evaluated the site using the JASPAR
transcription factor database. Using a consensus sequence for the GR (Matrix ID MA0113.1), JASPAR
detects this predicted site as a GR binding site on the mouse 5-HT2AR promoter (Fig. 7a). We therefore
performed chromatin immunoprecipitation (ChIP) to determine if the GR binds the 5-HT2AR promoter in
mouse frontal cortex. Locations of our ChIP-qPCR primers along the 5-HT2AR gene are shown in Fig. 7b.
ChIP-qPCR using an anti-GR antibody or species and isotype-matched IgG control reveals enrichment of
the GR at the predicted binding site, but not at other locations, on the 5-HT2AR gene in mouse frontal
cortex, confirming this GR binding site (Fig. 7c; Gene Site: F[5,73] = 2.80, p < 0.05; Antibody: F[1,73] =
3.96, p = 0.0503; Interaction: F[5,73] = 2.80, p < 0.05; Bonferroni’s post-hoc test: p < 0.001 for GR vs. IgG
at the predicted binding site, p > 0.05 for each other site).
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Fig. 7 | The glucocorticoid receptor binds a predicted site on the 5-HT2AR promoter in adult mouse
frontal cortex. a. The JASPAR database consensus sequence for the GR (shown here as reverse
complement of Matrix ID MA0113.1) is depicted alongside the 5-HT2AR promoter sequence predicted by
Falkenberg and Rajeevan (2010). JASPAR detects this consensus binding site (score 12.98) on the mouse
5-HT2AR promoter. b,c. Chromatin immunoprecipitation was performed in frontal cortex samples from
otherwise untreated adult mice using an anti-GR antibody or isotype and species matched IgG control.
b. The predicted GR binding site, TSS, and ATG site for the mouse 5-HT2AR gene are depicted alongside
the locations of the qPCR primers used for ChIP. c. There is a main effect of Gene Site, a trend towards
an effect of Antibody, as well as a Gene Site x Antibody Interaction (n = 8 mice/group; Gene Site: F[5,73]
= 2.80, p < 0.05; Antibody: F[1,73] = 3.96, p = 0.0503; Interaction: F[5,73] = 2.80, p < 0.05). Post-hoc tests
reveal that the GR is enriched over IgG at the predicted binding site (p < 0.001), but not at other sites
along the 5-HT2AR gene (p > 0.05). Statistical analysis was performed by two-way ANOVA followed by
Bonferroni’s post-hoc test. ***p < 0.001.
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RC.2. MIA induces a decrease in both GR enrichment at the 5-HT2AR promoter and GR
immunoreactivity in the nuclear compartment in mouse frontal cortex
Following this finding in untreated mice, we next sought to determine if MIA affects GR enrichment at
the 5-HT2AR promoter in mouse frontal cortex. MIA was induced with 20 mg/kg i.p. poly-(I:C) in pregnant
C57BL6/N female mice on E12.5 as before and ChIP was conducted in frontal cortex samples from adult
MIA and control offspring. ChIP reveals that MIA produces a decrease in GR enrichment at the 5-HT2AR
promoter binding site (Fig. 8a; t10 = 3.57, p < 0.01), but not a negative control site on the 5-HT2AR gene
(Fig. 8b; t10 = 0.23, p > 0.05), relative to control offspring. Western blotting for the GR in the nuclear and
cytoplasmic compartments of MIA and control mouse frontal cortex reveals that MIA induces a decrease
in GR immunoreactivity in the nuclear (Fig. 8c,e; t11 = 2.34, p < 0.05), but not cytoplasmic (Fig. 8d,f; t11 =
0.57, p > 0.05), compartment. Decreased GR immunoreactivity coinciding with decreased GR enrichment
at the 5-HT2AR promoter as well as increased 5-HT2AR mRNA suggests a negative regulatory relationship
between GR signaling at the 5-HT2AR promoter and 5-HT2AR expression in mouse frontal cortex.
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Fig. 8 | Maternal immune activation induces both decreased enrichment of the GR at the 5-HT2AR
promoter binding site as well as decreased GR protein expression in the nuclear, but not cytoplasmic,
compartment of mouse frontal cortex. a,b. ChIP using an anti-GR antibody or isotype-matched control
was performed in frontal cortex samples from adult mice born to poly-(I:C) or control-treated mothers
and qPCR was performed using primers encompassing the predicted binding site (a) or another site on
the 5-HT2AR gene (b) as a negative control. a. MIA induces decreased enrichment of the GR at the 5HT2AR promoter binding site (n = 4-8 mice/group; 3-4 litters/group; t10 = 3.57, p < 0.01). b. Enrichment of
the GR at a negative control site of the 5-HT2AR gene is not affected by MIA (t10 = 0.23, p > 0.05). c-f.
Western blotting for the GR was performed in nuclear (c,e) and cytoplasmic (d,f) compartments of
frontal cortex samples from adult mice born to poly-(I:C) or control-treated mothers. c. MIA produces a
decrease in nuclear GR immunoreactivity in mouse frontal cortex (n = 6-7 mice/group; 3-4 litters/group;
t11 = 2.34, p < 0.05). d. Cytoplasmic GR immunoreactivity in mouse frontal cortex remains unchanged (t11
= 0.57, p > 0.05). e,f. Representative WB images for the nuclear and cytoplasmic compartments are
shown. Molecular weight in kilodaltons (kDa) is reported to the right of the images. Statistical analysis
was performed by two-tailed Student’s t-test. *p < 0.05, **p < 0.01, n.s., not significant.
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RC.3. Postmortem samples from schizophrenia subjects exhibit increased cytoplasmic GR
immunoreactivity in prefrontal cortex relative to controls
Alterations in GR signaling pathways have been reported in postmortem prefrontal cortex samples from
schizophrenia subjects relative to controls88 and increased 5-HT2AR receptor density has been found in
prefrontal cortex samples from antipsychotic-free schizophrenia subjects.53 Given our findings in mouse
frontal cortex, we performed a similar fractionation protocol to separate nuclear and cytoplasmic
compartments in postmortem prefrontal cortex samples from human schizophrenia subjects and agematched controls. Western blotting in those compartments reveals that samples from schizophrenia
subjects exhibit increased GR immunoreactivity in the cytoplasmic compartment relative to controls
(Fig. 9a,c; t31 = 0.46, p > 0.05) while GR immunoreactivity in the nuclear compartment remains
unchanged (Fig. 9b,d; t28 = 2.25, p < 0.05). This establishes GR dysregulation in prefrontal cortex in
schizophrenia, reflecting alterations observed in MIA frontal cortex in mice.

Fig. 9 | Postmortem samples from schizophrenia subjects exhibit increased GR immunoreactivity
relative to matched controls in the cytoplasmic, but not nuclear, prefrontal cortex compartment.
Western blotting was performed in the nuclear (a,c) and cytoplasmic (b,d) compartments of
postmortem prefrontal cortex samples from schizophrenia subjects and age-matched paired controls. a.
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There is no difference in nuclear GR immunoreactivity in prefrontal cortex samples from schizophrenia
subjects and healthy controls (t31 = 0.46, p > 0.05). b. Prefrontal cortex samples from schizophrenia
subjects exhibit increased cytoplasmic GR immunoreactivity compared to healthy controls (t28 = 2.25, p <
0.05). c,d. Representative WB images for the nuclear (c) and cytoplasmic (d) compartments are shown.
Statistical analysis was performed by paired two-tailed Student’s t-test. *p < 0.05, n.s., not significant.

RD. Short term, high dose corticosterone produces increased 5-HT2AR mRNA and decreased
enrichment of the GR at the 5-HT2AR promoter in mouse frontal cortex
RD.1. A time course of corticosterone administration reveals FKBP5 mRNA induction in mouse frontal
cortex
MIA models have been shown to act as a pleiotropic insults, producing alterations in a variety of
signaling pathways.5 Following our data in mouse frontal cortex suggesting that MIA produces both
increased 5-HT2AR mRNA and decreased enrichment of the GR on the 5-HT2AR promoter, we decided to
investigate the effect of directly manipulating the glucocorticoid system on 5-HT2AR expression and
related phenotypes. Berendsen et al reported that a regimen of 50 mg/kg s.c. corticosterone twice a day
for four days produces increased head shakes in response to the 5-HT2AR agonist DOI in rats.94 To
evaluate and optimize this experimental system in mice, we administered 50 mg/kg s.c. corticosterone
or vehicle twice a day for 8 days to WT 129S6/SvEv mice before sacrifice. Mice received corticosterone
for 0 (the Vehicle condition), 1, 2, 4, 6, or 8 of the days. An additional group that received no injections
was also included. Following this treatment regimen, RT-qPCR was performed in mouse frontal cortex
for mRNA for the GR as well as its positive and negative regulators, FKBP4 and FKBP5, respectively. This
time course produces a trend towards an effect on GR (Fig. 10a; Treatment: F[6,21] = 2.17, p = 0.087),
but not FKBP4 mRNA (Fig. 10b; Treatment: F[6,21] = 1.38, p > 0.05). FKBP5 mRNA was altered during the
time course. Post-hoc testing comparing each group to Vehicle reveals that FKBP5 mRNA is increased
with 1 day of corticosterone administration and remains increased over Vehicle with up to 8 days of
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administration (Fig. 10c; Treatment: F[6,21] = 6.26, p < 0.001; Dunnett’s multiple comparisons test: p <
0.01 for 1 Day Cort. vs. Vehicle; p < 0.05 for 2 Day Cort vs. Vehicle, 4 Day Cort vs. Vehicle, 6 Day Cort vs.
Vehicle, and 8 Day Cort vs. Vehicle). This FKBP5 mRNA induction suggests that this time course results in
induction of, and negative feedback within, the GR pathway in mouse frontal cortex. We therefore
elected to use 4 days as the treatment duration for our studies.

Fig. 10 | A time course of corticosterone administration reveals that short term, high dose
corticosterone increases FKBP5, but not GR or FKBP4 mRNA expression in mouse frontal cortex. Mice
were treated with either 50 mg/kg s.c. corticosterone or vehicle twice a day for eight days or received
no treatment (the No Injection group) before being sacrificed 8.5-13 hours after the last injection. RTqPCR for GR pathway targets was performed in frontal cortex samples from these mice. a. The time
course of corticosterone administration produces a trend towards an effect on GR mRNA expression in
mouse frontal cortex (Treatment: F[6,21] = 2.17, p = 0.087). b. The time course did not affect FKBP4
mRNA expression in mouse frontal cortex (Treatment: F[6,21] = 1.38, p > 0.05). c. The time course
affects FKBP5 mRNA expression in mouse frontal cortex (Treatment: F[6,21] = 6.26, p < 0.001). All
durations of corticosterone administration produce an increase in FKBP5 mRNA compared to vehicle (p
< 0.01 for 1 Day Cort vs. Vehicle; p < 0.05 for 2 Day Cort vs. Vehicle, 4 Day Cort vs. Vehicle, 6 Day Cort vs.
Vehicle, and 8 Day Cort vs. Vehicle). Statistical analysis was performed by one-way ANOVA followed by
Dunnett’s multiple comparisons test, with all groups being compared to Vehicle. *p < 0.05, **p < 0.01.
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RD.2. Short term, high dose corticosterone results in increased 5-HT2AR mRNA in mouse frontal cortex
Adult WT mice were treated twice a day for four days with 50 mg/kg s.c. corticosterone or vehicle and
sacrificed roughly 8.5-13.5 hours later (Fig. 11a). RT-qPCR was then conducted in mouse frontal cortex
for neurotransmitter receptors. Short term, high dose corticosterone produces increased 5-HT2AR mRNA
in mouse frontal cortex relative to vehicle treatment (Fig. 11b; t16 = 2.98, p < 0.01), while leaving 5-HT2CR
(Fig. 11c; t16 = 0.065, p > 0.05) and dopamine D2 mRNA (Fig. 11d; t16 = 0.23, p > 0.05) unaffected. To
further clarify the pattern of GR activation and signaling occurring, RT-qPCR was also conducted for
known GR downstream targets.112 At least at this time point, short term, high dose corticosterone did
not produce changes in expression of DUSP1 (Fig. 12a; t16 = 0.12, p > 0.05), GILZ (Fig. 12b; t16 = 0.59, p >
0.05), or PER1 (Fig. 12c; t16 = 0.81, p > 0.05) mRNA expression in mouse frontal cortex. This regimen
therefore specifically increases 5-HT2AR mRNA, supporting a relationship between GR signaling and
5-HT2AR expression.
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Fig. 11 | Short term, high dose corticosterone increases 5-HT2AR, but not 5-HT2CR or D2, mRNA in
mouse frontal cortex. a. The corticosterone administration paradigm is depicted. Mice were
administered 50 mg/kg s.c. corticosterone or vehicle twice a day for four days and were sacrificed about
8.5-13.5 hours after the last injection. b-d. RT-qPCR for neurotransmitter receptors was performed in
mouse frontal cortex samples following treatment. b. Short term, high dose corticosterone treatment
produces an increase in 5-HT2AR mRNA in mouse frontal cortex (n = 9 mice/group; t16 = 2.98, p < 0.01). c.
Short term, high dose corticosterone does not affect 5-HT2CR mRNA in mouse frontal cortex (t16 = 0.065,
p > 0.05). d. Dopamine D2 mRNA is similarly unaffected (t16 = 0.23, p > 0.05). Statistical analysis was
performed by two-tailed Student’s t-test. **p < 0.01.
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Fig. 12 | Short term, high dose corticosterone does not affect DUSP1, GILZ, or PER1 mRNA expression
in mouse frontal cortex. Mice were administered 50 mg/kg s.c. corticosterone or vehicle twice a day for
four days and were sacrificed about 8.5-13.5 hours after the last injection (same mice as in Fig. 11). RTqPCR for downstream GR targets was performed in mouse frontal cortex samples following treatment.
a. Short term, high dose corticosterone treatment does not affect DUSP1 mRNA expression in mouse
frontal cortex (n = 9 mice/group; t16 = 0.1154, p > 0.05). b. GILZ mRNA expression is similarly unaffected
(t16 = 0.5865, p > 0.05) in mouse frontal cortex. c. PER1 mRNA is also unaffected (t16 = 0.8149, p > 0.05).
Statistical analysis was performed by two-tailed Student’s t-test.

RD.3. Short term, high dose corticosterone decreases GR enrichment at the 5-HT2AR promoter
To determine what might be occurring at the 5-HT2AR promoter following this manipulation, we
performed ChIP-qPCR for the GR on the 5-HT2AR promoter following corticosterone treatment. Mice
were administered corticosterone twice a day for four days as in Fig. 11 and frontal cortex samples were
collected about 8.5-13.5 hours later. ChIP was performed in these samples using an anti-GR antibody or
species and isotype-matched IgG control. qPCR using primers flanking the GR binding site on the 5-HT2AR
promoter demonstrates that short term, high dose corticosterone produces decreased enrichment of
the GR at the 5-HT2AR promoter in mouse frontal cortex (Fig. 13a; t6 = 6.96, p < 0.001). No change in GR
enrichment was observed at a negative control site of the 5-HT2AR gene (Fig. 13b; t6 = 0.38, p > 0.05).
Short term, high dose corticosterone therefore produces increased 5-HT2AR mRNA alongside decreased
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enrichment of the GR at the 5-HT2AR promoter, further suggesting a negative regulatory relationship
between GR signaling and 5-HT2AR expression.

Fig. 13 | Short term, high dose corticosterone produces decreased enrichment of the GR at the 5HT2AR promoter binding site. Mice were administered 50 mg/kg s.c. corticosterone or vehicle twice a
day for four days and were sacrificed about 8.5-13.5 hours after the last injection. ChIP was performed
in these samples using an anti-GR antibody or isotype-matched control. a. Short term, high dose
corticosterone produces decreased enrichment of the GR at the 5-HT2AR promoter binding site in mouse
frontal cortex (n = 4 mice/group; t6 = 6.96, p < 0.001). b. Short term, high dose corticosterone does not
affect GR enrichment at a negative control site of the 5-HT2AR gene (t6 = 0.38, p > 0.05). Statistical
analysis was performed by two-tailed Student’s t-test. ***p < 0.001, n.s., not significant.

RD.4. Short term, high dose corticosterone induces PPI deficits regardless of 5-HT2AR expression
In order to investigate the necessity of 5-HT2AR expression for the behavioral effects of corticosterone
administration in mice, we tested PPI in WT and 5-HT2AR KO mice who had been treated with
corticosterone or vehicle as before. Corticosterone decreases %PPI in WT mice (Fig. 14a; Prepulse
Intensity: F[2,84] = 67.28, p < 0.0001; Treatment: F[1,84] = 4.87, p < 0.05; Interaction: F[2,84] = 0.48, p >
0.05) without affecting startle magnitude (Fig. 14b; t28 = 1.28, p > 0.05). A similar decrease in %PPI was
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observed in 5-HT2AR KO mice treated with corticosterone (Fig. 14c; Prepulse Intensity: F[2,66] = 66.62, p
< 0.0001; Treatment: F[1,66] = 4.20, p < 0.05; Interaction: F[2,66] = 0.24, p > 0.05); startle magnitude
was similarly unaffected (Fig. 14d; t22 = 1.30, p > 0.05). Performing a three-way ANOVA comparing both
genotypes, main effects of Prepulse Intensity, Genotype, and Treatment were observed (Table 2).
Therefore, corticosterone induces decreased %PPI in a manner not dependent on 5-HT2AR expression. In
addition, 5-HT2AR KO mice exhibit increased %PPI when compared to WT mice. Comparing startle
magnitudes across the two genotypes, trends are observed towards decreased startle magnitude in 5HT2AR KO mice (Table 3; p = 0.091) and in mice treated with corticosterone (p = 0.090). Thus, although
corticosterone increases 5-HT2AR mRNA expression in WT mouse frontal cortex, this effect is not
necessary for corticosterone-induced PPI deficits.
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Fig. 14 | Short term, high dose corticosterone produces PPI deficits in both WT and 5-HT2AR KO mice.
The PPI experimental paradigm was performed as in Fig. 4. WT and 5-HT2AR KO mice were treated with
50 mg/kg s.c. corticosterone or vehicle twice a day for four days and were tested about 8.5-13.5 hours
after the last injection. Both %PPI (a,c) and VMax (b,d) are reported for both genotypes. a.
Corticosterone treatment produces a main effect of decreased %PPI in WT mice (n = 15 mice/group;
Prepulse Intensity: F[2,84] = 67.28, p < 0.0001; Treatment: F[1,84] = 4.87, p < 0.05; Interaction: F[2,84] =
0.48, p > 0.05). b. Startle magnitude was unaffected (t28 = 1.28, p > 0.05). c. Similarly, corticosterone
treatment produces a main effect of decreased PPI in 5-HT2AR KO mice (n = 11-13 mice/group; Prepulse
Intensity: F[2,66] = 66.62, p < 0.0001; Treatment: F[1,66] = 4.20, p < 0.05; Interaction: F[2,66] = 0.24, p >
0.05). d. Startle magnitude was unaffected (t22 = 1.30, p > 0.05). Statistical analysis was performed by
two-way ANOVA followed by Bonferroni’s post-hoc test (a,c) or two-tailed Student’s t-test (b,d). *p <
0.05.
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Source of Variation
Prepulse Intensity
Genotype
Treatment
Prepulse Intensity x Genotype
Prepulse Intensity x
Treatment
Genotype x Treatment
Prepulse Intensity x Genotype
x Treatment

% of total variation
58.68
1.595
1.995
0.3288

P value
<0.0001
0.0098
0.0040
0.50

P value summary
***
**
**
n.s.

Significant?
Yes
Yes
Yes
No

0.08142
0.02228

0.84
0.76

n.s.
n.s.

No
No

0.2516

0.58

n.s.

No

Table 2 | Three-way ANOVA reveals improved PPI in 5-HT2AR KO mice as well as PPI deficits in mice
treated with corticosterone. This table analyzes the same WT and 5-HT2AR KO mice treated with
corticosterone or vehicle described in Fig. 14. Three-way ANOVA reveals a main effect of Prepulse
Intensity (F[2,150] = 125.7, p < 0.0001). A main effect of Genotype reveals improved PPI in 5-HT2AR KO
mice (F[1,150] = 6.84, p < 0.01). A main effect of Treatment reveals PPI deficits in mice treated with
corticosterone (F[1,150] = 8.55, p < 0.01). No significant interactions were observed (Prepulse Intensity x
Genotype: F[2,150] = 0.70, p > 0.05; Prepulse Intensity x Treatment: F[2,150] = 0.17, p > 0.05; Genotype
x Treatment: F[1,150] = 0.095, p > 0.05; Prepulse Intensity x Genotype x Treatment: F[2,150] = 0.54, p >
0.05). **p < 0.01, ***p < 0.001, n.s., not significant.

Comparison

Significance

Veh. vs. Cort
WT vs. 2A KO
Interaction

p = 0.090
p = 0.091
n.s.

Main Effects

Table 3 | Two-way ANOVA reveals trends towards main effects of decreased startle magnitude in 5HT2AR KO and corticosterone-treated mice. This table analyzes the same startle magnitude values from
WT and 5-HT2AR KO mice treated with corticosterone or vehicle described in Fig. 14. Two-way ANOVA
reveals a trend towards a main effect of decreased startle magnitude in 5-HT2AR KO mice (Genotype:
F[1,50] = 2.98, p = 0.091). There is also a trend towards a main effect of decreased startle magnitude in
corticosterone-treated mice (Treatment: F[1,50] = 2.99, p = 0.090). No interaction was observed (F[1,50]
= 0.054, p = 0.82). Data were analyzed by two-way ANOVA. n.s., not significant. WT: wild type, 2A KO: 5HT2AR KO.
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RE. An AAV8-CaMKIIα-ΔGR-P2A-eYFP viral vector produces decreased 5-HT2AR mRNA in mouse frontal
cortex accompanied by increased PPI in WT mice
RE.1. A ΔGR construct can be used to express a constitutively translocating GR, expression of which
reduces 5-HT2AR expression in mouse frontal cortex
Systemically administered glucocorticoids exert a wide variety of effects throughout the body.99
Following our MIA and corticosterone findings supporting an apparent negative regulatory relationship
between GR signaling and 5-HT2AR expression, we searched for a third experimental system capable of
manipulating GR signaling specifically in mouse frontal cortex. A GR truncation, ΔGR, was first identified
due to its ability to activate a reporter gene even in the absence of hormone ligand. It was later found
that ΔGR lacked the hormone binding domain113 and was therefore able to constitutively translocate to
the nucleus, where it has the potential to affect transcription.114 We therefore generated a ΔGR
construct from murine cDNA (see methods for additional details) and cloned it to generate a CaMKIIαΔGR-P2A-eYFP plasmid for packaging into an adeno-associated viral vector of serotype 8 (AAV8).103 This
plasmid (Fig. 15a) is expressed under the control of the CaMKIIα promoter, which restricts expression to
pyramidal neurons in mouse cortex.115 In addition, the inclusion of a P2A peptide sequence allows for
expression of ΔGR and eYFP as independent proteins from the same transcript.116 To validate this
plasmid construct, we transfected Neuro-2a (N2a) mouse neuroblastoma cells, which endogenously
express CaMKIIα. To compare subcellular localization of ΔGR with that of WT, we transfected N2a cells
with a plasmid coding for a full-length human GR under the control of the CMV promoter. As a negative
control, additional N2a cells were mock transfected. N2a cells from all three of these experimental
groups were then processed for immunofluorescence (Fig. 15b), including incubation with an anti-GR
primary antibody and Alexa 568-conjugated fluorescent secondary to allow for visualization of the GR.
Nuclei were visualized with Hoechst staining. IF in these cells reveals absence of both eYFP (green
channel) and GR signal (red channel) in mock transfected cells. As expected, eYFP signal is only observed
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in cells transfected with the ΔGR construct. Alexa 568-GR signal is observed following transfection with
either the ΔGR construct or the human GR construct, but the ΔGR construct produces a more nuclear
fluorescence pattern than the full-length GR, suggesting appropriate ΔGR behavior. The difference in
localization patterns for ΔGR and eYFP suggest appropriate function of the P2A peptide. To further
demonstrate expression of the ΔGR plasmid, a WB was conducted in the nuclear fraction of cells
transfected with the ΔGR plasmid or left untransfected as a negative control (Fig. 15c). Probing with an
anti-GR antibody demonstrates GR overexpression relative to controls, further supporting appropriate
ΔGR expression in the nuclear compartment.

Fig. 15 | A CaMKIIα-ΔGR-P2A-eYFP construct independently expresses ΔGR and eYFP protein in Neuro2a cells. a. The structure for a construct coding for ΔGR and eYFP under the control of the CaMKIIα
promoter is depicted. A P2A peptide sequence is included to allow for expression of ΔGR and eYFP as
independent proteins from a single transcript. b. N2a cells were either mock transfected, transfected
with a plasmid coding for a full-length human GR under the control of the CMV promoter, or transfected
with the plasmid coding for the ΔGR truncation and eYFP construct under the control of the CaMKIIα
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promoter. The transfected cells were processes for immunofluorescence 48 hours later and an anti-GR
primary antibody and Alexa 568-conjugated fluorescent secondary antibody were used to visualize GR
protein. IF reveals that the ΔGR truncation exhibits a more nuclear localization pattern than the fulllength human GR. The ΔGR construct expresses eYFP independently from ΔGR as expected, indicating
appropriate function of the P2A peptide. c. N2a cells were transfected with a plasmid containing the
ΔGR construct or mock transfected and western blotting was performed using an anti-GR antibody in
samples from the nuclear compartment collected 48 hours after transfection. An anti-α-tubulin antibody
was used as a loading control. Molecular weight in kDa is reported to the right of the images.
Transfection with the ΔGR construct produces increased GR immunoreactivity in the nuclear
compartment of N2a cells.

RE.2. An AAV8-CaMKIIα-ΔGR-P2A-eYFP viral vector decreases 5-HT2AR mRNA in mouse frontal cortex
After validating the ΔGR construct in cells, we had the plasmid packaged into an AAV8 viral vector, which
was then stereotaxically injected into mouse frontal cortex (Fig. 16a; see methods for coordinates).
Three weeks after surgical injection, mice were perfused and sections were processed for IF, including
incubation with an anti-GR primary antibody and Alexa 568-conjugated fluorescent secondary (Fig. 16b).
Similar to N2a cells, distinct localization patterns of eYFP and Alexa 568-GR signal can be observed,
demonstrating expression and appropriate P2A function of the ΔGR vector in mouse frontal cortex. To
further validate the vector, we performed RT-qPCR for the GR and associated genes in frontal cortex
samples from mice that had been injected with AAV8-ΔGR or an AAV8-eYFP empty vector control. As
expected, AAV8-ΔGR produces increased expression of GR mRNA in mouse frontal cortex (Fig. 16c; t6 =
3.93, p < 0.01). While FKBP4 mRNA remains unaffected (Fig. 16d; t6 = 0.098, p > 0.05), FKBP5 mRNA is
also induced, suggesting negative feedback along the GR signaling pathway (Fig. 16e; t6 = 3.51, p < 0.05).
AAV8-ΔGR is therefore appropriately expressed and functions within mouse frontal cortex.
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Fig. 16 | An AAV8-CaMKIIα-ΔGR-P2A-eYFP viral vector independently expresses ΔGR and eYFP in
mouse frontal cortex. a. The construct described in Fig. 15 was packaged into an AAV8 serotype viral
vector and stereotaxically injected bilaterally into mouse frontal cortex. The Hamilton syringe needles
depict the injection sites (see methods for coordinates). Mice were sacrificed for analysis 3 weeks after
vector injection. b. A representative IF image reveals that the construct is expressed in mouse frontal
cortex and that ΔGR and eYFP are expressed independently due to the P2A peptide. An anti-GR primary
antibody and Alexa 568-conjugated fluorescent secondary were used for GR visualization. c-e. RT-qPCR
was conducted in mouse frontal cortex samples from mice that had been injected with the AAV8-ΔGR
vector or a negative control AAV8-eYFP vector. c. The AAV8-ΔGR vector produces increased GR mRNA
expression in mouse frontal cortex as expected (n = 4 mice/group; t6 = 3.93, p < 0.01). d. ΔGR expression
does not affect FKBP4 mRNA expression in mouse frontal cortex (t6 = 0.098, p > 0.05). e. ΔGR expression
produces increased FKBP5 mRNA expression in mouse frontal cortex (t6 = 3.51, p < 0.05). Statistical
analysis was performed by two-tailed Student’s t-test. *p < 0.05, **p < 0.01.

To further explore the effect of ΔGR expression on GR signaling in mouse frontal cortex, we performed
RT-qPCR for GR downstream target genes. At least at this time point, AAV8-ΔGR does not affect mRNA
expression for the GR targets DUSP1 (Fig. 17a; t6 = 1.14, p > 0.05), GILZ (Fig. 17b; t6 = 1.01, p > 0.05), or
PER1 (Fig. 17c; t6 = 0.17, p > 0.05) in mouse frontal cortex. We next evaluated the effect of the ΔGR
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construct on neurotransmitter receptor expression in mouse frontal cortex by conducting RT-qPCR in
the samples from mice that had been injected with either AAV8-ΔGR or AAV8-eYFP vectors. RT-qPCR for
5-HT2AR mRNA reveals decreased frontal cortex expression in mice injected with AAV8-ΔGR relative to
controls (Fig. 18a; t6 = 2.93, p < 0.05). In contrast, 5-HT2CR (Fig. 18b; t6 = 0.66, p > 0.05) and dopamine D2
(Fig. 18c; t6 = 0.32, p > 0.05) mRNA were not affected by ΔGR expression. Therefore, overexpression of
the GR using a ΔGR construct reduces 5-HT2AR expression, further supporting a negative regulatory
relationship between GR signaling and 5-HT2AR expression. Thus, three independent experimental
approaches support this regulatory relationship.

Fig. 17 | The AAV8-ΔGR vector does not affect DUSP1, GILZ, or PER1 mRNA expression in mouse
frontal cortex. a. RT-qPCR was performed in frontal cortex samples collected 3 weeks after mice were
injected with bilateral frontal cortex with the AAV8-ΔGR vector an AAV8-eYFP vector control (the same
mice as in Fig. 16). a. ΔGR expression does not affect DUSP1 mRNA expression in mouse frontal cortex
(n = 4 mice/group; t6 = 1.136, p > 0.05). b. Similarly, ΔGR expression does not affect GILZ mRNA
expression in mouse frontal cortex (t6 = 1.008, p > 0.05). c. PER1 mRNA expression was also unaffected
by ΔGR expression (t6 = 0.1718, p > 0.05). Statistical analysis was performed by two-tailed Student’s ttest.
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Fig. 18 | The AAV8-ΔGR vector decreases 5-HT2AR, but not 5-HT2CR or D2, mRNA in mouse frontal
cortex. RT-qPCR was performed in frontal cortex samples collected 3 weeks after mice were injected in
bilateral frontal cortex with the AAV8-ΔGR vector or an AAV8-eYFP vector control (the same mice as in
Fig. 16). a. ΔGR expression decreases 5-HT2AR mRNA expression in mouse frontal cortex (n = 4
mice/group; t6 = 2.93, p < 0.05). b. ΔGR expression does not affect 5-HT2CR mRNA expression in mouse
frontal cortex (t6 = 0.66, p > 0.05). c. ΔGR expression does not affect dopamine D2 mRNA expression in
mouse frontal cortex (t6 = 0.32, p > 0.05). Statistical analysis was performed by two-tailed Student’s ttest. *p < 0.05.

RE.3. An AAV8-CaMKIIα-ΔGR-P2A-eYFP viral vector increases PPI in a 5-HT2AR-dependent manner
Following from this finding that AAV8-ΔGR exerts an opposite effect than MIA on 5-HT2AR mRNA in
mouse frontal cortex, we sought to determine the behavioral effects of ΔGR expression on PPI. To
accomplish this, we injected adult WT and 5-HT2AR KO mice with either an AAV8-ΔGR or an AAV8-eYFP
control vector in frontal cortex and tested them for PPI three weeks later. In WT mice, ΔGR expression in
frontal cortex produces increased %PPI relative to control (Fig. 19a; Prepulse Intensity: F[2,84] = 159.6, p
< 0.0001; Vector: F[1,84] = 8.30, p < 0.01; Interaction: F[2,84] = 0.43, p > 0.05), as well as a trend
towards increased %PPI specifically at the 77 dB prepulse intensity (Bonferroni’s post-hoc test: p =
0.092). ΔGR expression had no effect on startle magnitude in WT mice (Fig. 19b; t28 = 0.27, p > 0.05). In
5-HT2AR KO mice, ΔGR expression did not affect %PPI (Fig. 19c; Prepulse Intensity: F[2,87] = 92.77, p <
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0.0001; Vector: F[1,87] = 1.32, p > 0.05; Interaction: F[2,87] = 0.36, p > 0.05) or startle magnitude (Fig.
19d; t29 = 1.22, p > 0.05). Performing a three-way ANOVA comparing both genotypes, main effects of
Genotype, Prepulse Intensity, and Vector are observed (Table 4). Thus, 5-HT2AR KO mice exhibit
increased %PPI relative to WT mice. ΔGR increases %PPI as well, an effect that seems to be driven by WT
mice given that there is no difference between 5-HT2AR KO mice treated with AAV8-ΔGR and AAV8-eYFP
vectors. In addition, WT mice exhibit increased startle magnitude relative to 5-HT2AR KO mice (Table 5),
with increased startle magnitude in WT mice treated with AAV8-ΔGR relative to 5-HT2AR KO mice treated
with AAV8-ΔGR. WT mice treated with AAV8-eYFP exhibit increased startle magnitude compared to 5HT2AR KO mice treated with AAV8-ΔGR (Bonferroni’s post-hoc test: p < 0.05). Therefore ΔGR expression
produces both decreased 5-HT2AR mRNA in mouse frontal cortex as well as increases %PPI in an 5-HT2ARdependent manner, in an apparently opposite pattern to the effects caused by MIA.
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Fig. 19 | AAV8-ΔGR expression in frontal cortex improves PPI in mice in a 5-HT2AR-dependent manner.
The PPI experimental paradigm was performed as in Fig. 4. WT and 5-HT2AR KO mice were injected with
AAV8-eYFP or AAV8-ΔGR vectors 3 weeks before the experiment. Both %PPI (a,c) and VMax (b,d) are
reported for both genotypes. a. ΔGR expression in frontal cortex produces a main effect of increased
%PPI in WT mice as well as a trend towards improved PPI at the 77 dB prepulse level (n = 14-16
mice/group; Prepulse Intensity: F[2,84] = 159.6, p < 0.0001; Vector: F[1,84] = 8.30, p < 0.01; Interaction:
F[2,84] = 0.43, p > 0.05; p = 0.092 at 77 dB prepulse level). b. ΔGR expression in frontal cortex does not
affect startle magnitude in WT mice (t28 = 0.27, p > 0.05). c. ΔGR expression in frontal cortex does not
affect %PPI in 5-HT2AR KO mice (n = 15-16 mice/group; Prepulse Intensity: F[2,87] = 92.77, p < 0.0001;
Vector: F[1,87] = 1.32, p > 0.05; Interaction: F[2,87] = 0.36, p > 0.05). d. ΔGR expression in frontal cortex
does not affect startle magnitude in 5-HT2AR KO mice (t29 = 1.22, p > 0.05). Statistical analysis was
performed by two-way ANOVA followed by Bonferroni’s post-hoc test (a,c) or two-tailed Student’s t-test
(b,d). **p < 0.01.
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Source of Variation
Prepulse Intensity
Genotype
Vector
Prepulse Intensity x Genotype
Prepulse Intensity x Vector
Genotype x Vector
Prepulse Intensity x Genotype
x Vector

% of total variation
70.51
2.906
1.116
0.4991
0.2285
0.1607

P value
<0.0001
<0.0001
0.0063
0.18
0.46
0.30

P value summary
***
***
**
n.s.
n.s.
n.s.

Significant?
Yes
Yes
Yes
No
No
No

0.0008252

0.997

n.s.

No

Table 4 | Three-way ANOVA reveals improved PPI in both 5-HT2AR KO mice as well as mice injected
with AAV8-ΔGR. This table analyzes the same WT and 5-HT2AR KO mice injected with AAV8-ΔGR or
AAV8-eYFP described in Fig. 19. Three-way ANOVA reveals a main effect of Prepulse Intensity (F[2,171] =
241.5, p < 0.0001). A main effect of Genotype reveals improved PPI in 5-HT2AR KO mice (F[1,171] =
19.90, p < 0.0001). A main Vector effect reveals improved PPI following AAV8-ΔGR (F[1,171] = 7.64, p <
0.01), which seems to be driven by the Vector effect in WT mice. No significant effects of interactions
were observed (Prepulse Intensity x Genotype: F[2,171] = 1.71, p > 0.05; Prepulse Intensity x Vector:
F[2,171] = 0.78, p > 0.05; Genotype x Vector F[1,171] = 1.10, p > 0.05; Prepulse Intensity x Genotype x
Vector: F[2,171] = 0.0028, p > 0.05). **p < 0.01, ***p < 0.001, n.s., not significant.

Comparison

Significance

Main Effects
eYFP vs. ΔGR
WT vs. 2A KO
Interaction
Post-hoc Tests
eYFP WT vs. eYFP KO
eYFP WT vs. ΔGR WT
eYFP WT vs. ΔGR KO
eYFP KO vs. ΔGR WT
eYFP KO vs. ΔGR KO
ΔGR WT vs. ΔGR KO

n.s.
**
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
*

Table 5 | Two-way ANOVA reveals a main effect of decreased startle magnitude in 5-HT2AR KO mice.
This table analyzes the same startle magnitude values from WT and 5-HT2AR KO mice injected with
AAV8-ΔGR or AAV8-eYFP described in Fig. 19. Two-way ANOVA reveals a main effect of decreased
startle magnitude in 5-HT2AR KO mice (Genotype: F[1,57] = 8.07, p < 0.01). No significant Vector (F[1,57]
= 0.34, p > 0.05) or Interaction (F[1,57] = 0.99, p > 0.05) effects were observed. Post-hoc tests reveal a
decrease in startle magnitude in AAV8-ΔGR injected 5-HT2AR KO mice relative to AAV8-ΔGR-injected WT
mice (p < 0.05). Data were analyzed by two-way ANOVA followed by Bonferroni’s post-hoc. *p < 0.05,
**p < 0.01, n.s., not significant. WT: wild type, 2A KO: 5-HT2AR KO.
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RE.4. ΔGR induces a negative correlation between average %PPI and startle magnitude in WT mice
Finally, we evaluated Pearson’s correlation between average %PPI and VMax in mice from our ΔGR PPI
experiment. WT mice injected with AAV-eYFP did not exhibit a correlation between Avg. %PPI and VMax
(Fig. 20a; r = 0.056, p > 0.05). However, a negative correlation between Avg. %PPI and VMax was
observed in WT mice injected with AAV-ΔGR (Fig. 20b; r = -0.66, p < 0.01). No significant correlation was
observed in 5-HT2AR KO mice injected with either AAV-eYFP (Fig. 20c; r = -0.26, p > 0.05) or AAV-ΔGR
(Fig. 20d; r = -0.24, p > 0.05). Therefore, ΔGR expression induces a negative correlation between average
%PPI and startle magnitude in WT, but not 5-HT2AR KO mice, which coincides with improved PPI
performance.
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Fig. 20 | AAV8-ΔGR induces a negative correlation between average %PPI and startle magnitude in WT
mice. This figure analyzes the startle magnitude and average of the three %PPI values in WT and 5-HT2AR
KO mice that had been injected with AAV8-eYFP or AAV8-ΔGR presented in Fig. 19. Pearson’s correlation
coefficient (r) was calculated between Avg. %PPI and VMax for mice from each treatment group. The fit
from a simple linear regression is also included in each figure. a. No correlation between Avg. %PPI and
VMax was observed in WT mice injected with AAV8-eYFP (p > 0.05). b. AAV8-ΔGR induces a negative
correlation between Avg. %PPI and VMax in WT mice (p < 0.01). c,d. No correlation was observed for 5HT2AR KO mice injected with either AAV8-eYFP (c) or AAV8-ΔGR (d). The p-value for Pearson’s r was
calculated by a two-tailed test.
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Discussion
D.1. Summary of Findings
These studies support, using three independent models, that GR signaling acts to suppress 5-HT2AR
expression via direct regulation of the 5-HT2AR promoter. Within frontal cortex in a MIA mouse model,
decreased GR immunoreactivity in the nuclear compartment and decreased enrichment of the GR at the
5-HT2AR promoter coincide with increased 5-HT2AR mRNA expression. In turn, MIA induces a 5-HT2ARdependent decrease in mushroom dendritic spine density on cortical pyramidal neurons. Thus, MIAinduced alterations in GR signaling appear to underlie 5-HT2AR dysregulation and associated phenotypes
within this model. Given that we also observe GR dysregulation in postmortem samples from
schizophrenia subjects, there is evidence for translational implications of these phenotypes. This pattern
of decreased GR signaling on the 5-HT2AR promoter and increased 5-HT2AR mRNA expression is further
supported by our findings in corticosterone-treated mice, which reflect the changes observed in MIA
offspring. Opposite to the pattern observed with MIA offspring and corticosterone-treated mice, ΔGR
expression in mouse frontal cortex produces a decrease in 5-HT2AR mRNA expression and improves PPI
in a 5-HT2AR-dependent manner. These data, taken as a whole, suggest that MIA produces reduction in
GR signaling in mouse frontal cortex, leading to increased 5-HT2AR expression and downstream
alterations with relevance to both synaptic structure and behavior. This may provide insight into the
mechanisms behind 5-HT2AR dysregulation and schizophrenia symptoms. Figure 21 depicts a flow chart
that integrates our findings with those of other MIA studies.

83

84

Fig. 21 | The process of maternal immune activation, from poly-(I:C) administration to adult
phenotypes, is summarized in this flow chart. Solid arrows represent relationships between confirmed
phenotypes, both from these studies and from the literature. Dashed arrows are potential relationships
that would need to be evaluated in further studies. Our novel findings from these studies related to MIA
offspring are underlined. Findings in these studies that replicate previous findings are both underlined
and cited.

Prior to these studies, although 5-HT2AR dysregulation in frontal cortex of MIA models had been
demonstrated by our lab and others, the underlying cause of this dysregulation had remained unknown.
Here, we provide strong evidence that altered GR signaling may participate in this process. To our
knowledge, despite the independent data supporting 5-HT2AR dysregulation in MIA21, 22, 32, 74 and 5-HT2AR
regulation by the GR,93-95 these are the first studies to investigate the relationship between these two
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phenomena. Our results are therefore significant both in light of the association between 5-HT2AR and
schizophrenia-related phenotypes53, 64, 73, 83 as well as the potential translational implications of a novel
approach to prefrontal cortex 5-HT2AR regulation in schizophrenia. Manipulations to correct GR
dysregulation in schizophrenia may, therefore, be useful strategies to ameliorate 5-HT2AR-implicated
schizophrenia symptoms related to domains such as synaptic dysfunction and sensorimotor gating.

D.2. GR Signaling within our Models
Despite the converging evidence from our three independent models, our current data linking GR
alterations and increased 5-HT2AR mRNA remain correlative. A variety of follow-up experiments could be
used to directly establish the regulatory relationship between the GR and 5-HT2AR. In vitro, a luciferase
reporter assay using the GR and 5-HT2AR promoter could be used to determine the result of GR binding
on 5-HT2AR promoter activity.108 Direct evaluation of the effect of GR on the 5-HT2AR promoter could be
accomplished in vivo through use of a clustered regulatory interspaced short palindromic repeat
(CRISPR)/ nuclease dead Cas9 (dCas9) approach. dCas9, when fused to a transcription factor and
expressed alongside a guide RNA (gRNA), can direct that transcription factor to a locus specified by the
gRNA sequence.117 Although our current AAV8-CaMKIIα-ΔGR vector approach is able to restrict GR
overexpression to frontal cortex pyramidal neurons in mice,84 the delivered GR remains able to interact
with other glucocorticoid response elements (GREs) throughout the genome. The lack of effect of ΔGR
on 5-HT2CR and D2 mRNA expression in our experiments suggests some degree of specificity to the effect
on 5-HT2AR mRNA, but alternative signaling explanations cannot be excluded. A CRISPR/dCas9 approach
involving a 5-HT2AR promoter gRNA and a GR-dCas9 fusion virally delivered to neuronal cells in mouse
frontal cortex, however, would allow direct determination of the effect of GR occupancy on 5-HT2AR
promoter activity.
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The currently available data raise the question of why corticosterone and frontal cortex ΔGR expression
exert opposite effects on both 5-HT2AR mRNA expression and PPI. Given that both approaches should
promote GR signaling, one might expect them to produce similar phenotypes. One possible explanation
for this discrepancy is the ability of negative feedback to constrain GR signaling.99 Although both
corticosterone and ΔGR result in increased FKBP5 mRNA, suggesting the presence of negative feedback
within both experimental systems, ΔGR results in a roughly fourfold, at least at the mRNA level,
induction of GR expression. In addition, the ΔGR truncation is capable of constitutive nuclear
translocation113, 114 and is not expressed under the control of the endogenous GR locus, both of which
could render it resistant to endogenous negative feedback mechanisms.99 Our observation that
corticosterone results in decreased enrichment of the GR at the 5-HT2AR promoter further supports the
hypothesis that negative feedback may explain this discrepancy. Within this model, sustained ΔGR
occupancy at the 5-HT2AR promoter would suppress 5-HT2AR expression while sustained glucocorticoid
stimulation with corticosterone would lead to negative feedback, reducing GR occupancy of the 5-HT2AR
promoter and stimulating 5-HT2AR expression. A follow-up study performing ChIP in frontal cortex of
mice injected with AAV-ΔGR or an AAV-eYFP control would clarify the degree of GR occupancy at the 5HT2AR promoter following ΔGR expression. In addition, while ΔGR-induced PPI improvements are 5HT2AR dependent, corticosterone-induced PPI deficits are not. While this might be explained by the
systemic nature of corticosterone administration, in contrast to frontal cortex-specific ΔGR expression,
further studies are needed to clarify what molecular alterations might underlie this difference.
While we observed decreased GR immunoreactivity in the nuclear compartment in MIA offspring frontal
cortex, we observed increased GR immunoreactivity in the cytoplasmic compartment in postmortem
schizophrenia prefrontal cortex. Increased 5-HT2AR expression has been observed within both systems.21,
53

Given that increased mRNA for the negative regulator FKBP5 has been reported in postmortem

schizophrenia prefrontal cortex, alongside dysregulation of mRNA for other GR interacting proteins,88
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there is the possibility that dysregulation of other components of the GR signaling system may affect GR
translocation in the context of schizophrenia frontal cortex. Increased FKBP5 expression could, for
example, act to sequester the GR in the cytoplasm, resulting in increased cytoplasmic GR expression in
the absence of increased GR signaling, though further studies would be needed to confirm this. Given
the molecular weight of the dysregulated GR isoform (about 65 kDa), its most likely identity is the GR-A
isoform. This isoform has been observed in humans, mice, and guinea pigs, but it has not been very well
characterized.118-120 Further studies are necessary to clarify the identity of the detected isoform as well
as what its implications might be for both MIA models and schizophrenia.

D.3. The GR Binding Site on the 5-HT2AR Promoter
In a follow-up to the paper reporting the 5-HT2AR promoter GR binding site, Falkenberg et al predict that
the GR acts to suppress 5-HT2AR promoter activity at the site.121 Our experiments confirm GR binding to
the site in vivo and support this negative regulatory relationship. As discussed in the previous paragraph,
negative feedback could explain the apparently divergent effects of GR manipulations on 5-HT2AR
expression reported in the literature, such as similar phenotypes being observed following
corticosterone administration and siRNA-mediated GR knockdown in vivo. Our studies therefore provide
a crucial advancement to work on the relationship between the two receptors and provide a potential
mechanism for the exquisite sensitivity of the 5-HT2AR to stress.89-92
Transcription factors can act at a common locus to produce their genomic effects.122 The follow-up
paper by Falkenberg et al proposes that GR signaling at the 5-HT2AR binding site interactions with
signaling from the E protein family transcription factor Th1-E47, part of which is a product of the TCF3
gene. In contrast to the GR, they predict Th1-E47 would promote 5-HT2AR expression.121, 123 While TCF3
and GR signaling have been shown to interact in the mouse liver,124 TCF3 expression diminishes
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dramatically in the mouse telencephalon after embryonic development.125 We have observed that TCF3
immunoreactivity is detectable in mouse fetal tissue and adult mouse liver, but absent in adult mouse
frontal cortex (data not shown). The closely related TCF4, however, is expressed in adult mouse cortex
and has been identified as a key schizophrenia hub gene.126 Investigation into TCF4 interaction with GR
signaling may therefore be a valuable follow-up study.

D.4. MIA and 5-HT2AR Dependence of Phenotypes
Given the numerous factors implicated in MIA processes,37, 38 discussion of our specific experimental
paradigms is warranted. In these studies, we used two strains of mice, 129S6/SvEv and C57BL/6N, for
experiments. While IL-6 induction by poly-(I:C) was clear in both strains, the degree of induction
observed between the strains was slightly different. In addition, mice from Charles River possess
significantly more cecal SFB than mice from other vendors. Given the importance of both of these
factors to MIA induction,38, 39 we cannot exclude involvement of strain in our observed phenotypes.
Follow-up studies to evaluate strain dependence of our observed phenotypes would therefore expand
our knowledge. Additionally, given that poly-(I:C) signals primarily through a downstream signaling
cascade starting with TLR3,33 use of other agents such as influenza or LPS to confirm our phenotypes
could be beneficial. MIA phenotypes have been demonstrated to rely on critical periods of induction.40
Inducing MIA at earlier or later stages of murine pregnancy could determine the critical period for our
observed phenotypes.
An important limitation of our studies is that they primarily use male mice. A sex difference has been
observed in age of schizophrenia onset in humans1 and autism spectrum disorder is diagnosed at
increased rates in males as compared to females.1 As discussed in the introduction, sex differences have
been found in other MIA models, with domains such as the effect of DOI on c-Fos immunoreactivity in
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MIA frontal cortex,32 FKBP5 dysregulation in MIA offspring amygdala,31 and hippocampal GR
immunoreactivity in juvenile MIA offspring being reported.30 There is therefore the possibility that sex
differences may play a role in the phenotypes observed in these studies. In addition, the GR binding site
on the 5-HT2AR promoter was identified as a progesterone response element, providing a potential
mechanism for sex-specific effects of hormones on 5-HT2AR regulation.100 Although there are examples
of previous studies that used both sexes without addressing potential sex differences20, 21 or used
exclusively males,35, 74 follow-up studies including sufficient numbers of female mice and properly
addressing sex as a biological variable are necessary to determine to what degree our observed
phenotypes are sex-dependent.
Our dendritic spine data show that the MIA-induced alterations in mushroom dendritic spine density are
5-HT2AR dependent. Of note, 5-HT2AR knockout mice exhibited lower mushroom spine density regardless
of maternal treatment. Within a different experimental paradigm, we observed similar decreases in
frontal cortex spine density in 5-HT2AR knockout mice.80 Given the implication of 5-HT2AR ligands in
synaptic plasticity,81, 83, 84 decreased mature dendritic spine density in mice lacking endogenous signaling
through the 5-HT2AR receptor is not surprising. Additional studies are necessary, however, to clarify this
mechanism. Given that MIA offspring have been shown to possess immune alterations relative to
controls,5 there is a possibility that altered immune responses may play a role in our dendritic spine
findings. This possibility is made less likely by the absence of effect of MIA on spine density in 5-HT2AR
knockout mice. A 5-HT2AR-dependent immune mechanism for altered dendritic spine density, however,
cannot be excluded. As follow-up experiments, virally-mediated direct 5-HT2AR overexpression in cortical
pyramidal neurons to determine if 5-HT2AR dysregulation is sufficient to affect its independent effect on
dendritic spine density or alternative approaches to dendrite labeling could be used.49, 127
In line with these limitations to our explanations for our dendritic spine data, an important unresolved
question within our MIA model is the cell type in which 5-HT2AR dysregulation occurs in frontal cortex.
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We hypothesize that the dysregulation occurs in pyramidal neurons, supported by their high degree of
5-HT2AR expression in layer 5 of mouse cortex60 and the sufficiency of ΔGR expression in pyramidal
neurons to produce decreased 5-HT2AR mRNA expression detectable at the whole frontal cortex level.
Given the absence of cell type-specific markers in our FISH studies and the fact that previous studies
demonstrating increased 5-HT2AR expression in frontal cortex have utilized approaches requiring
homogenized tissue,21, 22, 32, 74 this remains an open question. Combining our FISH approach with labeling
for cell type specific markers is a follow-up approach that could definitively specify the cell type in which
5-HT2AR is dysregulated within MIA.62 Identification of this cell type (or types) would facilitate hypothesis
generation into the mechanisms by which 5-HT2AR dysregulation might contribute to MIA-induced
phenotypes.
We independently demonstrate both PPI deficits in MIA models and 5-HT2AR-dependent PPI
improvement following ΔGR expression in frontal cortex pyramidal neurons. Follow-up experiments
comparing MIA and control wild type and 5-HT2AR knockout offspring could clarify to what degree 5HT2AR dysregulation is necessary for PPI deficits within the model. Our results suggest that decreased GR
signaling at the 5-HT2AR promoter is ultimately responsible for 5-HT2AR-dependent deficits in MIA
models. To test this hypothesis, restoration of GR expression in frontal cortex of MIA offspring would be
necessary. These experiments could be conducted using either our viral ΔGR approach or use of a dCas9GR construct in MIA offspring frontal cortex. If either of these approaches is able to prevent 5-HT2ARdependent alterations in MIA offspring, this pathway would be confirmed.
In addition to the effects we observed on PPI, several of our experimental manipulations also produced
effects on startle magnitude. MIA, corticosterone administration, and 5-HT2AR knockout status all
decrease startle magnitude and ΔGR induces a correlation between average %PPI and startle magnitude
in a 5-HT2AR-dependent manner. There is not a clearly established pattern of relationship between PPI
and startle magnitude128 and a variety of factors such as fear and habituation can influence startle
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magnitude.129 The significance of the observed effects on startle magnitude and the interpretation of 5HT2AR dependence in the effect of ΔGR on startle magnitude remain to be clarified by further studies.
For some of the phenotypes tested in these experiments, trends towards main or post-hoc effects were
observed. Table 6 contains power analysis to determine appropriate sample sizes for follow-up studies
that are sufficiently powered to determine if the trends reflect genuine effects on the relevant
phenotypes.

Fig. 2b
Fig. 4b
Fig. 6a
Fig. 6c
Fig. 6d
Fig. 6d
Table 3
Table 3
Fig. 18a

Comparison with Trend
Post-hoc Test: qPCR for SFB 16S rRNA in 129Sv and TAC mice
Post-hoc Test: PPI at the 85 dB prepulse level in MIA and Control offspring
Main Effect: Treatment effect for stubby spines in MIA and Control offspring
Main Effect: Genotype effect for mushroom spines in MIA and Control offspring
Main Effect: Genotype effect for total spines in MIA and Control offspring
Main Effect: Treatment effect for total spines in MIA and Control offspring
Main Effect: Treatment effect for startle magnitude in Cort and Veh-treated mice
Main Effect: Genotype effect for startle magnitude in Cort and Veh-treated mice
Post-hoc Test: PPI at the 77 dB prepulse level in ΔGR and eYFP-treated WT mice

Reported p-value
p = 0.059
p = 0.074
p = 0.057
p = 0.084
p = 0.059
p = 0.054
p = 0.090
p = 0.091
p = 0.092

Necessary sample size (per group)
7
46
197
238
200
192
34
34
51

Table 6 | Power analysis reveals samples sizes to detect genuine effects on phenotypes that exhibited
trends in the results. Power analysis was conducted using G*Power software. Both the experimental
paradigms and p-values for the trends are included in the table. For post-hoc tests, α was based on 0.05
and adjusted based on the number of comparisons using the Bonferroni correction and β was set at 0.2
for a power of 0.8. Effect sizes were calculated using means and standard deviations from the relevant
groups. For main effects, α was set at 0.05 and β was set at 0.2 for a power of 0.8. Effect sizes were
calculated using η2 calculated based on main effect and residual sums of squares from the relevant
ANOVA. Calculated sample sizes are reported per group. 129Sv = 129S6/SvEv, TAC = Taconic, Cort =
Corticosterone, Veh = Vehicle.

D.5. 5-HT2AR-mGluR2 Heteromerization
Although not directly addressed in these studies, previous work from our lab has proposed that the 5HT2AR forms a heteromeric complex with metabotropic glutamate receptor 2 (mGluR2).53 Crosstalk
between the two receptors has been extensively demonstrated in vitro69, 130 and mGluR2 expression has
been found to be necessary for 5-HT2AR agonist-induced head twitch response in mice.131 In both MIA
offspring frontal cortex and postmortem prefrontal cortex samples from antipsychotic-free human
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schizophrenia subjects, increased 5-HT2AR density is accompanied by decreased mGluR2 density.21, 22, 53
In contrast to the 5-HT2AR density from subjects testing positive for antipsychotics, which is not different
from controls, mGluR2 density remains dysregulated in these samples.53 This human finding is further
validated in mice by chronic treatment with the atypical antipsychotic clozapine, which reduces 5-HT2AR
density in frontal cortex while also, downstream, reducing mGluR2 density.108 MIA offspring and,
potentially, schizophrenia subjects as well, are therefore characterized by an imbalance in heteromer
component expression that is not corrected by antipsychotics. Our data propose a novel mechanism by
which 5-HT2AR expression is dysregulated and could therefore be manipulated within MIA offspring. In
light of the fact that mGluR2 agonists have been proposed as a novel class of antipsychotics,132 a GR
targeting approach to restrain 5-HT2AR expression might spare downstream mGluR2 expression,
potentially allowing for use of mGluR2 agonists within schizophrenia treatment regimens.

D.6. Conclusion
Our data using three independent models suggest that alterations in GR signaling, including both
decreased nuclear immunoreactivity and decreased GR enrichment at the 5-HT2AR promoter, underlie
increased 5-HT2AR mRNA expression in MIA offspring mouse frontal cortex. This 5-HT2AR dysregulation,
in turn, is necessary for decreased mushroom spine density in MIA offspring frontal cortex, implicating
this process in synaptic structure alterations in the model. Similar GR alterations are observed in frontal
cortex of postmortem schizophrenia subjects. These studies therefore provide key insights into
mechanisms producing 5-HT2AR dysregulation in the context of MIA, clarifying the GR to 5-HT2AR
signaling relationship and elucidating the mechanisms underlying synaptic and sensorimotor gating
phenotypes within the model. These findings, in turn, could direct investigation into novel approaches
to schizophrenia treatment.

93

References
1.
American Psychiatric Association., American Psychiatric Association. DSM-5 Task Force.
Diagnostic and statistical manual of mental disorders : DSM-5. 5th ed. Washington, D.C.: American
Psychiatric Association; 2013. xliv, 947 p. p.
2.
Fatemi SH, Folsom TD. Schizophrenia. In: Fatemi SH, Clayton PJ, editors. The medical
basis of psychiatry Fourth edition. ed. New York: Springer; 2016. p. xix, 1064 pages.
3.
Harvey PD, Koren D, Reichenberg A, Bowie CR. Negative symptoms and cognitive
deficits: what is the nature of their relationship? Schizophr Bull. 2006;32(2):250-8.
4.
Meltzer HY. Treatment-resistant schizophrenia--the role of clozapine. Curr Med Res
Opin. 1997;14(1):1-20.
5.
Estes ML, McAllister AK. Maternal immune activation: Implications for neuropsychiatric
disorders. Science. 2016;353(6301):772-7.
6.

Tsuang M. Schizophrenia: genes and environment. Biol Psychiatry. 2000;47(3):210-20.

7.
Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from
108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421-7.
8.
Du Q, de la Morena MT, van Oers NSC. The Genetics and Epigenetics of 22q11.2
Deletion Syndrome. Front Genet. 2019;10:1365.
9.
Cardno AG, Gottesman, II. Twin studies of schizophrenia: from bow-and-arrow
concordances to star wars Mx and functional genomics. Am J Med Genet. 2000;97(1):12-7.
10.
Brown AS. The environment and susceptibility to schizophrenia. Prog Neurobiol.
2011;93(1):23-58.
11.
Brown AS, Begg MD, Gravenstein S, Schaefer CA, Wyatt RJ, Bresnahan M, Babulas VP,
Susser ES. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry.
2004;61(8):774-80.
12.
Sorensen HJ, Mortensen EL, Reinisch JM, Mednick SA. Association between prenatal
exposure to bacterial infection and risk of schizophrenia. Schizophr Bull. 2009;35(3):631-7.
13.
Brown AS, Cohen P, Harkavy-Friedman J, Babulas V, Malaspina D, Gorman JM, Susser ES.
A.E. Bennett Research Award. Prenatal rubella, premorbid abnormalities, and adult schizophrenia. Biol
Psychiatry. 2001;49(6):473-86.
14.
Brown AS, Schaefer CA, Quesenberry CP, Jr., Liu L, Babulas VP, Susser ES. Maternal
exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am J Psychiatry.
2005;162(4):767-73.

94

15.
Patterson PH. Maternal infection and immune involvement in autism. Trends Mol Med.
2011;17(7):389-94.
16.
Atladottir HO, Thorsen P, Ostergaard L, Schendel DE, Lemcke S, Abdallah M, Parner ET.
Maternal infection requiring hospitalization during pregnancy and autism spectrum disorders. J Autism
Dev Disord. 2010;40(12):1423-30.
17.
Gilmore JH, Jarskog LF. Exposure to infection and brain development: cytokines in the
pathogenesis of schizophrenia. Schizophr Res. 1997;24(3):365-7.
18.
Knuesel I, Chicha L, Britschgi M, Schobel SA, Bodmer M, Hellings JA, Toovey S, Prinssen
EP. Maternal immune activation and abnormal brain development across CNS disorders. Nat Rev Neurol.
2014;10(11):643-60.
19.
Hsiao EY, McBride SW, Hsien S, Sharon G, Hyde ER, McCue T, Codelli JA, Chow J,
Reisman SE, Petrosino JF, Patterson PH, Mazmanian SK. Microbiota modulate behavioral and
physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013;155(7):1451-63.
20.
Shi L, Fatemi SH, Sidwell RW, Patterson PH. Maternal influenza infection causes marked
behavioral and pharmacological changes in the offspring. J Neurosci. 2003;23(1):297-302.
21.
Moreno JL, Kurita M, Holloway T, Lopez J, Cadagan R, Martinez-Sobrido L, Garcia-Sastre
A, Gonzalez-Maeso J. Maternal influenza viral infection causes schizophrenia-like alterations of 5-HT(2)A
and mGlu(2) receptors in the adult offspring. J Neurosci. 2011;31(5):1863-72.
22.
Holloway T, Moreno JL, Umali A, Rayannavar V, Hodes GE, Russo SJ, Gonzalez-Maeso J.
Prenatal stress induces schizophrenia-like alterations of serotonin 2A and metabotropic glutamate 2
receptors in the adult offspring: role of maternal immune system. J Neurosci. 2013;33(3):1088-98.
23.
Shi L, Smith SE, Malkova N, Tse D, Su Y, Patterson PH. Activation of the maternal
immune system alters cerebellar development in the offspring. Brain Behav Immun. 2009;23(1):116-23.
24.
Meyer U, Feldon J. To poly(I:C) or not to poly(I:C): advancing preclinical schizophrenia
research through the use of prenatal immune activation models. Neuropharmacology. 2012;62(3):130821.
25.
Harvey L, Boksa P. Prenatal and postnatal animal models of immune activation:
relevance to a range of neurodevelopmental disorders. Dev Neurobiol. 2012;72(10):1335-48.
26.
Chow KH, Yan Z, Wu WL. Induction of Maternal Immune Activation in Mice at Midgestation Stage with Viral Mimic Poly(I:C). J Vis Exp. 2016(109):e53643.
27.
Cunningham C, Campion S, Teeling J, Felton L, Perry VH. The sickness behaviour and CNS
inflammatory mediator profile induced by systemic challenge of mice with synthetic double-stranded
RNA (poly I:C). Brain Behav Immun. 2007;21(4):490-502.
28.
Whitfield C, Trent MS. Biosynthesis and export of bacterial lipopolysaccharides. Annu
Rev Biochem. 2014;83:99-128.

95

29.
Kentner AC, Khoury A, Lima Queiroz E, MacRae M. Environmental enrichment rescues
the effects of early life inflammation on markers of synaptic transmission and plasticity. Brain Behav
Immun. 2016;57:151-60.
30.
Connors EJ, Shaik AN, Migliore MM, Kentner AC. Environmental enrichment mitigates
the sex-specific effects of gestational inflammation on social engagement and the hypothalamic
pituitary adrenal axis-feedback system. Brain Behav Immun. 2014;42:178-90.
31.
Zhao X, Rondon-Ortiz AN, Lima EP, Puracchio M, Roderick RC, Kentner AC. Therapeutic
efficacy of environmental enrichment on behavioral, endocrine, and synaptic alterations in an animal
model of maternal immune activation. Brain Behav Immun Health. 2020;3.
32.
Wischhof L, Irrsack E, Dietz F, Koch M. Maternal lipopolysaccharide treatment
differentially affects 5-HT(2A) and mGlu2/3 receptor function in the adult male and female rat offspring.
Neuropharmacology. 2015;97:275-88.
33.
Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA
and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413(6857):732-8.
34.
Han M, Zhang JC, Yao W, Yang C, Ishima T, Ren Q, Ma M, Dong C, Huang XF, Hashimoto
K. Intake of 7,8-Dihydroxyflavone During Juvenile and Adolescent Stages Prevents Onset of Psychosis in
Adult Offspring After Maternal Immune Activation. Sci Rep. 2016;6:36087.
35.
Choi GB, Yim YS, Wong H, Kim S, Kim H, Kim SV, Hoeffer CA, Littman DR, Huh JR. The
maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring. Science.
2016;351(6276):933-9.
36.
Harvey L, Boksa P. A stereological comparison of GAD67 and reelin expression in the
hippocampal stratum oriens of offspring from two mouse models of maternal inflammation during
pregnancy. Neuropharmacology. 2012;62(4):1767-76.
37.
Estes ML, Farrelly K, Cameron S, Aboubechara JP, Haapanen L, Schauer JD, Horta A,
Prendergast K, MacMahon JA, Shaffer CI, Le CT, Kincheloe GN, Tan DJ, van der List D, Bauman MD,
Carter CS, Van de Water J, McAllister AK. Enhancing rigor and reproducibility in maternal immune
activation models: practical considerations and predicting resilience and susceptibility using baseline
immune responsiveness before pregnancy. bioRxiv. 2019:699983.
38.
Kim S, Kim H, Yim YS, Ha S, Atarashi K, Tan TG, Longman RS, Honda K, Littman DR, Choi
GB, Huh JR. Maternal gut bacteria promote neurodevelopmental abnormalities in mouse offspring.
Nature. 2017;549(7673):528-32.
39.
Smith SE, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters
fetal brain development through interleukin-6. J Neurosci. 2007;27(40):10695-702.
40.
Yim YS, Park A, Berrios J, Lafourcade M, Pascual LM, Soares N, Yeon Kim J, Kim S, Kim H,
Waisman A, Littman DR, Wickersham IR, Harnett MT, Huh JR, Choi GB. Reversing behavioural
abnormalities in mice exposed to maternal inflammation. Nature. 2017;549(7673):482-7.

96

41.
Meyer U, Nyffeler M, Yee BK, Knuesel I, Feldon J. Adult brain and behavioral
pathological markers of prenatal immune challenge during early/middle and late fetal development in
mice. Brain Behav Immun. 2008;22(4):469-86.
42.
Ibi D, Nakasai G, Koide N, Sawahata M, Kohno T, Takaba R, Nagai T, Hattori M,
Nabeshima T, Yamada K, Hiramatsu M. Reelin Supplementation Into the Hippocampus Rescues
Abnormal Behavior in a Mouse Model of Neurodevelopmental Disorders. Front Cell Neurosci.
2020;14:285.
43.
Saunders JM, Moreno JL, Ibi D, Sikaroodi M, Kang DJ, Munoz-Moreno R, Dalmet SS,
Garcia-Sastre A, Gillevet PM, Dozmorov MG, Bajaj JS, Gonzalez-Maeso J. Gut microbiota manipulation
during the prepubertal period shapes behavioral abnormalities in a mouse neurodevelopmental
disorder model. Sci Rep. 2020;10(1):4697.
44.
Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle:
normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl). 2001;156(23):234-58.
45.
Braff DL, Geyer MA. Sensorimotor gating and schizophrenia. Human and animal model
studies. Arch Gen Psychiatry. 1990;47(2):181-8.
46.
Swerdlow NR, Geyer MA, Braff DL. Neural circuit regulation of prepulse inhibition of
startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl). 2001;156(23):194-215.
47.
Giovanoli S, Engler H, Engler A, Richetto J, Feldon J, Riva MA, Schedlowski M, Meyer U.
Preventive effects of minocycline in a neurodevelopmental two-hit model with relevance to
schizophrenia. Transl Psychiatry. 2016;6:e772.
48.
Coiro P, Padmashri R, Suresh A, Spartz E, Pendyala G, Chou S, Jung Y, Meays B, Roy S,
Gautam N, Alnouti Y, Li M, Dunaevsky A. Impaired synaptic development in a maternal immune
activation mouse model of neurodevelopmental disorders. Brain Behav Immun. 2015;50:249-58.
49.
Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal
neurons in schizophrenia. Arch Gen Psychiatry. 2000;57(1):65-73.
50.
Baharnoori M, Brake WG, Srivastava LK. Prenatal immune challenge induces
developmental changes in the morphology of pyramidal neurons of the prefrontal cortex and
hippocampus in rats. Schizophr Res. 2009;107(1):99-109.
51.
Ikezu S, Yeh H, Delpech JC, Woodbury ME, Van Enoo AA, Ruan Z, Sivakumaran S, You Y,
Holland C, Guillamon-Vivancos T, Yoshii-Kitahara A, Botros MB, Madore C, Chao PH, Desani A,
Manimaran S, Kalavai SV, Johnson WE, Butovsky O, Medalla M, Luebke JI, Ikezu T. Inhibition of colony
stimulating factor 1 receptor corrects maternal inflammation-induced microglial and synaptic
dysfunction and behavioral abnormalities. Mol Psychiatry. 2020.
52.
Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical
review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry.
2005;10(1):79-104.
97

53.
Gonzalez-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, Lopez-Gimenez JF, Zhou M,
Okawa Y, Callado LF, Milligan G, Gingrich JA, Filizola M, Meana JJ, Sealfon SC. Identification of a
serotonin/glutamate receptor complex implicated in psychosis. Nature. 2008;452(7183):93-7.
54.
Kim K, Che T, Panova O, DiBerto JF, Lyu J, Krumm BE, Wacker D, Robertson MJ, Seven
AB, Nichols DE, Shoichet BK, Skiniotis G, Roth BL. Structure of a Hallucinogen-Activated Gq-Coupled 5HT2A Serotonin Receptor. Cell. 2020;182(6):1574-88 e19.
55.

Thompson AJ, Lummis SC. 5-HT3 receptors. Curr Pharm Des. 2006;12(28):3615-30.

56.
Roth BL, Willins DL, Kristiansen K, Kroeze WK. 5-Hydroxytryptamine2-family receptors
(5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets
function. Pharmacol Ther. 1998;79(3):231-57.
57.
Weisstaub NV, Zhou M, Lira A, Lambe E, Gonzalez-Maeso J, Hornung JP, Sibille E,
Underwood M, Itohara S, Dauer WT, Ansorge MS, Morelli E, Mann JJ, Toth M, Aghajanian G, Sealfon SC,
Hen R, Gingrich JA. Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science.
2006;313(5786):536-40.
58.
Snir O, Hesselberg E, Amoudruz P, Klareskog L, Zarea-Ganji I, Catrina AI, Padyukov L,
Malmstrom V, Seddighzadeh M. Genetic variation in the serotonin receptor gene affects immune
responses in rheumatoid arthritis. Genes Immun. 2013;14(2):83-9.
59.
Nichols CD. Serotonin 5-HT(2A) Receptor Function as a Contributing Factor to Both
Neuropsychiatric and Cardiovascular Diseases. Cardiovasc Psychiatry Neurol. 2009;2009:475108.
60.
Weber ET, Andrade R. Htr2a Gene and 5-HT(2A) Receptor Expression in the Cerebral
Cortex Studied Using Genetically Modified Mice. Front Neurosci. 2010;4.
61.
Glennon RA, Titeler M, McKenney JD. Evidence for 5-HT2 involvement in the mechanism
of action of hallucinogenic agents. Life Sci. 1984;35(25):2505-11.
62.
Gonzalez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore
M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA. Hallucinogens recruit specific cortical 5-HT(2A) receptormediated signaling pathways to affect behavior. Neuron. 2007;53(3):439-52.
63.

Nichols DE. Hallucinogens. Pharmacol Ther. 2004;101(2):131-81.

64.
Halberstadt AL, Geyer MA. LSD but not lisuride disrupts prepulse inhibition in rats by
activating the 5-HT(2A) receptor. Psychopharmacology (Berl). 2010;208(2):179-89.
65.
Karaki S, Becamel C, Murat S, Mannoury la Cour C, Millan MJ, Prezeau L, Bockaert J,
Marin P, Vandermoere F. Quantitative phosphoproteomics unravels biased phosphorylation of serotonin
2A receptor at Ser280 by hallucinogenic versus nonhallucinogenic agonists. Mol Cell Proteomics.
2014;13(5):1273-85.
66.
Lopez-Gimenez JF, Gonzalez-Maeso J. Hallucinogens and Serotonin 5-HT2A ReceptorMediated Signaling Pathways. Curr Top Behav Neurosci. 2018;36:45-73.

98

67.
de la Fuente Revenga M, Shin JM, Vohra HZ, Hideshima KS, Schneck M, Poklis JL,
Gonzalez-Maeso J. Fully automated head-twitch detection system for the study of 5-HT2A receptor
pharmacology in vivo. Sci Rep. 2019;9(1):14247.
68.
Schmid CL, Bohn LM. Serotonin, but not N-methyltryptamines, activates the serotonin
2A receptor via a ss-arrestin2/Src/Akt signaling complex in vivo. J Neurosci. 2010;30(40):13513-24.
69.
Fribourg M, Moreno JL, Holloway T, Provasi D, Baki L, Mahajan R, Park G, Adney SK,
Hatcher C, Eltit JM, Ruta JD, Albizu L, Li Z, Umali A, Shim J, Fabiato A, MacKerell AD, Jr., Brezina V,
Sealfon SC, Filizola M, Gonzalez-Maeso J, Logothetis DE. Decoding the signaling of a GPCR heteromeric
complex reveals a unifying mechanism of action of antipsychotic drugs. Cell. 2011;147(5):1011-23.
70.
Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D. Psilocybin
induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport.
1998;9(17):3897-902.
71.
Ebdrup BH, Rasmussen H, Arnt J, Glenthoj B. Serotonin 2A receptor antagonists for
treatment of schizophrenia. Expert Opin Investig Drugs. 2011;20(9):1211-23.
72.
Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C.
Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3
trial. Lancet. 2014;383(9916):533-40.
73.
Diez-Alarcia R, Muguruza C, Rivero G, Garcia-Bea A, Gomez-Vallejo V, Callado LF, Llop J,
Martin A, Meana JJ. Opposite alterations of 5-HT2A receptor brain density in subjects with
schizophrenia: relevance of radiotracers pharmacological profile. Transl Psychiatry. 2021;11(1):302.
74.
Malkova NV, Gallagher JJ, Yu CZ, Jacobs RE, Patterson PH. Manganese-enhanced
magnetic resonance imaging reveals increased DOI-induced brain activity in a mouse model of
schizophrenia. Proc Natl Acad Sci U S A. 2014;111(24):E2492-500.
75.
Vollenweider FX, Csomor PA, Knappe B, Geyer MA, Quednow BB. The effects of the
preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers
depend on interstimulus interval. Neuropsychopharmacology. 2007;32(9):1876-87.
76.
Wischhof L, Aho HE, Koch M. DOI-induced deficits in prepulse inhibition in Wistar rats
are reversed by mGlu2/3 receptor stimulation. Pharmacol Biochem Behav. 2012;102(1):6-12.
77.
Vohra HZ, Saunders JM, Jaster AM, de la Fuente Revenga M, Jimenez J, FernandezTeruel A, Wolstenholme JT, Beardsley PM, Gonzalez-Maeso J. Sex-specific effects of psychedelics on
prepulse inhibition of startle in 129S6/SvEv mice. Psychopharmacology (Berl). 2021.
78.
Quednow BB, Schmechtig A, Ettinger U, Petrovsky N, Collier DA, Vollenweider FX,
Wagner M, Kumari V. Sensorimotor gating depends on polymorphisms of the serotonin-2A receptor and
catechol-O-methyltransferase, but not on neuregulin-1 Arg38Gln genotype: a replication study. Biol
Psychiatry. 2009;66(6):614-20.
79.
Rochefort NL, Konnerth A. Dendritic spines: from structure to in vivo function. EMBO
Rep. 2012;13(8):699-708.
99

80.
de la Fuente Revenga M, Zhu B, Guevara CA, Naler LB, Saunders JM, Zhou Z, Toneatti R,
Sierra S, Wolstenholme JT, Beardsley PM, Huntley GW, Lu C, González-Maeso J. Prolonged epigenetic
and synaptic plasticity alterations following single exposure to a psychedelic in mice. bioRxiv.
2021:2021.02.24.432725.
81.
Dong C, Ly C, Dunlap LE, Vargas MV, Sun J, Hwang IW, Azinfar A, Oh WC, Wetsel WC,
Olson DE, Tian L. Psychedelic-inspired drug discovery using an engineered biosensor. Cell.
2021;184(10):2779-92 e18.
82.
Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R,
Martell J, Blemings A, Erritzoe D, Nutt DJ. Trial of Psilocybin versus Escitalopram for Depression. N Engl J
Med. 2021;384(15):1402-11.
83.
Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, Burbach KF, Soltanzadeh
Zarandi S, Sood A, Paddy MR, Duim WC, Dennis MY, McAllister AK, Ori-McKenney KM, Gray JA, Olson DE.
Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep. 2018;23(11):3170-82.
84.
Ibi D, de la Fuente Revenga M, Kezunovic N, Muguruza C, Saunders JM, Gaitonde SA,
Moreno JL, Ijaz MK, Santosh V, Kozlenkov A, Holloway T, Seto J, Garcia-Bea A, Kurita M, Mosley GE, Jiang
Y, Christoffel DJ, Callado LF, Russo SJ, Dracheva S, Lopez-Gimenez JF, Ge Y, Escalante CR, Meana JJ,
Akbarian S, Huntley GW, Gonzalez-Maeso J. Antipsychotic-induced Hdac2 transcription via NF-kappaB
leads to synaptic and cognitive side effects. Nat Neurosci. 2017;20(9):1247-59.
85.
Smith SM, Vale WW. The role of the hypothalamic-pituitary-adrenal axis in
neuroendocrine responses to stress. Dialogues Clin Neurosci. 2006;8(4):383-95.
86.
Sinclair D, Webster MJ, Wong J, Weickert CS. Dynamic molecular and anatomical
changes in the glucocorticoid receptor in human cortical development. Mol Psychiatry. 2011;16(5):50415.
87.
Bradley AJ, Dinan TG. A systematic review of hypothalamic-pituitary-adrenal axis
function in schizophrenia: implications for mortality. J Psychopharmacol. 2010;24(4 Suppl):91-118.
88.
Sinclair D, Fillman SG, Webster MJ, Weickert CS. Dysregulation of glucocorticoid
receptor co-factors FKBP5, BAG1 and PTGES3 in prefrontal cortex in psychotic illness. Sci Rep.
2013;3:3539.
89.
Sood A, Pati S, Bhattacharya A, Chaudhari K, Vaidya VA. Early emergence of altered 5HT2A receptor-evoked behavior, neural activation and gene expression following maternal separation.
Int J Dev Neurosci. 2018;65:21-8.
90.
Savignac HM, Couch Y, Stratford M, Bannerman DM, Tzortzis G, Anthony DC, Burnet
PWJ. Prebiotic administration normalizes lipopolysaccharide (LPS)-induced anxiety and cortical 5-HT2A
receptor and IL1-beta levels in male mice. Brain Behav Immun. 2016;52:120-31.
91.
Maple AM, Zhao X, Elizalde DI, McBride AK, Gallitano AL. Htr2a Expression Responds
Rapidly to Environmental Stimuli in an Egr3-Dependent Manner. ACS Chem Neurosci. 2015;6(7):113742.

100

92.
Chiu HY, Chan MH, Lee MY, Chen ST, Zhan ZY, Chen HH. Long-lasting alterations in 5HT2A receptor after a binge regimen of methamphetamine in mice. Int J Neuropsychopharmacol.
2014;17(10):1647-58.
93.
Trajkovska V, Kirkegaard L, Krey G, Marcussen AB, Thomsen MS, Chourbaji S, Brandwein
C, Ridder S, Halldin C, Gass P, Knudsen GM, Aznar S. Activation of glucocorticoid receptors increases 5HT2A receptor levels. Exp Neurol. 2009;218(1):83-91.
94.
Berendsen HH, Kester RC, Peeters BW, Broekkamp CL. Modulation of 5-HT receptor
subtype-mediated behaviours by corticosterone. Eur J Pharmacol. 1996;308(2):103-11.
95.
Islam A, Thompson KS, Akhtar S, Handley SL. Increased 5-HT2A receptor expression and
function following central glucocorticoid receptor knockdown in vivo. Eur J Pharmacol. 2004;502(3):21320.
96.
Sever R, Glass CK. Signaling by nuclear receptors. Cold Spring Harb Perspect Biol.
2013;5(3):a016709.
97.
Gong S, Miao YL, Jiao GZ, Sun MJ, Li H, Lin J, Luo MJ, Tan JH. Dynamics and correlation of
serum cortisol and corticosterone under different physiological or stressful conditions in mice. PLoS
One. 2015;10(2):e0117503.
98.
Grad I, Picard D. The glucocorticoid responses are shaped by molecular chaperones. Mol
Cell Endocrinol. 2007;275(1-2):2-12.
99.
Oakley RH, Cidlowski JA. The biology of the glucocorticoid receptor: new signaling
mechanisms in health and disease. J Allergy Clin Immunol. 2013;132(5):1033-44.
100. Falkenberg VR, Rajeevan MS. Identification of a potential molecular link between the
glucocorticoid and serotonergic signaling systems. J Mol Neurosci. 2010;41(2):322-7.
101. Enga RM, Rice AC, Weller P, Subler MA, Lee D, Hall CP, Windle JJ, Beardsley PM, van den
Oord EJ, McClay JL. Initial characterization of behavior and ketamine response in a mouse knockout of
the post-synaptic effector gene Anks1b. Neurosci Lett. 2017;641:26-32.
102. Kiraly DD, Walker DM, Calipari ES, Labonte B, Issler O, Pena CJ, Ribeiro EA, Russo SJ,
Nestler EJ. Alterations of the Host Microbiome Affect Behavioral Responses to Cocaine. Sci Rep.
2016;6:35455.
103. Aschauer DF, Kreuz S, Rumpel S. Analysis of transduction efficiency, tropism and axonal
transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain. PLoS One. 2013;8(9):e76310.
104. Rodriguez A, Ehlenberger DB, Dickstein DL, Hof PR, Wearne SL. Automated threedimensional detection and shape classification of dendritic spines from fluorescence microscopy images.
PLoS One. 2008;3(4):e1997.
105. American Psychiatric Association., American Psychiatric Association. Task Force on DSMIV. Diagnostic and statistical manual of mental disorders : DSM-IV. 4th ed. Washington, DC: American
Psychiatric Association; 1994. xxvii, 886 p. p.
101

106. American Psychiatric Association., American Psychiatric Association. Task Force on DSMIV. Diagnostic and statistical manual of mental disorders : DSM-IV-TR. 4th ed. Washington, DC: American
Psychiatric Association; 2000. xxxvii, 943 p. p.
107. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis
program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175-91.
108. Kurita M, Holloway T, Garcia-Bea A, Kozlenkov A, Friedman AK, Moreno JL, Heshmati M,
Golden SA, Kennedy PJ, Takahashi N, Dietz DM, Mocci G, Gabilondo AM, Hanks J, Umali A, Callado LF,
Gallitano AL, Neve RL, Shen L, Buxbaum JD, Han MH, Nestler EJ, Meana JJ, Russo SJ, Gonzalez-Maeso J.
HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity.
Nat Neurosci. 2012;15(9):1245-54.
109. Nguyen VT, Farman N, Maubec E, Nassar D, Desposito D, Waeckel L, Aractingi S, Jaisser
F. Re-Epithelialization of Pathological Cutaneous Wounds Is Improved by Local Mineralocorticoid
Receptor Antagonism. J Invest Dermatol. 2016;136(10):2080-9.
110. Lebsack TW, Fa V, Woods CC, Gruener R, Manziello AM, Pecaut MJ, Gridley DS, Stodieck
LS, Ferguson VL, Deluca D. Microarray analysis of spaceflown murine thymus tissue reveals changes in
gene expression regulating stress and glucocorticoid receptors. J Cell Biochem. 2010;110(2):372-81.
111. Zheng D, Sabbagh JJ, Blair LJ, Darling AL, Wen X, Dickey CA. MicroRNA-511 Binds to
FKBP5 mRNA, Which Encodes a Chaperone Protein, and Regulates Neuronal Differentiation. J Biol Chem.
2016;291(34):17897-906.
112. Ng SS, Li A, Pavlakis GN, Ozato K, Kino T. Viral infection increases glucocorticoid-induced
interleukin-10 production through ERK-mediated phosphorylation of the glucocorticoid receptor in
dendritic cells: potential clinical implications. PLoS One. 2013;8(5):e63587.
113. Godowski PJ, Rusconi S, Miesfeld R, Yamamoto KR. Glucocorticoid receptor mutants that
are constitutive activators of transcriptional enhancement. Nature. 1987;325(6102):365-8.
114. Revest JM, Di Blasi F, Kitchener P, Rouge-Pont F, Desmedt A, Turiault M, Tronche F,
Piazza PV. The MAPK pathway and Egr-1 mediate stress-related behavioral effects of glucocorticoids.
Nat Neurosci. 2005;8(5):664-72.
115. Dittgen T, Nimmerjahn A, Komai S, Licznerski P, Waters J, Margrie TW, Helmchen F,
Denk W, Brecht M, Osten P. Lentivirus-based genetic manipulations of cortical neurons and their optical
and electrophysiological monitoring in vivo. Proc Natl Acad Sci U S A. 2004;101(52):18206-11.
116. Szymczak-Workman AL, Vignali KM, Vignali DA. Design and construction of 2A peptidelinked multicistronic vectors. Cold Spring Harb Protoc. 2012;2012(2):199-204.
117. Hamilton PJ, Lim CJ, Nestler EJ, Heller EA. Neuroepigenetic Editing. Methods Mol Biol.
2018;1767:113-36.
118. Saif Z, Dyson RM, Palliser HK, Wright IM, Lu N, Clifton VL. Identification of Eight Different
Isoforms of the Glucocorticoid Receptor in Guinea Pig Placenta: Relationship to Preterm Delivery, Sex
and Betamethasone Exposure. PLoS One. 2016;11(2):e0148226.
102

119. Cuffe JSM, Saif Z, Perkins AV, Moritz KM, Clifton VL. Dexamethasone and sex regulate
placental glucocorticoid receptor isoforms in mice. J Endocrinol. 2017;234(2):89-100.
120. Leventhal SM, Lim D, Green TL, Cantrell AE, Cho K, Greenhalgh DG. Uncovering a
multitude of human glucocorticoid receptor variants: an expansive survey of a single gene. BMC Genet.
2019;20(1):16.
121. Falkenberg VR, Gurbaxani BM, Unger ER, Rajeevan MS. Functional genomics of
serotonin receptor 2A (HTR2A): interaction of polymorphism, methylation, expression and disease
association. Neuromolecular Med. 2011;13(1):66-76.
122. Diamond MI, Miner JN, Yoshinaga SK, Yamamoto KR. Transcription factor interactions:
selectors of positive or negative regulation from a single DNA element. Science. 1990;249(4974):126672.
123. Belle I, Zhuang Y. E proteins in lymphocyte development and lymphoid diseases. Curr
Top Dev Biol. 2014;110:153-87.
124. Hemmer MC, Wierer M, Schachtrup K, Downes M, Hubner N, Evans RM, Uhlenhaut NH.
E47 modulates hepatic glucocorticoid action. Nat Commun. 2019;10(1):306.
125. Li H, Zhu Y, Morozov YM, Chen X, Page SC, Rannals MD, Maher BJ, Rakic P. Disruption of
TCF4 regulatory networks leads to abnormal cortical development and mental disabilities. Mol
Psychiatry. 2019;24(8):1235-46.
126. Doostparast Torshizi A, Armoskus C, Zhang H, Forrest MP, Zhang S, Souaiaia T, Evgrafov
OV, Knowles JA, Duan J, Wang K. Deconvolution of transcriptional networks identifies TCF4 as a master
regulator in schizophrenia. Sci Adv. 2019;5(9):eaau4139.
127. Feng G, Mellor RH, Bernstein M, Keller-Peck C, Nguyen QT, Wallace M, Nerbonne JM,
Lichtman JW, Sanes JR. Imaging neuronal subsets in transgenic mice expressing multiple spectral
variants of GFP. Neuron. 2000;28(1):41-51.
128. Curzon P, Zhang M, Radek RJ, Fox GB. The Behavioral Assessment of Sensorimotor
Processes in the Mouse: Acoustic Startle, Sensory Gating, Locomotor Activity, Rotarod, and Beam
Walking. In: nd, Buccafusco JJ, editors. Methods of Behavior Analysis in Neuroscience. Frontiers in
Neuroscience. Boca Raton (FL)2009.
129. Valsamis B, Schmid S. Habituation and prepulse inhibition of acoustic startle in rodents. J
Vis Exp. 2011(55):e3446.
130. Moreno JL, Miranda-Azpiazu P, Garcia-Bea A, Younkin J, Cui M, Kozlenkov A, Ben-Ezra A,
Voloudakis G, Fakira AK, Baki L, Ge Y, Georgakopoulos A, Moron JA, Milligan G, Lopez-Gimenez JF,
Robakis NK, Logothetis DE, Meana JJ, Gonzalez-Maeso J. Allosteric signaling through an mGlu2 and 5HT2A heteromeric receptor complex and its potential contribution to schizophrenia. Sci Signal.
2016;9(410):ra5.

103

131. Moreno JL, Holloway T, Albizu L, Sealfon SC, Gonzalez-Maeso J. Metabotropic glutamate
mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5HT2A receptor agonists. Neurosci Lett. 2011;493(3):76-9.
132. Kinon BJ, Millen BA, Zhang L, McKinzie DL. Exploratory analysis for a targeted patient
population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in
schizophrenia. Biol Psychiatry. 2015;78(11):754-62.

104

